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SUMMARY
The oxidation of low density lipoprotein (LDL) by free radicals (FR) may be one of the 
early events in the production of atheroma. 1  have taken several approaches to test the 
overall hypothesis that more PR oxidation of LDL occurs in diabetes explaining its 
associated excess risk of atherosclerosis.
Before embarking on the body of the work a methodological problem was first clarified. 
Diene conjugated fatty acids (DCFA) are one of the products of FR attack on lipids, 
and are used as markers of FR activity however dietary fat also contains DCFA. 
Therefore a study was designed to test the hypothesis that:- diet is an important source 
of DCFA in human serum and tissues, thereby questioning the use of DCFA as a 
marker of FR activity. The major DCFA species in human tissues is the 9,11- 
octadecadieneoic acid isomer [18:2,(9,11)] of linoleic acid [18:2,(9,12)]. Fourteen 
subjects altered their diets, either increasing ("high diet") or decreasing ("low diet") 
their intake of foods rich in 18:2,(9,11). Seven day diet histories were kept and scored 
for their content of 18:2,(9,11). The concentrations of 18:2(9,11) and 18:2(9,12) in 
serum phospholipids were measured by HPLC with UV detection. The percentage 
molar ratio (%MR) of 18:2(9,11) to 18:2(9,12) was calculated. It was found that the 
%MR rose significantly on the "high diet" [1.3(0.4) vs 1.9(0.7); p = 0.01] and fell 
significantly on the "low diet" [1.6(0.6) vs 1.1(0.4); p =0.004]. Also there was a 
significant correlation between the change in dietary intake of 18:2(9,11) and the change 
in the %MR [ r= 0.829; p=0.001]. Thus the DCFA content of human tissues is greatly 
influenced by diet and its use as FR marker limited.
One situation in which diabetes might be associated with more FR oxidation of lipids 
would be if more FR were generated in diabetes. Since platelet eicosanoid metabolism 
involves FR intermediates, is altered in diabetes, and platelets have been attributed a 
role in atherogenesis a study was designed to test the hypothesis that:- platelets are 
capable of superoxide anion release, this release being greater by the platelets from 
diabetic subjects. Superoxide release was taken as the superoxide dismutase (SOD) 
inhibitable reduction of ferricytochrome-C (Fc) measured as the increase in UV 
absorbence at 550nm. Gel filtered platelet aggregation was induced by shaking platelets 
with collagen. During 60 minutes exposure to aggregating platelets no Fc reduction 
attributable to aggregation was seen in the presence or absence of SOD [WITH SOD:
0.013(0.064) vs WITHOUT SOD: 0.012(0.101) OD units, p=0.987]. Similar results 
were obtained at 1 0  minutes and with resting platelets and no significant differences
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existed between diabetic and non-diabetic platelets. Hence platelets do not act as a 
source of excess FR production in diabetes.
Existence of impaired FR protective mechanisms would be another situation in which 
more FR oxidation of lipids could occur. Estimating the total peroxyl radical 
antioxidant parameter (TRAP) a study tested the hypothesis that:- plasma total 
antioxidant activity, as measured by TRAP, is lower in diabetic subjects than in healthy 
controls, tliereby exposing diabetics to increased risk of FR mediated damage. The 
TRAP assay measures the inhibition, by plasma, of tlie peroxidation of aqueous 
dispersions of linoleic acid, induced by peroxyl radicals generated by thermal 
decomposition of 2,2’ azo-bis [2 amidinopropane hydrochloride]. TRAP was measured 
in seventeen non-diabetic healthy volunteers and in twenty six diabetic subjects. In the 
diabetic subjects plasma peroxidisability was also assessed by measuring the increase 
in the products of lipid peroxidation, namely total diene conjugated (tDC) species and 
thiobabituric acid reactive species (TBARS), in plasma following incubation for 24 
hours at pH 5.5. Thus it was possible to test the further hypotliesis that:- the ease with 
which the lipids from diabetic subjects peroxidise is inversely related to plasma total 
antioxidant activity, as measured by TRAP. Comparing non-smoking diabetic and 
non-diabetics no significant difference in TRAP was found (736.5(151.8) vs 754.6(84.3) 
pm ol.L, p=0.70) whereas in smokers TRAP was lower in diabetics than non-diabetics 
(558.5(161.5) vs 838.3(147.5) /rm ol.l'\ p=0.02) and in diabetics TRAP was lower in 
smokers than non-smokers (558.5(161.5) vs 736.5(151.8) /rmol.L, p=0.01). Also no 
correlation was found between plasma peroxidisability and TRAP [ (tDC; r = 0.008, 
p =0.972), (TBARS: r ,=0.184, p=0.390) ]. These results suggest that diabetes per se 
is not associated with a lower TRAP but that an interaction may exist between diabetes 
and smoking which would help explain the even greater risk that smoking poses to 
diabetics and suggests that smoking diabetics would be more vulnerable to FR damage 
in circumstances of increased FR load such as following ischaemic episodes. Many 
explanations for the lack of correlation between peroxidisability and TRAP are 
discussed in the text. One possibility is that peroxidisability is infuenced by the balance 
between lipid soluble antioxidants and the availibility of oxidisable substrate and that 
TRAP is chiefly contributed to by water soluble antioxidants.Vitamin E is the major 
lipid soluble antioxidant and this balance can be represented by the ratio of the 
concentrations of vitamin E to cholesterol plus triglyceride termed the vitamin E status. 
A study was undertaken to test the hypothesis that:- individuals suffering from diabetes 
have lower vitamin E levels relative to levels of oxidisable lipids than do non-diabetics;
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or in other words, have lower vitamin E status which is in turn associated with evidence 
of greater lipid peroxidation in diabetes.
Plasma vitamin E status and TBARS concentration were determined in thirty five 
diabetic and twenty nine non-diabetic subjects. Vitamin E status was not significantly 
different in the diabetic and non-diabetic subjects (5.19(1.22) vs 5.48(1.03) /tM.mM \  
p=0.309). TBARS concentrations were significantly higher in diabetics than non­
diabetics (2.40(0.69) vs 1.67(0.63) /rmolMDA.L, p < 0.001) but did not correlate with 
vitamin E status. This study confirmed reports that increased lipid peroxidation occurs 
in diabetes but suggest that this is little influenced by vitamin E status. 
Epidemiological evidence suggests an inverse correlation between dietary antioxidants 
and the risk of atherosclerotic disease. Ten diabetics and non-diabetics took part in a 
study aimed at testing tlie hypothesis that:- vitamin C and vitamin E dietary 
supplementation increase the TRAP and vitamin E status of plasma respectively, and 
reduces lipid peroxidation in diabetics and non-diabetics. In addition to the effect of 
vitamin supplementation upon plasma TBARS the effect on copper stimulated oxidation 
of LDL isolated by ultracentrifugation was also assesed. Vitamin C, Ig per day, was 
associated with a rise in TRAP, a reduction in vitamin E status and possibly with a 
delayed rise in TBARS. These findings could be explained by a pro-oxidant effect of 
high dose vitamin C in individuals on a normal diet containing iron. Vitamin E, 300mg 
per day, was associated with a rise in vitamin E status, no change in TRAP, no change 
in several parameters of LDL oxidation but with a fall in TBARS. Altliough the latter 
result is consistent with a reduction in FR lipid oxidation in response to vitamin E 
supplementation several other explanations are discussed in the text. The presence of 
diabetes did not alter the response to vitamin supplementation.
Overall the studies in this thesis do not provide evidence for the contention that diabetes 
might be a state of excess FR lipid oxidation thus explaning its associated high risk of 
atherosclerotic disease.
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CHAPTER ONE
INTRODUCTION 
LOW DENSITY LIPOPROTEIN OXIDATION IN 
ATHEROSCLEROSIS 
AND THE INFLUENCE OF DIABETES.
1.1. CARDIOVASCULAR DISEASE RISK FACTORS AND DIABETES
Atherosclerotic cardiovascular disease (ACVD) is the major cause of death in the 
western world. For unidentified reasons, individuals suffering from diabetes are at 
even greater risk of being affected than non-diabetics (1,2). In diabetes, the 
underlying pathology of atheroma arises earlier and more extensively than in non­
diabetics (3). Thrombotic events which herald acute crises in the condition, such as 
myocardial infarction, occur more frequently in diabetic subjects, and tlie outcome 
of each event is more often fatal (4).
Many risk factors for atherosclerosis in the general population have been identified; 
the main factors being hyperlipidaemia, especially raised concentrations of low 
density lipoprotein (LDL), hypertension, smoking, age and male sex (5). The same 
risk factors are believed to operate in diabetes (6 ) except that the relative protection 
afforded to pre-menopausal women is lost in diabetic women (7). However, neither 
the fact that these risk factors do tend to cluster in diabetes (8 ) nor the fact that they 
may positively interact with diabetes (5,9) accounts for the excess risk associated 
with diabetes. Diabetes appears to be an independent risk factor (6 ).
Regardless of the combination of risk factors to which an individual is exposed, the 
underlying atheromatous pathology of cardiovascular disease is essentially the same. 
Similarly, histological studies of atheroma in diabetes have shown the pathology to 
be equivalent to that in non-diabetics (3). This suggests that the basic insults to the 
vessel walls are the same and that even if the different risk factors mark different 
causal mechanisms they may ultimately work tlirough a common pathway.
The association of a factor with a disease is not proof of causality but any proposed 
theory for tlie development of atherosclerosis will hold up only if it is also able to 
explain the associations. Current opinion increasingly favours a mechanism 
involving free radical (FR) oxidation of low density lipoprotein (LDL) as an early
17
event in the development of atheroma ( 1 0 ), hence this mechanism provides an 
explanation for the observed associations between LDL and atherosclerosis. In this 
thesis I explore the possibility that this mechanism is enhanced in diabetes, thereby 
explaining the greater risk of atheroma seen in association with diabetes. I also 
discuss briefly the possible links between LDL oxidation and other cardiovascular 
risk factors and so, the ability of this theory to tie all the major associations together 
when viewed as a final common pathway for the generation of atherosclerosis.
1.2. THE LOW DENSITY LIPOPROTEIN OXIDATION THEORY OF
ATHEROGENESIS
Many of the topics dealt with in this introduction will be expanded upon in later 
chapters but are discussed here to provide the background for the developement of 
the hypotheses explored in this thesis. Since free radical (FR) activity is an integral 
part of the proposed mechanism I will first summarise some relevant features of FR 
biology.
1.2.1. Free Radicals.
a  ^ The Nature of Free Radicals
FRs are atoms or molecules in which one or more electronic orbital contains a 
single, unpaired, electron. This concept can be more easily appreciated with 
reference to a schematic model of atomic structure (Fig 1.1.). Orbitals have an 
associated energy level and electrons fill them in accordance with two basic 
principles. Firstly, electrons fill orbitals from the lowest energy level up. Secondly, 
the magnetic properties of spinning electrons mean that electrons must have opposite 
spins to occupy the same orbital. Hence, no more than two electrons can exist in 
a single orbital and they must be of opposite spin.
When atoms covalently bond to form molecules, two atomic orbitals interact to form 
two new molecular orbitals; one "bonding" orbital of lower energy, one 
"antibonding" orbital of higher energy (Fig 1.1b). In forming the molecule, the 
electrons rearrange but fill the new molecular orbitals obeying the same principles 
as above.
In the figure, oxygen is used as an example. The oxygen atom, having 8  electrons 
(atomic number 8 ), has orbitals filled as shown (Fig 1.1.a.). Since it has two
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unpaired electrons it is a radical. A more stable state is reached when tlie oxygen 
atom has a filled outer electron shell similar to that of neon. It achieves this state 
by sharing two electrons as in H^O or 0%. In the 16 electrons fill the orbitals 
as indicated in Fig 1.1.b. Again there are two unpaired electrons so although 
more stable than O, is also a radical, in fact a biradical. If 0% is reduced by tlie 
acceptance of a single electron it remains a radical, namely the superoxide anion. 
This is represented as Og", the superscripted dot being the standard symbol 
indicating a free radical species. Two electron reduction of produces the non­
radical peroxide ion (Og^  ), however as the extra electron enters antibonding orbitals 
the 0 - 0  bonding is weakened helping to explain the reactivity of peroxide species. 
In biological systems, two electron reduction of usually results in hydrogen 
peroxide (H^O^) which can decompose to give two highly reactive hydroxyl radicals 
(OH).
Because their electronic arrangement is unstable, FRs are, on the whole, highly 
reactive, although the degree of reactivity varies from species to species. They can 
achieve increased stability by losing or gaining an electron and so are capable of 
oxidation or reduction, and so of initiating, and taking part in, chain reactions ( 1 1 ).
Free Radical Sources in vivo.
One of the first processes to be identified as a FR chain reaction was the 
rancidification of fats in vitro which involves their oxidation and peroxidation ( 1 2 ). 
Subsequently the critical role of FRs in much of polymer chemistry was recognised 
and revolutionised industrial chemistry, nevertheless it was believed, until relatively 
recently, that such reactive species could not possibly be tolerated witliin living 
organisms and so would not exist in vivo ( 1 1 ).
It is now recognised, however, that FRs arise in vivo as essential intermediates in 
many metabolic pathways, especially those which involve cycles of oxidation and 
reduction and that intermediary metabolism might actually be regarded as making 
use of their reactive features. Perhaps tlie best example of such a pathway is the 
mitochondrial electron transport chain which may be the major source of FR in vivo 
(13). Single electrons are transferred from one species to another within the chain, 
finally reducing O2  in a stepwise fashion to HgO. Such single electron transfer 
inevitably means that FR intermediates are formed but in general they remain 
enzyme bound, for example O2  and its partially reduced intermediates are bound to 
cytochrome oxidase. FR intermediates also arise during the enzymatic production
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of prostaglandins, thromboxanes and leukotrienes. During these reactions oxygen 
is incorporated into polyunsaturated fatty acids (PUFA) (14,15) and the isolated 
enzymes, prostaglandin endoperoxide synthetase and lipoxygenase, have been shown 
capable of generating and releasing into the medium (16). The oxidation 
reactions controlled by cytochrome P4 5 0  (13) are another source of FR in vivo. 
Since the FR intermediates in these pathways are tightly enzyme bound their further 
reactions are limited to those specified by the enzyme’s activity. However, some 
of the electrons being transferred are believed to escape or leak from their intended 
patli to react with any neighbouring molecule capable of acting as an electron 
acceptor, such molecules being termed oxidising agents, and such reactions 
inadvertently give rise to an unbound radical. Oxygen (Og), a bi-radical, is freely 
available and is a willing acceptor of single electrons which, as described above, 
results in the formation of the more active superoxide radical (Og") (Equation 1.1) 
(17). This radical can then react further giving rise to a family of reactive O2  
species including the non-radical hydrogen peroxide (H^Og) (Equation 1.2) and the 
very active hydroxyl radical (OH ) (Equation 1.3). This formation of OH", by what 
is called the Haber-Weiss reaction (Equation 1.3), would occur so slowly as to be 
biologically irrelevant, however, this reaction is greatly catalysed by transition 
metals, especially ferrous iron (Fe^^).
E quation  1 .1  Og + e  “ -  Og
E quation  1 .2  + O f  + O f  HgOg + Og
E quation  1 .3  HgOg + Og -  OH + OH + Og
Transition metal ions are actually FRs and the ease witli which they change valency 
allows them to catalyse the formation and interconvertion of these reactive oxygen 
species and gives them a central role in FR biology (Fig 1.2) (17). In addition to 
reactions with H 2 O2 , transition metals can react with other organic peroxides, giving 
rise to a series of oxygen centered radicals (Fig 1.2) The binding of transition 
metals in protein complexes such as transferrin and caeruloplasmin may partially, 
but not completely, restrict tliis catalytic activity (15). FR are also produced in vivo 
during the spontaneous oxidation of molecules such as haemoglobin, catecholamines 
and even glucose itself (13,18).
In addition to their existence as both useful intermediates and inadvertent by­
products of enzymatic and non-enzymatic reactions, FR’s are also the intended end
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product of a few reactions thus neutrophil NADPH Oxidase produces a superoxide 
radical to take part in bacterial killing (19). However even when production is 
intended, inappropriate or excess release of FR by activated neutrophils may add to 
the tissue damage associated with infective and inflammatory processes (19,20).
A pathological situation in which increased FR production is believed to occur, and 
then contribute to tissue damage, arises in association with ischaemia. There is 
increasing evidence that during periods of tissue ischaemia changes occur which 
allow for the formation of reactive oxygen species when Oj is reintroduced to the 
system. These changes may include release of iron from storage proteins, altered 
substrate specificity of Xanthine Oxidase, and a build up of hypoxanthine. When 
is returned to the system, hypoxanthine is metabolised by Xanthine Oxidase, 
resulting in Oj" production (21,22,23).
Çi Free Radical Defensive Mechanisms
Inevitably such reactive species are potentially hazardous and for FRs not generated 
in a controlled, restricted environment, protective mechanisms have evolved. 
Indeed, perhaps as evidence of their potential escape, and biology’s perception of 
them as a possible threat, many aerobic organisms have been found to have an 
enzyme. Superoxide Dismutase (SOD) (24), with no apparent role other than 
removal of O  ^' which is done by catalysing its dismutation to H^O^ (Equation 1.4).
Equation 1.4 O2" + + 2H+ -  HgOg + Og
H2 O2  is not an innocuous substance and when generated in this, and other reactions, 
it is in turn removed by Glutathione Peroxidase and Catalase (Fig 1.3.) (17). 
Selenium (Se) is necessary for the activity of Glutathione Peroxidase and glutathione 
(GSH) is a co-substrate in this reaction being oxidised, and so temporarily 
inactivated, during this process. GSH is then reduced and reactivated by a NADPH- 
dependent reductase. NADPH is thus the ultimate antioxidant in this series of 
recycling reactions (Fig 1.3) and its availability is determined by the balance 
between the activity of processes during which it is produced and during which it 
is utilised. The pentose phosphate pathway is an important source of NADPH. The 
polyol pathway, a pathway believed to be more active in diabetes, is among many, 
a net user of NADPH (25). The significance of an imbalance in these pathways in 
terms of antioxidant reserve in diabetes is discussed further in section 1.3.2.
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In addition to these enzymatic defenses, non-enzymatic protective mechanisms 
against FR activity are also available. Exogenous species such as the vitamins E, 
C, and A, and 6 -carotene, and endogenously generated molecules such as uric acid, 
bilirubin and the thiol groups on proteins, can act as antioxidants reacting with and 
inactivating FRs (26-30). Many of these species have roles in metabolism in 
addition to that of antioxidant however no otlier role has been identified for vitamin 
E.
i .  Consequences Of Unwanted Free Radical Activity
Should all of these defensive mechanisms be overwhelmed FRs would theoretically 
be capable of reacting with endogenous lipids, proteins, nucleic acids and 
carbohydrates thus altering their ability to function. As frequently reviewed, the 
potential consequences are legion; from changes in membrane fluidity and fiinction, 
to effects on cell division and repair mechanisms (11,15,17), As a result, FR 
activity has been implicated in many disease processes, such as rheumatoid arthritis, 
carcinogenesis, emphysema and including atherosclerosis. The consequences of FR 
attack on lipids, and in particular lipids within LDL, are of most immediate interest 
in this thesis and are dealt with in more detail in chapter three. Such attack on the 
most vulnerable of the lipid classes, namely the polyunsaturated fatty acids (PUFA), 
gives rise to several detectable oxidation products (Fig 3.1). Diene conjugated fatty 
acids (DCFAs), produced by changes in electronic structure, have a typical UV 
absorption peak, allowing their spectrophometric detection (31). Other changes in 
chemical structure give rise to species such as hyproperoxides and malondialdehyde, 
detectable by their reaction with thiobarbituric acid (thiobarbituric acid reactive 
substances (TBARS)) (32). Both DCFAs and TBARS are detectable in biological 
samples,implying tliat tliese reactions also occur in vivo, and so concentrations of 
these compounds are used as markers of FR activity in vivo (Fig 3.1).
1.2.2. Modification Of Low Density Lipoproteins And Foam Cell Generation
Having described some of the salient features of FRs, I will now discuss their role 
in LDL oxidation and its relevance to atlierosclerosis.
(L Formation Of Foam Cells.
Epidemiological and pathological evidence has long implicated low density
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lipoprotein (LDL) as pivotal in the generation of atheroma (33). However, until 
recently, the mechanisms proposed to explain the connection have not been 
persuasive. An early pathological feature of atheroma is tlie foam cell. Foam cells 
are mainly monocyte-derived macrophages laden with cytoplasmic lipid droplets 
(34). The lipid present in a foam cell is derived from plasma LDL (35). 
Macrophages have specific receptors for LDL which recognise sites on the 
apoprotein B component of the LDL particle and are referred to as the Apo-B 100 
receptors. Macrophage cholesterol content is an equilibrium between cholesterol 
uptake from LDL bound by this receptor, its de novo synthesis and its release from 
cells. This balance is normally maintained by down regulation (negative feedback) 
on the receptor and on cholesterol synthesis when the cell is replete with cholesterol 
(36). Thus this method of lipid uptake by macrophages could not explain the 
overloading required to generate foam cells. In keeping with this observation, 
macrophages cannot be converted to foam cells in vitro even when exposed to very 
high concentrations of LDL (37). In addition, individuals suffering from familial 
hypercholesterolaemia, who have a hereditary lack of frmctional classical LDL 
receptors (38), nevertheless do form foam cells which contain LDL derived 
cholesterol and are subject to even greater risk of atherosclerosis than the general 
population (39). Therefore, the lipid loading of macrophages in vivo inferred the 
involvement of pathways other than the classical pathway for LDL uptake.
K Modification Of Low Densitv Lipoprotein.
This possibility of alternative uptake pathways of LDL-cholesterol was supported 
when a chemical modification of LDL in vitro, namely acétylation of Apo-B e-amino 
groups, was noted to result in accelerated macrophage LDL uptake and foam cell 
formation (37). This uptake was saturable and not inhibited by native LDL, 
implying the involvement of a receptor distinct from the Apo-B 100 LDL receptor. 
This new receptor was called the acetyl or scavenger receptor. Other modifications 
of LDL have subsequently been found which allow uptake by this patliway (40). It 
is now also recognised that more than one scavenger receptor exists (41). Uptake 
by these receptors is not subject to down regulation, and hence would enable foam 
cell formation in vivo if LDL modification occurred in vivo. The discovery that 
LDL incubated with endothelial cells, smooth muscle cells or fibroblasts, could 
result in a modification which also allowed uptake via scavenger receptors made in 
vivo modification more probable (42,43).
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Cell mediated modification is not, however, a simple protein acétylation. The 
modified LDL formed has been characterised and is chemically, physically and 
functionally different from native LDL (10,43,44). Among its many chemical 
differences it contains oxidised derivatives of the lipid component including lipid 
hydroperoxides (45). As mentioned earlier, lipid oxidation is a FR, peroxidative, 
process in vitro (11). There is now a large body of evidence suggesting that cell 
mediated LDL modification also intimately involves, and indeed is initiated by, FR 
oxidation of the lipid component. Transition metals catalyse FR lipid oxidation and 
are necessary in trace amounts for cell mediated modification (45) also if LDL is 
exposed to Cu^  ^ or Fe^^ in a cell free system the modified LDL which results has 
similar characteristics to cell modified LDL (45,46). Other conditions associated 
with FR generation, such as steady state radiolysis, also result in LDL oxidation and 
an LDL modification similar to that induced by cells (47). Also it has been found 
that the ability of cells to modify LDL related to their ability to generate Og and 
that FR scavengers and superoxide dismutase inhibit cell mediated modification of 
LDL (43,44). All of these findings suggest that cell mediated modification is also 
a free radically mediated oxidative process. The alterations in the protein 
component of LDL are believed to be secondary to this lipid oxidation in that the 
lipid peroxide products ultimately breakdown to a series of aldehydes which react 
with and lead to derivitization of the protein lysine residues (48). It may be that 
these secondary changes in the protein component of LDL which alters it’s receptor 
interactions and so macrophage uptake. Apoprotein B is also fragmented in the 
modification process, with reduction of its lysine, histidine and proline content 
(47,48). In addition to acting as a possible source of FRs the cells capable of 
oxidising LDL may do so via a second mechanism. Cellular lipoxygenase activity 
has been shown to have a possible role in endothelial cell oxygenation of LDL and 
it may be that lipids enzymatically oxidised within cells are transferred to LDL 
where they can then fiirter react in the presence of transition metals (49). A 
phospholipase Ag, cleaving oxidised lipids from the second carbon of 
phosphatidylcholine, also has been shown to be involved in the cellular modifacation 
of LDL but the exact role that it plays is not yet clear (10,45,50).
Çi Consequences Of Low Densitv Lipoprotein Modification.
The oxidative chemical changes of LDL are associated with typical physical changes 
in density and charge, and with many functional changes. In addition to the altered
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uptake of oxidised LDL by macrophages which allows foam cell formation (42), an 
ever increasing number of other activities theoretically of importance to 
atherogenesis are also being ascribed to oxidised LDL. For example it has been 
found to be immunogenic (51), chemotactic for monocytes, and cytotoxic to 
endothelial, smooth muscle cells and fibroblasts (52). In addition the lipid peroxides 
in which it is enriched may alter eicosanoid metabolism, and so haemostatic and 
fibrinolytic mechanisms (53). Since platelets appear to have a role in the 
development of atherosclerosis and their aggregation is closely linked to eicosanoid 
metabolism (54) any ability of oxidised lipids to modify eicosanoid metabolism raises 
the possibility that alteration in platelet function might be another mechanism 
whereby oxidised lipids could enhance atherosclerosis. Furthermore fibrinolysis 
may also be impaired by the endothelial cell syntliesis of plasminogen activator 
inhibitor (PAI) which has been shown to be stimulated by oxidised LDL (55). Other 
endothelial cell flinctions, such as endothelial cell induced vascular relaxation, may 
also be altered by oxidised LDL (56,57).
di Oxidised Low Density Lipoprotein in vivo.
Although several cell types can induce modifications of LDL capable of supporting 
foam cell generation in vitro it cannot be assumed that such reactions occur in vivo. 
However, in support of this possibility is the finding of evidence indicating the 
existence of oxidised LDL in vivo. Autoantibodies to oxidised LDL have been 
found in human serum (51,58). Moreover, antibodies raised to oxidised LDL stain 
rabbit aortic atherosclerotic lesions (51,59) and oxidised LDL can be eluted from 
such lesions (51). In addition, LDL gently extracted from human and rabbit 
atherosclerotic plaques was found to have density, electrophoretic mobility and 
alterations in cholesterol and apo-B comparable to those reported for in vitro 
oxidised LDL (60,61). Also, lesion LDL and oxidised LDL were taken up and 
degraded by macrophages using the scavenger receptor whereas native LDL was not 
and lesion LDL was chemotactic for macrophages (60).
The oxidised LDL discussed so far is a highly modified form of LDL, explaining 
its marked functional difference from native LDL and the evidence for its existence 
in atherosclerotic lesions is as cited. However, this highly modified species is not 
found circulating in plasma and current opinion is that it is probably only formed 
extravascularly (9). On the contrary tlie term "minimally modified LDL" has been 
adopted to describe an oxidised LDL which is found in plasma and which contains
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small, but detectable, concentrations of TBARS, but in which the apo-B is not 
modified. Minimally modified LDL is thus still recognised by the apoB-100 
receptor (62), is not immunologically different from native LDL and does not 
support foam cell generation. Nevertheless, minimally modified LDL may be 
important in the even earlier stages of atherogenesis, as it has been shown to induce 
endothelial cells to produce macrophage binding, chemotactic and colony stimulating 
factors (63,64). Minimally modified LDL could then be responsible for the initial 
movement of macrophages into the intima. Once there, macrophages would 
contribute to the further oxidation of extruded LDL and eventually, foam cell 
generation takes place. Further progression of the early fatty streak to advanced 
atherosclerotic lesions may be enhanced by the cytotoxic and immunogenic features 
of highly oxidised LDL (9). The source of minimally oxidised LDL is not 
established but dietary lipids are oxidised to varying degrees and so diet may be one 
source.
1.3. LOW DENSITY LIPOPROTEIN OXIDATION IN DIABETES.
As outlined in the previous section, FR oxidation of LDL does seem an attractive 
mechanism to explain both the development of tlie foam cell and the association 
between LDL and atheroma, but can it explain the associations with the other risk 
factors, particularly diabetes? Is there any reason, or evidence, to suspect that more 
undesirable LDL oxidation might occur in diabetes? Using the indirect approach of 
measuring concentrations of products of FR attack on endogenous molecules, some 
evidence of excess oxidation in diabetes does exist. Lipid peroxides are one of the 
products of attack on lipids and are most frequently measured as TBARS. Plasma 
TBARS have been reported to be higher in diabetic subjects than controls by many 
groups (65-67). However, there is some debate as to the independence of diabetes 
in producing this effect since it is also reported that diabetic subjects without 
angiopathy had plasma TBARS not significantly different from controls (67). Also, 
Velàzquez et al reported no independent correlation of TBARS with measures of 
glycaemia (67). On the other hand, Jain et at found that in a group of diabetic 
children erythrocyte membranes had a higher TBARS content compared to controls 
and that TBARS content did correlate with HbAj^ (68). Other diabetic tissues have 
also been found to have increased TBARS. Cataractous lenses from diabetic subjects
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were found to have greater TBARS than lenses bearing senile cataracts or clear 
lenses (69).
Another consequence of FR attack on lipids is the formation of diene conjugated 
fatty acid species (DCFA). These have also been reported to be elevated in diabetics 
with angiopathy (70). However, Collier et al reported reduced DCFA in a group 
of uncomplicated insulin-dependant diabetic subjects (71). This contradiction may 
be partially explained by the possibility that DCFAs within tissues do not arise solely 
as a result of FR activity (72). DCFAs exist in dietary compounds and so diet may 
be a confounding source. Products of FR attack on molecules other than lipids, 
such as proteins (73), are less well characterised, however, it is possible that the 
changes in proteins seen in diabetes, and attributed solely to glycosylation, partially 
reflect such attack (74, 75). Such protein changes may be further evidence of 
greater FR oxidative damage in diabetes (75).
If, as is suggested, these differences mean that more FR oxidation does occur in 
diabetes it begs the question why? More oxidation could occur in circumstances 
of ;~
(1) more FR generation,
(2) reduced availability of protective mechanisms or
(3) greater availability of oxidisable substrate.
I would like to discuss each of these possibilities in turn.
1.3.1. Free Radical Generation In Diabetes
In very general terms diabetes can be considered a disorder of intermediary 
metabolism resulting from impaired action of insulin. The basis of tliis impairment 
may not be the same in the two major types of diabetes. Insulin deficiency is 
accepted as the basic abnormality in Type 1 diabetes but it is currently debated 
whether absolute or relative insulin deficiency and/or insulin resistance with 
hyperinsulinaemia is the underlying problem in Type 2 diabetes (76-79). Part of the 
difficulty in fesolving this debate has arisen because of the lack of specificity of 
older insulin assays but with the advent of newer more specific techniques this issue 
may soon become clearer (79,80). Nevertheless, individuals suffering from both 
types of diabetes are at greater risk of atherosclerosis than non-diabetics (81, 82). 
In Type 1 diabetes the increased risk of mortality from coronary heart disease is 
most marked in those subjects with nephropathy (83, 84). However, those without
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nephropathy have also been shown to experience a greater risk than the non-diabetic 
population (83). The coronary heart disease mortality rate in Type 2 diabetic 
subjects has been estimated as 2 to 4 times greater than that in non-diabetic subjects
(2). Since both types of diabetes are associated with coronary heart disease it is 
reasonable to look for factors common to both to explain the association. Even if 
abnormalities of insulin concentration per se may not be common to both types of 
diabetes impaired insulin action, and some of its metabolic consequences, is. In 
both types of diabetes, whether the problem is insulin deficiency or resistance, 
impaired insulin action is accompanied by major alterations in many metabolites, 
including the pathognomonic rise in plasma glucose and the consequent excess of 
non-enzymatic glycosylation of structurally and functionally important 
macromolecules (85, 86). It has always been tempting to try to ascribe the 
complications of diabetes to these metabolic alterations, especially to hyperglycaemia 
as the most prominent and universal abnormality. Microvascular complications do 
seem to be closely associated with hyperglycaemia (87) but the picture is much less 
clear when considering atherosclerosis. As I will describe below, I would like to 
speculate that looked at from a FR point of view the links between hyperglycaemia, 
and some other fundamental metabolic abnormalities of diabetes, and atherosclerosis 
might be more clearly seen and this approach also allows for the fact that both types 
of diabetes are associated witli atherosclerosis.
The ultimate aim of intermediary metabolism is to provide the energy for all 
functions necessary to maintain life. High energy phosphate bonds, predominantly 
in adenosine triphosphate (ATP), but also in guanosine triphosphate (GTP), are the 
immediate source of that energy. Their generation is a basic fiinction of 
intermediary metabolism and is coupled mainly to reduction of in the 
mitochondrial electron transport chain, in turn powered by the oxidation of organic 
fuels in the form of carbohydrates, fats and proteins. Theoretically, the stoichiometry 
of tills overall reaction can be determined and is such that the most efficient 
generation of ATP comes about when glucose is oxidised via glycolysis and the 
citric acid cycle. When this is the case 3 moles of ATP are produced for every 
mole of oxygen reduced. When fats are oxidised this number is reduced to 2.8 
moles of ATP per mole of O2  (88). Another way of expressing this is in terms of 
the energy produced per litre of consumed whilst oxidising different fuels. 
Indirect calorimetry shows again that more energy is derived per litre of O2  when 
oxidising carbohydrate than when oxidising fats (89). The consequence is that,
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should circumstances arise in which relatively more fat oxidation occurs in order to 
maintain energy supplies, then, more electrons would have to move through the 
electron transport chain. Since this chain is possibly the major source of FR 
production, increased fat oxidation might result in increased FR load. Because FRs 
initiate chain reactions, only a relatively small change in absolute FR production 
would have disproportionately large consequences. There is evidence that more fat 
oxidation does occur in both types of diabetes. In hyperglycaemic, non-obese, non­
insulin dependent diabetic subjects lipid oxidation was found to be greater than in 
controls using indirect calorimetry (90). In poorly controlled insulin dependent 
diabetes excess oxidation of fat is a classic feature (25). Why fat oxidation is 
increased in diabetes may result from several mechanisms and is closely linked to 
glucose metabolism. In fact, carbohydrate and fat oxidation are regulated such that 
effects upon one are frequently associated with reciprocal effects on the other. 
Insulin stimulates several of the steps involved in glucose oxidation but inhibits 
oxidation of fat (25, 91). Also, operation of the Randle cycle means that greater 
oxidation of fat is associated with reduced carbohydrate oxidation and vice versa 
(92). This cycle would allow a vicious circle of falling carbohydrate oxidation and 
rising lipid oxidation to arise. Such reciprocal regulation may help to explain the 
inverse relationship between glucose and lipid oxidation reported in non-obese 
NIDDM subjects (93, 94). In addition to reports of increased fat oxidation, it is also 
reported that glucose oxidation is reduced in diabetes (94, 95). Although it is 
recognised that the development of hyperglycaemia, by a mass action effect, may 
return glucose oxidation towards normal in NIDDM (93, 96), it has also been 
reported that even in the presence of hyperglycaemia, glucose oxidation remains 
impaired (94). Hence, there is evidence that energy production in both types of 
diabetes may be associated witli a shift in the ftiels used, with more fat oxidation and 
less glucose oxidation (97, 98).
Assuming that diabetic subjects require at least the same amount of ATP as their 
non-diabetic counterparts, and if they are oxidising more fat to obtain it, then, as 
argued above, this may be one source of excess FR load in diabetes. The situation 
may even be further exacerbated as their is evidence that diabetes is associated with 
increased resting energy expenditure, and so ATP requirements, perhaps because 
ATP is consumed during gluconeogenesis which occurs to excess in diabetes (90, 
99).
Another of the basic features of diabetes is non-enzymatic glycosylation of
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macromoiecules. The initially reversible product of the reaction between glucose 
and protein lysine groups undergoes many rearrangements via a stable Amadori 
product to a denatured, fragmented macromolecule which can not function normally 
and contains cross-links and fluorescent structures. The exact nature of these final 
products is not clearly known but they are referred to as advanced glycosylation end 
products (AGE) (86). It was felt that these chemical and functional changes were 
the direct consequence of glycosylation and might be involved in the 
pathophysiology of the complications of diabetes (85, 86, 100). However, the end 
products thought typical of protein glycosylation can also be produced by FR attack 
upon proteins (73) and more recently it has been realised that glycosylation may 
actually involve FR mechanisms (75, 101).
Glucose oxidises in the presence of Og and transition metals to a ketoaldehyde 
accompanied by the production of H^Og (74) and OH" (18, 102). During 
experiments in which albumin was incubated with glucose it was found that when 
glucose oxidation was inhibited, by chelating agents such as diethylenetriaminepenta- 
acetic acid (DETAPAC), then glucose incorporation into albumin was reduced 
although not completely inhibited. Also it was found that preformed ketoaldehyde 
could react with protein, leading to glucose incorporation (73). These findings 
suggested that more than one mechanism may be involved in glycosylation and that 
some glycosylation results from the direct reaction of glucose with protein whilst a 
proportion of the glycosylation which occurs requires the oxidation of glucose and 
then the reaction of the resulting ketoaldehyde with protein. Consistent with such 
a theory is the finding that glycosylated haemoglobin formation is reduced by the 
presence of antioxidants (103). In addition, when OH' radicals, also a product of 
glucose oxidation, were scavenged by sorbitol, then glycosylation was found to 
occur but the development of conformational changes and protein fragmentation did 
not. This suggested that glycosylation could be dissociated from these other changes 
and that they are not a direct consequence of glycosylation but involve further 
reactions which require the presence of OH (18). Hence, glucose oxidation 
provides a ketoaldehyde, which contributes to glycosylation, and FRs, which induce 
the fragmentation and conformational changes in proteins exposed to glucose. There 
is also evidence that the early products of glucose and ketoaldehyde linkage to 
proteins go on to ftirther oxidise, with formation of yet more FRs capable of 
contributing to the damage done (18, 104). In keeping with these findings 
glycosylated proteins have been shown capable of production (105), and this
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may explain the reported greater production of that ion by diabetic plasma (106). 
Singer et al argue that the lack of association seen over the years between 
atherosclerosis and plasma glucose is due in part to inadequate measures of 
glycaemia. This seemed consistent with their finding that when glycosylated 
haemoglobin (HbA^J, believed to be a good measure of overall long term glycaemia 
was used, an association between the prevalence of cardiovascular disease in the 
female survivors of the original Framingham study cohort and HbA^^ was found 
(107). HbAi^ is a measure of glycaemia but if i f  s formation is also determined by 
FR mechanisms, as suggested above,then perhaps HbAj^ relates better to 
atheromatous complications because it is a "marker" of two of the processes 
important in the development of those complications or of tlie one process directly 
involved.
As already mentioned, eicosanoid metabolism may be another source of FRs in vivo 
and is also perturbed in diabetes (54, 108-110). Eicosanoids may influence 
atherogenesis in several ways (111, 112), one mechanism may operate through 
platelet aggregation. Platelet aggregation is controlled by platelet and endothelial 
eicosanoids so tliat diabetes related alterations in eicosanoid metabolism offers one 
possible explanation for the enhanced platelet aggregation found in diabetes (110, 
113). Platelet aggregation per se has been attributed a role in the generation of 
atherosclerosis however, I would like to speculate that in addition the increased 
thromboxane production reported in diabetic platelets means increased production 
and release of Og with its attendant implications for atlierosclerosis and this 
possibility is discussed further in chapter four. Such an interplay between 
release and eicosanoid formation has been suggested by work on glomerular 
monocyte/macrophages isolated from nephritic rat kidneys (114).
Yet another source of FR is the respiratory burst of activated neutrophils, and it has 
been shown that mononuclear cells from hypertriglyceridaemic diabetic subjects 
produce more superoxide tlian those from controls (115) although no explaination 
for this phenomenon was found.
1.3.2. Free Radical Protective Mechanisms In Diabetes
In addition to excess generation of FR species, a second situation in which more FR 
oxidation of LDL could occur is where protective mechanisms are reduced. In 
diabetes, along with less efficient glucose utilization in insulin sensitive processes,
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by a mass action effect in the face of hyperglycaemia more glucose is shunted 
through alternative pathways and this can have secondary effects on FR activity via 
the protective mechanisms. For example, excess flux of glucose through the polyol 
pathway occurs in diabetes (116, 117). Aldose reductase is the rate limiting enzyme 
in this pathway and converts glucose to sorbitol using NADPH as reductant (25, 
116). Hence the over-activity of this pathway in diabetes results in greater 
consumption of NADPH (116, 117). As already indicated, NADPH is necessary for 
the reduction of glutathione and thus for its reactivation as an antioxidant (Fig 1.3). 
Thus the normal redox recycling of antioxidants may be deficient in diabetes 
exposing subjects to the risk of FR damage even in the face of unaltered FR 
generation.
Reduced plasma levels of vitamin C have been reported in diabetic humans (119, 
120) and rats (121, 122), as have reductions in the levels of protein thiol groups and 
the protective enzyme Superoxide Dismutase (123, 124). Karpen reported reduced 
platelet levels of vitamin E (125) and Chari reduced glutathione concentration in 
polymorphonuclear leucocytes (126). However, measurement of only one, or a few, 
of these protective factors is not without its problems. One of these problems is that 
interaction and synergy between the factors may mean that they can compensate for 
each other’s deficiencies, so that an overall measure of antioxidant activity would 
be more informative. Wayner et al (127) described such an assay and determined 
the total peroxyl radical antioxidant activity of plasma (TRAP). The TRAP assay 
measures the ability of plasma,and its contained antioxidants, to inhibit attack on 
linoleic acid by peroxyl radicals, produced by the thermal decomposition of a known 
radical source, 2,2’-azo-bis(2 amidinopropane) hydrochloride (ABAP). The TRAP 
assay is discussed further later and has been used in several of the studies presented 
in this thesis.
1.3.3. Oxidisabilitv Of Low Density Lipoprotein In Diabetes
In addition to excess FR production and impaired protective mechanisms, a third 
situation in which excess FR damage to LDL might be expected to occur in diabetes 
would be the presence of greater quantities of LDL or the appearance of LDL 
altered in such a way as to make it more easily oxidised. LDL particles are a 
composite of proteins, lipids and antioxidants (128). Alterations in any of these 
components could enhance the particles’ oxidisability. Some alterations have already
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been observed in diabetes and are discussed below, but their effects on oxidisabilty 
await exploration.
Dyslipidaemias do occur in diabetes and differ depending on the sex of the patient, 
the type of diabetes and the degree of control. However, LDL levels are not 
typically abnormal, diabetes being more commonly associated with 
hypertriglyceridaemia and low HDL concentrations (82). Therefore, simply 
increased availability of LDL would not offer an explanation for the possibility of 
enhanced LDL oxidation in diabetes.However glycosylation of LDL apoproteins has 
been reported in diabetes (129) and, bearing in mind the possible links between 
glycosylation and oxidation, may enliance LDL oxidation. Consistent with this idea 
exposure of LDL to glucose in vitro resulted in the appearance of lipid peroxidation 
products (102, 130), this being inhibited in the presence of DETAP AC (102). 
Apart from possibly increasing tlie risk of oxidation of LDL, glycosylation of LDL 
per se has been reported to have other consequences of relevance to atherosclerosis 
(131). Whilst attempting to dissociate glycosylation from oxidation others report 
tliat glycosylated LDL enhances macrophage accumulation of cholestyl ester in its 
own right (131, 132). A receptor distinct from the classical LDL receptor and the 
scavenger receptor may be involved. Also, glycosylated LDL alters platelet and 
endothelial eicosanoid metabolism in ways which are believed to increase 
atherosclerotic risk in tliat platelet thromboxane production was increased and 
endothelial cell production of prostacyclin reduced (133). Glycosylation of LDL 
also seemed to be responsible for the greater ability of diabetic LDL to stimulate 
platelet aggregation (134).
Apart from glycosylation, diabetic LDL has also been shown to differ 
compositionally in several ways from non-diabetic LDL. One aspect of LDL 
composition which is altered is the ratio of lipid to apoprotein content (135, 136). 
These ratios help to determine the particle size and density and it has been shown 
in non-diabetic populations that small, dense LDL particles are associated witli 
increased risk of myocardial infarction (137). Small, dense LDL particles have been 
reported in both type 1 and type 2 diabetes (138, 139). The reason why such 
particles might be associated with increased risk of atherosclerosis is unknown but 
Austin et al (137) argues that they are not an independent risk factor and merely 
mark other atherogenic features such as hypertriglyceridaemia and low HDL. The 
effect of LDL particle size and density distribution upon LDL oxidisability is 
debated (140,141). Studying the susceptability of isolated fractions of LDL to
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copper stimulated oxidation groups such as that of Rengstrom et al (140) have 
suggested tliat size and density are not important determinants of oxidisability but 
found an association between LDL triglyceride content and the susceptibility to 
oxidation. Interestingly, tliere are reports of triglyceride enrichment of LDL in 
diabetes (136, 138, 139), and in both diabetics and non-diabetics with coronary heart 
disease (142). However, other groups, for example Tribble et al (141) have 
reported that the susceptibility of LDL to oxidation does increase witli increasing 
density of the LDL particle. There are several differences in the conduct of these 
studies by Rengstrom and Tribble which might explain their apparently contradicting 
results. One difference is that although both investigate the copper induced 
oxidation of isolated LDL, they measure different parameters to assess susceptibility 
to oxidation. One measures the lag time before oxidation starts (140), the other 
measures time taken to reach half maximal oxidation (141). Which of these 
parameters is the most important pathophysiologically is not known and they may 
be governed by different features of LDL. This problem is discussed fiirther in 
sections 6.6.2 and 8.1.1. Also, in the Rengstrom study, LDL was provided by men 
with coronary artery disease and separated into only two fractions, whereas Tribble 
isolated LDL from healthy controls and separated it into six fractions.
Vitamin E and otlier lipid soluble antioxidants are also an integral component of 
LDL particles (46, 143, 144). If antioxidant content were lower relative to 
oxidisable substrate, such as polyunsaturated fatty acids and cholesterol, this might 
be expected to expose LDL to increased risk of oxidation. The appropriateness of 
vitamin E levels in diabetes is not clear. Karpen et al (109) found plasma vitamin 
E levels to be normal in diabetics but did not correct for the elevated levels of lipids 
in their subjects and it is now recognised that vitamin E levels are really only 
interpretable in the light of plasma lipids (145). As noted earlier, vitamin E levels 
relative to platelet number were found to be lower in diabetics (125). The 
appropriateness of vitamin E concentrations in diabetics is dealt with further in 
chapter seven and it’s effectiveness in protecting against lipid oxidation discussed in 
chapter eight.
The last component of LDL particles I want to discuss in terms of oxidation are the 
lipids themselves. One of the major types of lipid in LDL are the fatty acids 
esterified within cholesterol esters, triglycerides and phospholipids. Of these, the 
polyunsaturated fatty acids (PUFAs) are more vulnerable to FR attack than 
monounsaturated (MFAs) or saturated fatty acids (SFAs) (146). A rise in the
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PUFA:SFA ratio of LDL might, therefore, be expected to increase its oxidisability 
and vice versa. This seemed to be confirmed by the finding that enriching LDL 
with oleic acid, a MF A, and reducing its content of linoleic, a PUFA, resulted in 
resistance to oxidation in vitro (146). Relatively little is known about the 
PUFA:SFA ratio of serum lipid in diabetes but, since fatty acid metabolism is 
abnormal in diabetes (128, 147), it would not be surprising if the ratio were 
perturbed. The information actually available is conflicting. Faas et al, studying 
non-insulin dependent diabetic sujects (NIDDM), reported no difference in the fatty 
acid composition of diabetic erythrocytes or plasma, compared to controls (148), 
whereas Taylor et al reported higher linoleic acid and lower arachadonic acid 
content of erythrocyte membranes but, again, normal plasma fatty acid profiles in 
insulin dependent (IDDM) subjects (149). More recently, Pelikânovd reported 
reduced levels of the essential fatty acids, linoleic and linolenic acid, and increased 
levels of their desaturated derivatives in the plasma and erythrocyte phospholipids, 
and plasma cholesterol esters, of NIDDM subjects (150). These differences could 
be explained in terms of the presumed action of insulin on FA metabolism, as insulin 
is believed to stimulate desaturase enzymes (150, 151) hence allowing, for example, 
the conversion of linoleic acid to arachadonic acid. Therefore it was proposed that 
in the relative insulin deficiency of IDDM such conversions would be reduced 
whereas, assuming that the insulin resistance of NIDDM applies less to FA 
metabolism than to glucose metabolism, in the hyperinsulaemia of NIDDM this 
mechanism would actually enlianced (150). If this were correct, NIDDM subjects 
would be more likely to have highly unsaturated, oxidisable, lipids in their 
lipoproteins then IDDM subjects. Although I have emphasised the similarities 
between NIDDM and IDDM with regard to atherosclerosis and so have argued that 
metabolic abnormaliteis in common to the two conditions are needed to explain their 
common association with atherosclerosis there are differences in the pattern of 
presentation of atherosclerosis in IDDM and NIDDM. Biochemical differences such 
as that proposed for PUFA metabolism would offer an explaination for the 
dissimilarities also in terms of FR mechanisms.
However, the whole idea that an increased PUFA:SFA in LDL might be 
disadvantageous seems at odds with epidemiological evidence that a rise in this ratio 
in the diet and tissues confers protection from vascular disease (152-154) and that 
diets high in saturated fats are associated with atherosclerosis. This anomaly may 
be explained by the fact that PUFAs cannot be regarded only as substrates for non-
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enzymatic FR oxidation, nor can they be treated as one amorphous entity. There 
are many different PUFAs derived from the diet or synthesised from the two 
essential fatty acids, linoleic and linolenic acid (151). On the basis of structural 
similarities, and hence similar biochemistry, they fall into groups, linolenic acid and 
its derivatives comprise the Omega-3 group, linoleic acid, and derivatives, the 
Omega-6 group. Each PUFA has a unique function or set of fonctions, being more 
than passive structural components or sources of energy (155). They have roles in 
membrane structure and fluidity, potentially altering the function of cells (156). As 
substrates in enzymatic processes, they are converted to metabolically active 
substances such as thromboxanes and prostacyclins which help in the control of 
thrombosis, fibrinolysis and platelet function, processes also believed to be relevant 
in atherogenesis (157). Their influence on eicosanoid metabolism may also be 
involved in their ability to lower blood pressure (158). They have also been 
reported to influence plasminogen activator inhibitor and fibrinogen levels (159, 
160). Lipoprotein metabolism is also influenced by PUFAs, especially those of the 
Omega-3 series (161) which consistently lower VLDL-triglyceride levels (162,163) 
although have less predictable effect on HDL and LDL levels (164,165). In non- 
diabetic subjects Omega-3 fatty acids also generally lower LDL concentration 
however in diabetics they may cause deleterious changes in LDL and glycaemic 
control (166-168).
Thus, whilst PUFAs are generally more oxidisable, and so tlieoretically more 
atherogenic, this effect may be completely confounded by the complicated balance 
of their specific effects on other factors important in the genesis of atheroma. 
However all of these effects may need to be considered if manipulations of 
PUFA:SFA ratio are to be attempted in efforts to reduce atherogenesis (169) and the 
need for caution is suggested by work such as that of Brown et al who showed that 
PUFA supplementation, in the form of fish oil concentrate (Maxepa), was associated 
with evidence of increased lipid peroxidation (TBARS) in normal subjects. Their 
work also suggested that unless accompanied by vitamin E supplementation, PUFA 
could actually cause increased whole blood aggregation and elevation of plasma 
glucose (170).
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1.4. LOW DENSITY LIPOPROTEIN OXIDATION IN RELATION TO
ATHEROSCLEROTIC RISK FACTORS OTHER THAN DIABETES.
I have argued that tlie biochemical abnormalities of diabetes are compatible with the 
proposal tliat it is a state in which more FR might be produced and more FR damage 
might occur. In turn this offers an explanation for the fact that diabetes is a risk 
factor for atherosclerosis which is consistent with the oxidation of LDL theory of 
atherogenesis. For the latter theory to hold it should also offer explanations for the 
association between atherosclerosis and the other risk factors. As so many risk 
factors, or more correctly, risk markers, are associated witli atheromatous 
cardiovascular disease (ACVD), I will limit myself to a brief discussion of only the 
major ones.
1.4.1 Hvoertension
Hypertension is one of the major risk factors for ACVD (171). Whereas 2-3 yrs of 
antihypertensive treatment reduced stroke mortality by a factor predicted from earlier 
epidemiological studies, the same is not true for coronary artery disease mortality 
(172,173). In fact, whilst reviewing evidence from 14 randomised trials of 
antihypertensive drugs Collins et al concluded that lowering blood pressure reduced 
coronary artery disease mortality, at best, by only half the epidemiologically 
expected amount (172). Although this observation may be explained by the fact that 
the drugs used to treat hypertension in trials to date cause deleterious effects in other 
risk factors, such as glucose tolerance and plasma lipids (81, 173), other
explanations are also possible. One such possibility is that hypertension is not
actually a major cause of ACVD but another manifestation of a more basic
abnormality which causes both hypertension and ACVD. Treating hypertension 
would then not necessarily be expected to alter the course of ACVD.
Even in non-diabetic individuals, insulin resistance (IR) and hyperinsulinaemia have 
been noted to be strongly associated with hypertension and other ACVD risk factors 
(174). In addition plasma insulin concentration has been identified as an independent 
risk factor for the development of coronary artery disease (175) thus it has been 
proposed that IR and hyperinsulinaemia may be responsible for, and so provide the 
link between, both the development of hypertension and ACVD (174). The
mechanisms involved are unclear but hyperinsulinaemia may act via effects on the
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sympathetic nervous system (176), the renal handling of Na^ (177), or 
transmembrane ion pumps, to modulate blood pressure (178). These same systems 
may also be involved in the control of cell growth and proliferation and so insulin 
may stimulate the smooth muscle cell proliferation seen in atheroma via these 
mechanisms however insulin may also act more directly to stimulate atheroma, via 
its own growth promoting activity (179). The apparent contradiction of proposing 
that insulin driven mechanisms may be responsible for hypertension despite the 
existence of insulin resistance hinges on the concept that insulin resistance 
predominantly affects insulin sensitive glucose utilization and that other insulin 
modulated activities remain insulin sensitive (174). Apart from suggesting a 
mechanism for the association of hypertension witli atherosclerosis, if insulin 
resistance and hyperinsulinaemia are the basic defects explaining both tliis would 
also explain the association of hypertension and atherosclerosis with other insulin 
resistant states such as non-insulin dependant diabetes, obesity, impaired glucose 
intolerance and even with insulin dependant diabetes if it is accepted that peripheral 
hyperinsuliaemia is a feature of insulin treated insulin dependant diabetes (180). 
However, there are anomalies with this theory in that hyperinsulinaemia is not 
always associated with hypertension such as in the situation of insulinoma (181), 
other factors must be involved, and sol would like to speculate that FR activity 
might also be a useful area in which to look for a link between hypertension, 
atherosclerosis and diabetes.
I have already argued that FR processes may be important in the development of 
atheroma and may be increased in diabetes. There is also evidence that FR may be 
involved in blood pressure control. One of the most important mediators of 
resistance vessel relaxation is the endothelial derived relaxation factor (EDRF), 
which has been identified as nitric oxide (NO) (182, 183). NO is degraded by 
reaction with O  ^ (183, 184) hence, in circumstances of increased FR load with 
either increased O^' production, or reduced removal, impaired vascular relaxation 
might occur and lead to hypertension. Preservation of NO might tlien explain the 
reported acute antihypertensive effect of bolus injections of the antioxidants vitamin 
C, glutathione and thiopronine which was observed in diabetic and hypertensive 
human subjects (185). In keeping with a role for FR in disrupting endothelial 
relaxation is the work of Cameron et al (186). Endothelial derived relaxation of 
smooth muscle is believed to be reduced in diabetes (183) but in streptozotocin- 
diabetic rats Cameron et al found that this abnormality could be corrected by an
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aldose reductase inhibitor (ARI) (186). A mechanism proposed to explain this effect 
relates to the fact that aldose reductase inhibitors preserve NADPH which is a co­
factor for NO synthesis and, as discussed before, is also necessary for antioxidant 
recycling and protection against FRs such as Og" (186). In addition, there is 
evidence that increased FR activity does occur in essential hypertension with the 
finding that lipid peroxides are elevated in the plasma and erythrocytes of 
hypertensive patients (187). Why FR activity might be increased in hypertension is 
unknown but could tlieoretically be due to its association with IR. Even when the 
IR associated with essential hypertension is of insufficient degree to cause glucose 
intolerance or frank diabetes with hyperglycaemia it is nevertheless associated with 
some subtle metabolic abnormalities which overlap those of diabetes (188). 
Essential hypertension was found to be accompanied by impaired insulin mediated 
glucose disposal and possibly insulin mediated inhibition of lipid oxidation (188). 
One could hypotliesise that these metabolic abnormalities due to IR wihtout diabetes 
would have consequences in terms of FR production similar to those postulated for 
diabetes but of lesser degree. Thus a spectrum of biochemical alterations is 
envisaged with increasing IR being accompanied by increasingly abnormal 
metabolism with increasing FR production and accompanied by hyperglycaemia and 
manifest diabetes at its extreme. With the developement of diabetes, hyperglycaemia 
would then in turn add further to the FR load by the mechanisms described in 1.3.1.
1.4.2. Cigarette Smoking
Cigarette smoking is another of the major cardiovascular risk factors, many 
mechanisms have been proposed to explain this association. Smoking may have 
effects upon platelet aggregation, thrombolysis and fibrinolysis (189, 190). Also, 
atherogenic changes in serum lipid profiles are associated with smoking (191) but 
these changes alone are not believed to be enough to account for the increased risk 
incurred by smoking (191, 192). In fact, it has recently been postulated that these 
lipid changes themselves are secondary to the existence of insulin resistance and 
hyperinsulinaemia in smokers (193). As discussed, syndromes of insulin resistance 
are associated with cardiovascular disease and could possibly be associated with 
increased FR activity but there are more obvious associations between smoking and 
FRs.
Among the many toxic substances contained in cigarette smoke are a vast array of
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FRs (13, 194, 195) which could cause direct injury to endothelial walls and also 
induce FR oxidation of LDL. Indeed, it has now been shown tliat smoking enhances 
oxidation of plasma lipoproteins, an effect which can be inhibited by antioxidant 
vitamins (196). Consistent with this, Duthie et al reported that levels of plasma 
diene conjugates were higher, and vitamin C concentrations were lower, in smokers 
(197). In addition, they also showed tliat, although erythrocyte vitamin E levels 
were not reduced in smokers, induced peroxidation of erythrocytes was
increased in smokers and could be corrected by vitamin E (197). By increasing FR 
load, smoking may cause a fall in antioxidant levels due to their increased 
consumption and low vitamin E and C levels have been found to correlate with risk 
of ischaemic heart disease (198, 199).
1.4.3. Gender
The differences in incidence, and timing, of coronary artery disease between men 
and women is largely unexplained (200) in terms of the major risk factors as is the 
loss of the protection conferred by female gender beyond the menopause and in 
diabetes (6) but FR mechanisms may be involved. Female sex may confer 
protection from cardiovascular disease by being associated with reduced availability 
of the transition metal, and FR catalyst, iron, due to losses in menstruation (201). 
Ferritin levels, and so iron stores, are known to be lower in pre-menopausal women 
than in men and it is particularly interesting that protection from vascular disease is 
lost even when the "menopause" is induced surgically by hysterectomy wihtout 
oopherectomy (202).
1.4.4. Age
Age may be associated with cardiovascular disease by simply being another process 
resulting from the accumulated effects of FR attack. One of the theories of aging is 
tliat it is itself a FR process (13, 203). At a biochemical level the changes in 
structural molecules that occur with aging, such as fluorescence and cross-linking 
of proteins, are similar to those induced by FR damage and to those that occur in 
diabetes (75). It is interesting, in the context of arguments regarding oxidative 
metabolism as a source of FRs, that one of the features of the condition of 
accelerated aging, progeria, is an increased metabolic rate (204) and tliat when
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comparing different species, aging rate is generally correlated with metabolic rate 
(203). Also, in rats food restriction, which induces protective adaptive reductions 
in metabolic rate, results in delayed aging and prolongation of life (205), These 
observations are consistent with the idea that the more rapid the metabolism the 
more rapid the process of aging and this correlation results from the more rapid 
production of FR during metabolic activity.
Further suggestion that FRs are implicated in the damaging effects of more rapid 
metabolic rates is provided by the finding that when species are compared in terms 
of tissue concentrations of antioxidants relative to metabolic rate, then long lived 
species are found to have the highest relative antioxidant concentrations (203), Also, 
the activities of enzymatic antioxidand defences have been shown to alter with age 
(206) and processes associated with aging such as Alzheimer’s disease, have been 
associated with reductions in vitamin E, A and carotenoid levels (207).
1.4.5. Geo graph V And Social Class
Many possible explanations are proposed for the wide geographical and social class 
variation of atherosclerotic vascular disease. Dietary differences are one of the more 
frequently proposed explanations and diet may influence FR mechanisms by altering 
the balance between substrates for FR attack and antioxidants (152, 153, 198, 199). 
However, the atherogenicity of a diet will be determined by a complicated balance 
of the positive and negative effects of ingested PUFA, SEA, cholesterol and 
antioxidants on many processes which could influence atherosclerosis (169),
Whilst not proof, the ability of the oxidation of LDL theory to offer a model 
explaning the observed associations between risk factors and atherosclerosis does 
lend the theory indirect support. The major identified risk factors do have possible 
associations with FR mechanisms and so could operate through a common final 
pathway of FR oxidation of LDL to generate atherosclerosis. I have summarised in 
Fig 1.4 a proposed model of these interactions and 1 have indicated the position, as 
possible final common pathway, held by FR mechanisms in the generation of 
atherosclerosis.
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1.5. CONCLUSIONS AND HYPOTHESES TO BE TESTED.
In summary, a compelling mechanism for the genesis of atheroma has been proposed 
involving the FR oxidation of LDL. The theory gains interest as a result of its 
ability to suggest explanations for, and new approaches to investigating, the 
associations between atheroma and its major risk factors. Should any of these 
currently speculative explanations be proven correct they would also lend power to 
the theory. This thesis investigates the links with diabetes.
Diabetes is a major risk factor for atherosclerosis, therefore, it seemed reasonable 
to ask might this association arise because more FR oxidation of LDL occurs in 
diabetes. There is some evidence from DCFA and TBARs concentrations that 
increased lipid oxidation does occur in diabetes but results are conflicting. Also, 
these markers of lipid oxidation are not specific and one of tlie unanswered 
methodological problems in this area was the role of diet in determining DCFA 
levels. The first study in this thesis was designed to test the hypotheses tliat
1. Diet is an important source of the diene conjugated fatty acids (DCFAs) in 
human serum and tissues, thereby questioning the use of DCFAs as a marker 
of FR activity.
One of the circumstances in which more FR oxidation of lipids might occur in 
diabetes would be if diabetes was a state in which more FR production and release 
occurred. Proposed and reported sources of increased FR production in diabetes 
have been discussed. Since platelet eicosanoid metabolism involves FR 
intermediates and is more active in diabetes, the second study explored the 
hypothesis that
2. Platelets are capable of releasing superoxide anion (O /)  and those from diabetic 
subjects release more than those from nod-diabetic subjects.
Impairment of the mechanisms protecting against FR attack would be a second 
situation in which more FR oxidation of lipids could occur in diabetes. There are 
reports of altered antioxidant concentrations in diabetes but, because co-operation 
between antioxidants occurs, it was not clear that measurement of the concentrations 
of selected species reflected overall antioxidant capacity. Using an assay reflecting
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total antioxidant capacity, TRAP, I set out to determine if plasma from diabetic 
subjects did have reduced total antioxidant activity, testing the hypothesis that
3. Plasma total antioxidant activity, as measured by TRAP, is lower in diabetic 
subjects than in healthy controls, thereby exposing diabetics to increased risk 
of FR mediated damage.
and ;■
4. The extent to which the lipids in plasma from diabetic subjects peroxidise will 
be inversely related to plasma total antioxidant activity, as measured by TRAP.
Changes in the composition of LDL in diabetes might also allow for increased FR 
oxidation of lipids. Vitamin E is not only a major lipid soluble antioxidant but is 
also an integral component of lipoprotein particles, including LDL. The vitamin E 
concentration in diabetic plasma has been reported to be normal but the 
concentration, per se, may not be the relevant parameter, it may be more important 
to determine vitamin E concentration relative to the concentration of lipids. In this 
thesis I have employed the ratio of vitamin E to cholesterol plus triglyceride 
concentrations to reflect vitamin E status and to clarify the situation as regards the 
appropriateness of vitamin E levels in diabetes. A study was undertaken to test the 
hypothesis that
5. Individuals suffering from diabetes have lower vitamin E levels relative to 
levels of oxidisable lipid (vitamin E status) than do non-diabetics and lower 
vitamin E status will be associated with evidence of greater lipid peroxidation 
in diabetes.
In keeping with the theory tliat oxidation of LDL by FR is important in the 
generation of atheroma is epidemiological evidence that the risk of atherosclerotic 
disease is greatest in populations ingesting diets low in antioxidants. A study was 
begun to test the hypothesis that
6. Vitamin C and vitamin E dietary supplementation will increase the TRAP and 
vitamin E status of plasma respectively, and reduce lipid peroxidation in
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diabetics and non-diabetics.
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CHAPTER TWO
METHODS
2.1. INTRODUCTION
Several standard methods are used in more than one of the studies in this thesis and 
are described here. A few methods which are specific to a single study, or employ 
non-standard procedures and need explanation in the light of the study, are described 
in the relevant chapters. Where an understanding of the principle of the assay is 
necessary for interpretation of the results, the principle is described in the relevant 
chapter(s). Where a standard kit assay is employed, and provides all the reagents, 
the reagents are not listed individually. Where coefficients of variability (CV) are 
given they refer to between batch estimates unless stated otherwise. Ethical approval 
was sought and obtained where necessary from the Whittington Hospital Ethical 
Commitee.
2 2  SAMPLE COLLECTION AND STORAGE
For all assays whole venous blood was collected into a plastic syringe from an 
antecubital vein using a 19G needle and tourniquet. Blood was immediately 
transferred to collection tubes containing appropriate anticoagulants or antioxidants 
as indicated. Serum was obtained by collecting blood without anticoagulants, and 
following coagulation and centrifugation at lOOOg for lOmin, serum was removed 
and stored as described.
2.3. ASSAYS
2.3.1. Plasma Glucose
Blood was collected into "Vacutainer" tubes containing sodium fluoride (Vacutain- 
system, Becton-Dickson, Cowley, Oxford, UK.) and centrifuged at lOOOG for 10 
min. Plasma was separated and immediately analyzed using the GLUCOSE 
OXIDASE METHOD (Beckman, Brea, CA). (CV = 2.0%)
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2.3.2. Glycosylated Haemoglobin (HbA T^
Blood was collected into "Vacutainer" tubes (Vacutain System. Becton-Dickinson, 
Cowley, Oxford, UK.) containing ethylenediamidetetracetic acid (EDTA) and stored 
at 4"C. All samples were analyzed within 3 days of collection by AGAR GEL 
ELECTROPHORESIS (Ciba-Corning, Halstead, Essex, UK). (CV = 4.3%)
2.3.3. Serum Lipids
Serum was stored at 4"C and analyzed within 4 days using standard kits.
a. Total Serum Triglycerides (TGI
Following lipase hydrolysis, the total concentration of TG was estimated by an 
ENZYMIC COLORIMETRIC TEST with glycerol phosphate oxidase and 4- 
aminophenazone (Roche, Welwyn Garden City, Herts., UK), run on a Baker 
CentrifiChem 600 (Baker Inst.,Liverpool, UK). (CV = 3.4%)
b. Total Serum Cholesterol ttotal-ChoB
Following cholesterol esterase hydrolysis, the concentration of t-Chol was estimated 
by an ENZYMIC COLORIMETRIC METHOD using cholesterol oxidase and 4- 
aminophenazone (Boehringer-Mannheim, Lewes, Sussex, UK.), run on a Baker 
CentrifiChem 600. (CV = 1.7%)
c. High Density Lipoprotein Cholesterol (HDL-ChoD
Following phosphotungstic acid (0.55mmol.L) precipitation of VLDL, LDL and 
chylomicrons, leaving only HDL in the supernatant (Randox Lab Ltd., Crumlin, 
Antrim, UK) the remaining cholesterol in the supernatant was determined by the 
above method. (CV =  4.6%)
d. Low Density Lipoprotein Cholesterol (LDL-ChoB
LDL-Chol concentration was determined by calculation using tlie Friedewald 
equation (208). Since the assumptions made in deriving this equation do not hold 
when hypertriglyceridaemia exists, LDL-Chol was not calculated when the TG 
concentration exceeded S.Ommol.f'.
2.3.4. Serum Uric Acid
Uric acid was determined by an ENZYMATIC COLORIMETRIC ASSAY 
employing Uricase (Randox Lab Ltd., Crumlin, Antrim, UK), run on a Baker 
CentrifiChem 600. (CV = 2.8%)
46
2.3.5. Serum Vitamin E (vitamin E)
Serum was analyzed immediately or stored at -20°C. Samples were analyzed within 
2 months by the method described by Hansen and Warwick (209).
Methanol/hexane extraction was followed by measurement of the fluorescence of the 
hexane layer in a Perkin-Elmer MPF-36 spectrofluorimeter (Perkin-Elmer, 
Beaconsfield, Bucks., UK) with excitation wavelength of 295nm and emission 
wavelength at 330nm. 0.2ml 20jLigmI'  ^of Vitamin E, in HPLC grade methanol, was 
used as a standard and 0.2ml HPLC grade water as the blank. Vitamin E 
concentration of the serum is then calculated from
Vitamin E ngml x 20
Where
Fi = Fluorescence of test corrected for the blank 
Fg = Fluorescence of standard corrected for the blank
(CV =  4.8%)
Taking the molecular mass of vitamin E as 430.7 the vitamin E concentration was 
converted to umol.U by multiplying by a factor of 2.3.
2.3.6. Total Peroxvl Radical Trapping Activity Of Plasma tTRAPI
The principle behind this assay and tlie derivation of the equation for calculation of 
TRAP is given in Chapter 5. TRAP was estimated using a modification of the 
method described by Wayner et al (127). Serum was stored -20“C and used within 
one month.
3,0ml of phosphate buffered saline was placed in the chamber of a Clark O2  
electrode (Rank Brothers, Bottisham, Cambridge, UK), stirred continuously and 
allowed to equilibrate to 37°C. 2/xl of linoleic acid (free acid, 99%) was dispersed 
into the buffer, giving a final concentration of 2.1 m m o l . f o l l o w e d  by 50/xl of 
serum. Finally, 30/xl of 0.4 mol.l'^ 2,2’-azo-bis(2amidinopropane) hydrochloride 
(ABAP) was added. The chamber was tlien covered to exclude light. The output 
from the electrode was recorded by means of a Vitatron-2000 recorder (MSE/Fisons
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Inst., Crawley, UK). After a variable time lapse (Tp), due to plasma inhibition of 
peroxidation, uptake accelerates as peroxyl radicals derived from the 
decomposition of ABAP attack and peroxidise lipid in the reaction mixture (first 
peroxidation phase). When the rate of O2  uptake had become constant, 25/xl of 
500jamol.r^ ascorbic acid was added. Peroxidation was inhibited for a second period 
(TJ. When peroxidation resumed and reached a steady state, recording was 
stopped.
Tp and T  ^are determined by measurements from the recording and are proportional 
to the antioxidant activity of plasma and the added ascorbate respectively (Fig 5.3 
and 5.4). TRAP is calculated as follows
Since ^ [TRAP] X Vol. plasm a[Cone. Ascorbate] x n x Vol. ascorbate
Where n = the number of peroxyl radicals trapped per ascorbic acid 
molecule and was taken as 1.7 (26).
TRAP = 425 X - 5
Where samples were analyzed in duplicate the results varied by less than 10%.
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2.3.7. Serum Thiobarbituric Reactive Substances ('TBAE.S')
The principle behind this assay is described in Chapter 6. TEARS were estimated 
using a modified fluorom etric method of Yagi (210). Serum was stored at -20°C and 
used within 2 months
a. The Standard ( =  M P A  0 .2 5 |fm o l.D
Since malondialdehyde (MDA) is not stable, it is formed during the course of the 
test from 1,1,3,3-tetram ethoxypropane which hydrolyses under the test conditions, 
releasing MDA.
H CO OGH O O
3 \  /  ^ II II
H C -C H - C H  .........— .■> C C + 4GH OH/ 2 \ \  /  3
H G O  OGH GH
3  3  2
1,1,3,3-Tetramethoxypropane Malondialdehyde + Methanol
(MDA)
Stock Standard Solution 10.25mmol.Ml
1.62ml of 1 ,1 ,3 ,3-tertamethoxypropane was diluted to 40ml with methanol. This 
was stored at 4°C in the dark.
Working Standard Solution (0.25wmol.l'D
The stock solution was diluted by 10* in HPLC grade water immediately before use.
b.TBA Reagent (23.3m m o l.D
0.335g TEA  was dissolved in 50ml water and heated to 80°C. After cooling, 50ml 
glacial acetic acid was added. The solution was stored in the dark at 4°C.
c. TEARS Assay
Acidification and precipitation of lipoproteins
To 50//1 of serum  4ml 0.042mol.l'^ sulphuric acid and 0.5ml 0.035mol.l  ^
tungstophosphoric acid were added and allowed to stand for 5min. After 
centrifugation at lOOOG for lOmin, the supernatant was discarded and the tubes 
drained by inversion. The sediment was resuspended in 4ml water.
Reaction with T EA
1ml TEA  reagent was added to each sample and to 2ml of working stândard. A  
blank was prepared by adding 1ml T EA  reagent to 4ml water. Samples, standard
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Then
FMDA, = 10 X -™ pmoll"1
Fs
(CV = 12.0%)
and blank were heated in a waterbath for 60min at 95"C and then cooled. 
Extraction of the chromogen
3.0ml of n-butanol was added to all tubes and the contents mixed vigorously for 
3min. After centrifugation at lOOOG for 15min, the upper butanol layer was 
removed.
Measurement and calculation of TEARS
A Perkin-Elmer MPF-3L scanning spectrofluorimeter (Perkin-Elmer, Eeaconsfleld, 
Bucks., UK) was used, with an excitation wavelength of 515nm and emission 
wavelength of 553nm. Correcting for the fluorescence of the blank, the fluorescence 
of the test sample (FJ and of the standard (FJ were determined and TEA reactivity, 
expressed in terms of MDA, was calculated as follows:- 
Since
[MDA], X Vol, (ml) ^ ^
[M D A ]g  X V o ls  (m l )  F s
F Vol[MDA],|xmol|-^ = ^  X [MDA|3 x ^  Fg Vol,
Where
[MDAJt -  conc. of MDA in test serum Obtmol.l' )^
[MDA], =  conc. of MDA in standard (jLimol.l'O
= 0.25/imol.r'
Volt = volume serum (ml) =  0,05ml
Vol, = volume standard (ml) =  2ml
Ft = peak fluorescence of serum, corrected for the
blank
F, = peak fluorescence of standard, corrected for
the blank
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2.3.8 Total Diene Conjugated Fattv Acid (tPC) In Serum
tDC was determined using a modification of the method of Lunec et al (20). Lipids 
are extracted from serum and diene conjugated species detected by their ability to 
absorb at 230-240nm. Serum was stored at -20“C and used within 2 months.
a. Extraction
4ml of chloroform;methanol (2:1 v:v) was added to 0.5ml of sample and vortexed 
for 3min. After centrifugation at lOOOG for lOmin, 2.5ml of the lower phase was 
separated and vortexed with I ml HPLC grade water for 30sec. Following a ftirther 
centrifugation, the lower chloroform layer was removed to a quartz cuvette with a 
1cm light-path length.
b. Measurement
Absorbance at 240nm was measured using a Pye-Unicam 8-100 recording 
spectrophotometer (Pye-Unicam, Cambridge, UK). Results, in OD units, represent 
tDC.
2.3.9 Serum Phospholipid Content Of Linoleic Acid (18:2t9.12E And It's Diene 
Conjugated ('18:2(9.1111 Derivative
The serum phospholipid content of 18:2(9,11) and 18:2(9,12) isomers were 
determined by a modification of the method of Ivensen et al (211). Serum was 
stored at -80"C and used within 2 months.
a. Hydrolysis Of Phospholipids
100^1 of serum was mixed with lOOjttl of a solution containing O.lmol.U tris 
(hydroxymethyl)aminomethane (TRIS), pH 8.9, Imol.L methanol and 5000U.l'^ 
phospholipase A .^ This mixture was incubated at 25°C for 15min.
b. Addition Of Internal Standard
50fx\ of methanol, containing 0.5% acetic acid and 10/xmol.U of 18:2(9,11) linoleic 
acid was added.
c. Extraction Of Fatty Acid And Precipitation Of Proteins
300jal of 0.042M sulphuric acid and 1.5ml of chloroform:methanol (2:1 v:v) were 
added and the mixture vortexed. After centrifugation at lOOOG for lOmin three 
layers form; an upper methanol layer, a lower chloroform layer and an intermediate 
protein layer. The chloroform layer was removed and evaporated to dryness under 
Og-free nitrogen. The residue was resuspended in lOOjal of the HPLC mobile phase.
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cl. Fattv Acid Separation. Detection And Measurement
20fji\ of the resuspended sample was applied to a Spherisorb OD52, 250 x 4mm, 
HPLC column, containing 5jtcm capped spherical particles (Hichrom, Reading, 
Berks., UK). The mobile phase was acenotnitrile/water/acetic acid (90:10:0.1). 
Two U.V. detectors in series were set at 234nm and 200nm to detect diene 
conjugated and non-conjugate fatty acid, respectively. Fatty acid concentrations 
were calculated using a programme devised by Griffin (212).
e. Percentage Molar Ratio t%MRl
The %MR of 18:2(9,11) to 18:2(9,12) concentrations was calculated as follows:-
MR% =  ^1)1 M'lTlol.l  ^ ^  100
[conc 18:2(9,12)] nmol.l '^
2.3.10. Peroxidisabilitv Of Serum Fatty Acids
The principle behind this assay is discussed further in Chapter 6 .
1 volume of serum (=  2 ml) was mixed with 2  volumes of 0 .2 mol.i‘* sodium acetate 
buffer to acheive a final pH of 5.5. Immediately samples were removed for 
estimation of tDC and TEARS by the methods described in Sections 2.3.8 and 2.3.7 
respectively. The mixture was then incubated at 37”C in the dark for 24hrs. At the 
end of that period, samples were removed for tDC and TEARS estimates and the 
change in these concentrations from baseline were calculated.
2.3.11. Low Density Lipoprotein ILDLl Isolation
LDL, in the density range d 1.020-d 1.050g.ml'', was isolated by potassium bromide 
(KBr) density gradient ultracentrifugation. 20ml of blood was collected into glass 
tubes, on wet ice, containing sodium ethylenediamine tetracetic acid (EDTA) and 
Butyl ated Hydroxy toluene (BHT) to achieve final concentrations of Ig.U EDTA and 
4.4mg.L EHT. Tubes were centrifuged at lOOOG for lOmin at 4°C and the plasma 
removed. Further manipulations were carried out with plasma on wet ice.
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Solid potassium bromide (KBr) was added to 5ml plasma in centrifugation tubes 
(Beckman, UK) to adjust density to 1.020g,ml k The tubes were capped and mixed 
until the salt was dissolved.
Using a 50.3Ti rotor, installed in a Beckman L8-55 ultracentrifuge, samples were 
spun for 18hr at 39000 rpm at 4°C. The supernatant (VLDL/IDL) was removed by 
tube slicing. The infranatant (LDL/HDL/plasma proteins) was made up to 5ml 
using dl.020gmM KBr salt solution (28.5g KBr in 11 deionised, distilled water). 
The density of the sample was then increased to 1.050 by further addition of solid 
KBr (0.218g/5ml). The tube was then capped, mixed and ultracentrifuged as before, 
but for 24hr. Supernatant LDL was removed by tube slicing and its volume adjusted 
to 2.0ml with dl.05  salt solution. This stock solution of LDL was sealed and stored 
at 4"C, in the dark for no more than one week. It was dialysed immediately before 
use.
2.3.12. Dialysis Of Low Density Lipoprotein
Dialysis was performed as described by Esterbauer et al (213) against 100-fold 
volume of degassed O.OIM phosphate buffered, 0.16M saline, pH 7.4 containing 
0. Ijug.mL chloramphenicol. Dialysis was performed over 48hrs in tlie dark at 4”C.
2.3.13. Low Density Lipoprotein Protein Content
Protein content was determined COLORIMETRICALLY (Sigma, Poole, Dorset, 
UK) employing the Lowry method (214).
2.3.14. Oxidation Of Isolated Low Density Lipoprotein
The principle behind this assay is discussed further, and the equations derived, in 
chapter eight. The method employed is a modification of the method described by 
Esterbauer (213). The protein content of dialysed LDL was first determined by the 
Lowry method then dialysed LDL was diluted to achieve a final concentration of 
0.25mg.ml ‘ (in terms of LDL protein) in O^-saturated, O.OIM phosphate buffered, 
0.16M Sodium Chloride, pH 7.4. Fresh copper sulphate (final concentration 
1.66/xM) was added to catalyse oxidation and the mixture was maintained at 37°C. 
The change in absorbence at 234nm was monitored using a Pye-Unicam SPB-100
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Spectrophotometer (Pye-Unicam, Cambridge, UK) and has three phases as shown 
in Fig 8.1. The duration of the lag phase, (LAG), the duration of the propagation 
phases, (PROP), and the maximal change in absorbence were measured (AAb). 
Taking the extinction co-efficient (6 5 3 4 ) of conjugated lipid peroxides to be 29500M' 
^cm'% and bearing in mind the 0.25mg.ml ‘ concentration of LDL, the nanomoles 
of DC formed per mg of LDL (DC-mg'^) and their rate of formation (DC-RATE) 
were calculated as follows
D C -m g X 10® X 4  nm oles mg LDL
^234
DC-RATE = X ^0° X 0 .25
€234 PROP
Where LAG was estimated on duplicate samples results varied by 5-10%
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2.4. SOURCES OF REAGENTS
BDH Chemicals Ltd, Poole, Dorset, UK, supplied Analar grade:-
acetic acid (glacial), ascorbic acid, n-butanol, betahydrotoluene (BHT), copper 
sulphate, methanol, sodium acetate, sodium chloride, sulphuric acid, 
tungstophosphoric acid, potassium ùfLhydrogen orthophosphate, and <7/-sodium 
hydrogen orthophosphate.
They also supplied "Spectrasol" grade chloroform.
Sigma Chemical company Ltd., Poole, Dorset, UK, supplied :-
e th y le n e d ia m in e - te tr a -a c e t ic  ac id  (E D T A ), l in o le ic  a c id , 
malondialdehydetetramethylacetal(l,l,3,3-tetramethoxypropane),phospholipase 
Aj, thiobarbituric acid (TBA), a-tocopherol (vitamin E) and 
tris(hydroxymethyl)aminomethane (TRIS).
Rathburn Chemical Ltd., Walkerburn, Peebleshire, UK, supplied:
HPLC grade water, acetic acid and acetonitrile.
2 ,2’-azo-bis-(amidinopropane hydrochloride) (ABAP) was supplied by Polyscience
Incorporated, Northampton, UK.
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2.5. SUBJECTS: DEFINITION OF CLINICAL CHARACTERISTICS
The groups of subjects who took part in the different studies are described in the 
relevant chapters.The presence or absence of tlie complications of diabetes was 
established by patient history, supplemented by reference to the patient’s notes. 
Subjects were classified as having macrovascular complications as follows:- 
(a) Ischaemic heart disease: previous myocardial infarction or history of
angina or an abnormal ECG. 
claudication or two more absent foot pulses, 
previous cerebrovascular accident or history of 
transient ischaemic event 
Subjects were classified as having microvascular complications as follows:-
abnormal dilated fimdoscopy recorded by 
experienced fundoscopist. 
albustix positive proteinuria recorded on the 
day of study and on one or more previous 
visits (urinary tract infection excluded), 
symptoms or signs of sensory impairment or 
absent ankle jerks recorded.
(b) Peripheral vascular disease:
(c) Cerebrovascular disease:
(a) Diabetic retinopathy:
(b) Diabetic nephropathy:
(c) Neuropathy:
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l Â  STATISTICAL METHODS
Statistical analyses were performed using SPSS (SPSS-INC., Chicago, USA.) or C- 
Stat (Chartwell Scientific Publishing Limited, Oxford, UK.) statistical packages.
For Normally Distributed data results are given as mean (standard deviation). 
Comparison between groups was tested by paired or unpaired Student t-tests and 
correlations between continuous variables evaluated by linear regression analysis. 
Pearson correlation co-efficients (r) and their level of significance (p value) are 
quoted for the results of linear regression analysis.
For non-normallv distributed data results are expressed as median (25*, 75* 
percentiles). Comparison between groups was tested by Wilcoxon Signed Rank Test 
(paired data) or Mann-Whitney U-test (unpaired data). Correlation between variables 
was evaluated by Spearman rank test. Spearman rank correlation coefficients (i;) 
and their p values are quoted.
For Categorical data the distribution within groups was compared by the Chi-squared 
test. Chi-squared statistic (x^) and p value are given.
Possible interactions between variables were evaluated by multiple linear regression 
analysis (MLR) or analysis of covariance, with logarithmic transformation of skewed 
data. Categorical variables were coded as follows:- male (1), female (0); smoker 
(1), non-smoker (0); presence of diabetes (1) and its absence (0). Results of MLR 
are described by partial regression coefficients (B) with their 95% confidence 
intervals (95%Cl) and p values. For analysis of variance results are described by 
the variance ratio (F) and p value. Statistical significance was accepted at a p value 
of 0.05. Estimates of statistical power were made using the calculations and tables 
described by Cohen (215).
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CHAPTER THREE
DIET AS A SOURCE OF PHOSPHOLIPID ESTERIFIED 9.11-QCTADECADIENOIC
ACID IN HUMANS
3 J . INTRODUCTION
Free radicals are believed to be mediators of tissue damage in many disease states 
(11,15,18, 21), including diabetes (70, 123, 216) and atherosclerosis (9,217). 
However, much of the evidence for such proposals is based on indirect measures of 
FR activity because direct techniques, such as electron spin resonance, are not 
widely available. The most frequently used indirect metliod of measuring FR 
activity is the measurement of the products of FR attack on endogenous molecules, 
especially lipids. I will describe the reactions involved in the process of FR attack 
on lipids and how the major products are generated as this knowledge is necessary 
to aid the understand of the measurements made.
3.1.1. Free Radical Attack On Lipids And Peroxidation (Fig 3.1)
PUFA are vulnerable to FR attack because of the arrangement of double bonds in 
their side chains. The usual configuration of double bonds found within PUFA side 
chains in biological material is termed unconjugated meaning that the double bonds 
are separated by at least two single bonds (-C = C-C-C = C). This arrangement 
provides a "weak spot", as far as FR attack is concerned, at the methylene groups 
(-CH^-) which interrupt the double bonds (13, 15, 218) because FR attack and 
hydrogen atom abstraction (H ) from this group (Fig 3.1) is relatively favoured by 
the fact that the single electron can then be delocalised along the unsaturated chain. 
Hydrogen abstraction leaves a carbon centred radical. An electron rearrangement 
follows resulting in the loss of the unconjugated configuration and the production of 
a diene conjugated system, where double bonds are separated by only one single 
bond (-C =C -C =C-) (218). The process continues with the reaction of the carbon 
centred radical with O ,^ giving rise to a highly reactive peroxyl radical. The peroxyl 
radical is then capable of propagating the chain reaction by abstracting a H ' from 
another suitable PUFA residue whilst itself becoming a diene conjugated
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hydroperoxide (15, 219). This peroxidation sequence is believed to be the major 
reaction pathway followed when a FR attacks a PUFA hence the term peroxidation 
is often used as if synonymous with FR attack on lipids but this is not strictly correct 
as anotlier pathway may also exist. In the presence of protein, reaction with O2  need 
not occur and FR attack can then result in isomérisation and the formation of diene 
conjugated, non-peroxide products (Fig 3.1) (218, 220).
These initial FR products ,especially the hydroperoxides, may undergo further 
reactions and fragmentation, with the formation of a series of compounds, the exact 
nature of which is determined by the original PUFA. These compounds include 
aldehydes such as malondialdehyde (MDA), and gases such as pentane and methane. 
Also, hydroperoxides may react in the presence of transition metals to produce other 
radicals such as alkoxyl and peroxyl radicals (Fig 1.2) which may then initiate 
secondary chain reactions (Fig 3.1) (13, 221).
All of the species formed in the above reactions have been found in biological 
samples, suggesting such processes do occur in vivo and many of tliem have been 
used as markers of FR activity in vivo. DCF A are one of the most stable and most 
frequently measured products however recently otlier potential sources of DCFA 
have been identified raising doubts about the specificity of DCF As as FR markers. 
These other sources are discussed below and the study described in this chapter 
explores the possibility that diet is a source in humans.
3.1.2. Alternative Sources Of Diene Conjugated Species
Using HPLC with U.V. detection it has been shown that the major DCFA in human 
tissues is 9,11-octadecadienoic acid which is the 18:2(9,11) isomer of linoleic acid 
(9,12-octadecadienoic acid) (220). Assuming its only source to be FR attack on the 
parent isomer tlie percentage molar ratio (%MR) of 18:2(9,11) to 18:2(9,12) in 
biological samples could then be used as an index of FR activity (211, 220). 
However, the same entity has been found in animal tissues where it arises as a result 
of enzymatic processes, as in rat liver microsomes where desaturation of 11- 
octadecaenoic acid (18:1(11)) to 18:2(9,11) occurs (222). Also, the bacteria residing 
in the bovine rumen can dihydrogenate 18:2(9,12) to octadecanoic acid (18:0) via 
an 18:2(9,11) intermediate (223). Similar processes may occur in human tissue, for 
example, local production and raised concentrations of DCF As in the human cervix 
may result from bacterial colonization and activity (224). Also, several respiratory
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pathogens have been shown to produce 18:2(9,11) in vitro (225).
In addition to the possibility of non-FR production of 18:2(9,11) in human tissues, 
the fact that this isomer appears in animal tissue suggests that ingestion may be 
another source for humans (72). Food-stuffs, mainly those of ruminant origin, have 
been shown to be rich in 18:2(9,11) (226). Fogerty et al have shown food-stuffs to
have a very wide range of 18:2(9,11) content for example, lean beef contained 6-
43mg of 18:2(9,1 l)/100g (227). This fatty acid was mainly distributed in the fat 
component of the meat, beef fat containing 960-13 lOmg/lOOg in addition butter was 
found to contain 720-9lOmg per lOOg. Fogerty et al also showed that some foods 
of non-ruminant origin, such as margarine, contained no 18:2(9,11), but that some 
contained a range of concentrations explicable in terms of tlie animal food chain. 
Eggs contained up to 31mg/100g but eggs from hens feeding free-range with no 
animal fat source having no detectable 18:2(9,11) (227).
Thus, controversy existed as to the origin of DCFA in human tissues and to the 
importance of diet as a source. The study described in this chapter was designed to 
clarify the situation by observing the effect of altering tlie intake of foodstuffs high 
in 18:2(9,11) upon the serum phospholipid content of 18:2(9,11).
3 ^  HYPOTHESIS
Diet is an important source of diene conjugated fatty acids (DCF As) in human serum 
and tissues, thereby questioning the use of DCFAs as a marker of FR activity.
3 J  SUBJECTS AND STUDY DESIGN
Fourteen healthy subjects (3 males, 11 females; mean age 35.1 (SD 8.7) yrs took 
part in the study. All were non-smokers.
Two diets were devised using the work of Fogerty et al (227) to identify foodstuffs 
rich in 18:2(9,11). The "high diet" was rich in tliese foodstuffs, whereas the "low 
diet" was poor in such foodstuffs. Stringent dietary instructions were not given, but 
volunteers were simply given a list of foodstuffs (Table 3.1) either to avoid or to 
increase their intake of. Subjects recorded a 7-day diet history on each phase of the 
diet. These were scored allowing a score of 1 for a typical portion of each item 
appearing on the prescribed list of foodstuffs. Because previous work has shown an 
enormous range of 18:2(9,11) concentration in food of similar origin (227), we did
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1 Red meat:beef, lamb, pork, ham.
2 Meat products:pies, sausages, pasties, meat spread
3 Animal fats:butter, lard.
4 Dairy foods:dairy ice-cream, cream soups and sauces 
full fat cheeses, milk, yoghurts.
Table 3.1: Foodstuffs rich in the 18:2(9,11) isomer of linoleic acid.
Subjects were asked to increase the intake of these foodstuffs during the ’high diet’ phase and 
to reduce their intake during the ’low diet’ phase.
not attempted to use any more than semi-quantitative score of its intake. Semi­
skimmed milk was scored as 1 and full fat milk as 2 (per half pint). An average 
daily score of number of items eaten was calculated. All subjects were studied at 
baseline on their normal diet and again after a period of 3 weeks on one of the test 
diets. Where both diets were undertaken, the order was randomized and a washout 
period of at least 3 weeks was allowed between phases. Four subjects undertook 
both dietary phases, four only the "high diet" and six only the "low diet".
3.4 METHODS
The analytical and statistical methods employed are described in chapter 2, All 
assays were performed within 8 weeks of sample collection. Serum samples taken 
before and after each dietary phase were analysed in the same batch. Serum 
phospholipids were subjected to enzymatic hydrolysis and DCFAs were determined 
by HPLC with u.v. detection at 234nm. Concentrations of 18:2(9,11) and 
18:2(9,12) were determined and expressed as a percentage molar ratio (%MR):-
o/oMR = 18:2(9,11) LA x 100%
18:1(9,12) LA
3.5 RESULTS
The daily diet score of subjects on the"low diet" was significantly lower than at 
baseline on their normal diet [0.6(0.5) vs 2.6(0.7) items/day, n =  10, p -  0.0003]. 
On the "high diet" it was significantly higher [5.3(0.8) vs 2.9(1.0) items/day, n -
8, p =  0.001],
The concentration of 18:2(9,11) increased from 12.1(3.7) to 18.8(7.4) ^m ol.L on 
the "high diet" (p =  0.006) and decreased from 14.3(6.7) to 8.9(4.7) jumol.U on 
the "low diet" (p =  0.01). Correcting for changes in 18:2(9,12) by expressing the 
value as the %MR to 18:2(9,12), the %MR increased on the "high diet" [1.3(0.4) 
vs 1.9(0.7); p = 0.01] and decreased on the "low diet" [1.6(0.6) vs 1.1(0.4); 
p =0.004] (Fig 3.2). Of the 18 pairs of results, 17 changed in the direction 
predicted by the hypothesis. Eleven subjects kept diet histories, allowing 25 pairs
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of diet scores and related %MR be analysed. There was no correlation between 
baseline diet score and baseline %MR. When all diet scores and %MR were 
analysed together, there was highly significant correlation between diet score and 
%MR (r =  0.636, p =  0.001)(Fig 3.3). The change in diet score and the change 
in %MR also correlated significantly (r = 0.829, p = 0.001) (Fig 3.4).
3.6 DISCUSSION
The aim of this study was to determine whether changes in the dietary intake of 
18:2(9,11) would be reflected in the serum concentration of that entity thus 
suggesting that diet contributed to the variability in it’s serum concentration. Since 
I wished the test diets to be different for that individual, but remain realistic, dietary 
instructions were given to subjects as simple guidelines, rather than the more 
artificial recommendation of strictly measured quantities of defined foodstuffs. It 
was felt this less rigid approach would also improve compliance.
The results support the hypothesis that the serum concentration of 18:2(9,11) is 
influenced by dietary intake. Despite deliberately, uncontrived test diets, the 
percentage change in %MR in human serum on the "high diet" ranged from 10% 
to 88% and on the "low diet" from 7% to 60%. This suggests that normal dietary 
variation in a population would also be sufficient to have a major influence on serum 
concentration of 18:2(9,11).
Seventeen of the eighteen dietary interventions produced changes in the %MR in the 
direction predicted by the hypothesis. The one paradoxical result arose in the 
subject with the lowest baseline %MR (0.54). It may be that it is impossible to 
lower the concentration beyond a certain level, a level determined by factors other 
than diet.
Dietary compliance and 18:2(9,11) intake were estimated using a simple diet score. 
Acknowledging the inaccuracy of this method it was adopted for the following 
reasons. Unlike better recognised dietary components the 18:2(9,11) content of very 
few foodstuffs is known, therefore it does not appear in food tables. In known 
sources its concentration varies widely and will be greatly influenced by fat content 
(227). Therefore, even if careful weighed records of dietary intake had been kept, 
calculation of 18:2(9,11) content with any degree of accuracy would have been 
impossible. On the other hand, considering the items in Table 3.1, although a 
typical portion of red meat would weigh more than a typical portion of pâté or
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cheese, its fat content would be less, therefore typical portions of these items might 
be assumed to be more equivalent in terms of 18:2(9,11) content than initial 
inspection would suggest. Also, the errors introduced by this assumption of near 
equivalence are likely to be small relative to the differences produced in the 
comparison between presence or absence of a typical portion of these items in the 
diet for example, changing butter (720mg 18:2(9,11)/I00gm) for margarine 
(Omg/lOOgm) will produce such relatively large alterations in 18:2(9,11) intake as 
to swamp errors in equivalence between portions of steak and pâté. Moreover, any 
inaccuracy of this method would be likely to disguise, rather than exaggerate, any 
relationship with plasma DCFAs ratios.
The lack of correlation between diet score and %MR at baseline may be due to the 
inaccuracies of the diet score, may be a statistical problem owing to small numbers, 
or again may imply tliat other factors contribute to %MR besides diet. Free radical 
activity may be tliat other factor, but the extent of the influence of diet alone is so 
great as to confound the situation completely. When all pairs of dietary scores and 
%MR are considered there is a significant correlation (Fig 3.3). The fact that the 
regression line for diet score vs %MR does not pass through zero also suggests a 
minimum concentration produced by sources other than tliose identified here. There 
is also remarkably good correlation between change in diet score and change in 
%MR (Fig 3.4), suggesting that the dietary assessment and scoring system does 
identify tlie major contributors to serum concentration despite its simplicity. Some 
workers have found low levels of DCFA in a group of young insulin-dependent 
diabetic patients, despite the theory that in diabetic patients FR activity is increased 
and relates to complications (71). It is possible that these findings could be 
explained by the subjects consuming diets low in animal fats. Similar considerations 
may explain my findings of lower levels of DCFA in a group of Asian diabetic 
patients than in a Caucasian group, despite the former being more at risk of 
cardiovascular complications (228).
3.7 CONCLUSION
In conclusion, the use of DCFA as a marker of free radical activity when comparing 
groups or individuals over a prolonged period is limited, as diet is perhaps the major 
source of these compounds in humans. The magnitude of the day-to-day variation 
in DCFA levels within an individual has not been studied here. If this were not
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great, sudden major alterations might still be attributed to bursts of FR activity in 
short-term longitudinal studies, for example witliin hours of a significant event such 
as myocardial infarction (229) or major surgery (230).
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CHAPTER FOUR 
PLATELETS AS A SOURCE OF SUPEROXÏDE.
4.1. INTRODUCTION
The explanation for the greater cardiovascular risk associated with diabetes is 
unclear. As discussed in chapter one a compelling theory for the development of 
atheroma is evolving which suggests that oxidation of low density lipoprotein (LDL) 
renders it more atherogenic and evidence suggests that this oxidation is a free radical 
process (43-48) and so in situations where greater production of free radicals 
occured one might expect more LDL oxidation and greater risk of atherosclerosis. 
Platelets are more active in diabetes (113, 231) and have been attributed a role in 
the development of atheroma (232, 233) but the mechanism(s) whereby they might 
do so remain unclear. Histologically platelets are found in close association with 
macrophages in atheromatous plaques (234). They have been reported capable of 
enhancing macrophage accumulation of cholesterol esters (235) and, like 
macrophages, of enliancing oxidation of LDL (236). Platelets are not known to 
have an enzyme system specifically geared to the production of oxygen centred free 
radicals (eg superoxide, O^") as macrophages do. However like stimulated 
macrophages, platelets stimulated to aggregate do display a burst of oxygen uptake 
attributed to mitochondrial electron transport and cyclooxygenase/1 ipoxygenase 
activation (237). Activity of the latter enzyme cascade is an integral part of the 
platelet response to many of the agonists of platelet aggregation and essentially it 
involves the insertion of molecular oxygen into arachidonic acid with the production 
of prostaglandins, thromboxanes and leukotrienes (13, 238). In vitro purified 
prostaglandin synthetase and lipoxygenase have been shown capable of Og' 
production (16).
In this chapter the possibility is explored that a mechanism explaining the role of 
platelets in the generation of atherosclerosis is that they act as a source of FRs 
allowing the leak of oxygen centred free radicals such as O2 ' during aggregation 
thereby contributing to oxidative stress and so to LDL oxidation. Free radicals may 
also cause direct injury to endothelial cells. These effects might be more marked 
in diabetic subjects since their platelets have been found to be more aggregable (113, 
231). Particularly relevant to the current proposal is the finding of reduced vitamin
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E concentration in diabetic platelets (125). Vitamin E is a  free radical scavenger and 
a major lipid antioxidant, it also has a modulating effect on platelet function 
inhibiting platelet aggregation (109, 239). The aim of the study described in this 
chapter was to establish whether or not platelets did release O^*', especially during 
aggregation, and if so to assess whether the effect differed in extent in platelets from 
diabetic and non-diabetic subjects.
Like otlier radicals can act as either an oxidising or reducing agent. It’s ability 
to reduce ferricytochrome C (Fc) to ferrocytochrome C (Equation 4.1), producing 
a change in absorbance at 550nm was made use of to enable it’s detection.
Equation 4.1 Fc -  + Oô  ^ Fc -  Fe^^ + O2
Reduction of Fc is not specific to so that specificity of detection was ensured by 
looking only at that component of reduction inliibited by superoxide dismutase 
(SOD) (19, 24, 240).
Preliminary experiments were performed with platelets suspended in plasma but, as 
will be seen, plasma contained substances capable of Fc reduction and so to avoid 
this interference definative experiments were performed with platelets isolated from 
plasma by gel filtration.
4.2. HYPOTHESIS.
Platelets are capable of releasing O^' and those from diabetic subjects release more 
than those from non-diabetic subjects.
4.3. STUDY DESIGN.
Diabetic platelets were harvested from diabetic subjects chosen at random from 
among routine attenders at the diabetic clinic. Non-diabetic platelets were harvested 
from normal healthy laboratory workers. Subjects were all fasting at tlie time of 
blood sampling. In preliminary experiments platelets in plasma were studied. In 
the definitive study platelets isolated from plasma by gel filtration were studied. All 
experiments were performed on multiple platelet samples, the exact number varying 
from experiment to experiment but as indicated in the results section.
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4.4. METHODS.
Because the analytical and experiment methods used in this chapter are not used 
elsewhere they are described here as opposed to in tlie metliods chapter.
4.4.1. Platelet Preparations.
a. Platelet Rich Plasma fPRPT
Whole blood was collected by venepuncture using a 19 gauge needle and 
immediately added to 3.8% citrate [9:1 volivol] followed by centrifugation at 150 
G for 10 mins. The supernatant PRP was removed.
b.Platelet Poor Plasma tPPPl
PRP was centrifudged at 1,500 G for 10 mins. The supernatant PPP was removed.
c.Platelet Rich Suspension fPRSl
PRP was applied to a gel filtration column (diameter 2.5cm, height 8cm.) packed 
with cross linked sepharose 2B (Pharmacia, Milton Keynes, UK). The column was 
equilibrated by prior washing with the elution buffer (NaCl : 8 g/1; KCl : 0.2 g/1; 
NaH^PO., : 0.065 g/1; MgCl^ : 0.415 g/I; NaHCOg : 1 g/1, corrected to pH 7.3). 
All salts were Analar grade, (BDH, Poole, Dorset, UK). Those fractions judged 
visually to be rich in platelets were pooled to form PRS. The platelet rich 
suspension contained platelets at a mean count of 213 (SD 94) x lO^.mm'^.
d. Platelet Poor Suspension (TPSl
PRS was centrifuged at 10,000 G for 1 min in a Beckman minifuge (Beckman 
Instruments, Inc., Brea CA, USA). The platelet free supernatant was harvested.
4.4.2. Platelet Aggregation
Platelet aggregation was achieved by agitating platelets with collagen (1 mg/ml in 
isotonic glucose) (Hormon-chemie, München, Germany) using such volumes as 
would give a final collagen concentration of 3 /xg/ml in reaction mixtures. In the 
preliminary experiments agitation was achieved by stirring, whilst in the definitive 
experiments platelets were shaken.
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The extent of platelet aggretion was determined by counting platelets using an 
Ultraflow 100 (Beckton-Dickinson. Abingdon, Oxon, UK).
In experiments in which platelet aggretion was assessed the fall in platelet 
concentration at 10 and 60 mins from that at 0 min was expressed as a percentage 
of that at 0 mins.
4.4.3. Ferricytochrome C Reduction And Superoxide Generation
Ferricytochrome C (Fc) type 111 and bovine erythrocyte superoxide dismutase (SOD) 
were obtained from Sigma (Sigma Chem Co, St Louis, Missouri, USA).
a. Preliminarv Experiments- Fc reduction bv stirred platelets in plasma
Fc, at a final concentration of 50/tM, was stirred for 15mins with aggregating 
platelets (PRP+ collagen), resting platelets (PRP-collagen) or with plasma 
(PPP + collagen). As a blank Fc was also stirred in the presence of collagen alone. 
The CD at 15 mins was measured after centrifigation at 10,000 G to remove 
platelets.
b. Definitive Experiments-Fc reduction and Superoxide Generation bv gel filtered 
platelets.
The experimental procedure is depicted in Fig 4.1. SOD and Fc solutions were 
made fresh daily. The final concentration of Fc in the reaction mixture was 
increased to 200ju.M. Initial experiments were performed with larger volumes to 
allow sampling at more frequent intervals. Ultimately sampling was performed only 
at 10 and 60 min of incubation. Samples were immediately centrifuged (10,000 g 
for 1 min) to remove platelets, diluted and read at 550 nm in an LKB Biochem 
Ultrospec 4050 (LKB Pharmacia, Milton Keynes, UK).
4.4.4 Presentation Of Results
The effect "attributable to resting platelets" on Fc reduction is calculated as the 
difference between the OD at 550 nm after exposure to non-aggregating platelets 
(PRP or PRS) and that after exposure to a suspension free of platelets (PPP or PPS). 
In the definative experiments, and with reference to Fig 4.1, this means that the 
effect attributable to resting platelets was calculated as the difference between the
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Reactants 
(final conc.
Combination of reactants 
added to each tube.
Step one 
Fc (200/iM)
Collagen (3 /ig .m l')
+ + +
+ +
1 2 3 4 5 6
Step two. 
Time:0 min.
p U le le lsr e s t i n g p la te le t saggregating p la te le t sa b s e n t
Platelet rich suspension (1ml) 
Platelet poor suspension(lml)
Step three ('five'). 
Time: lOmin (60min)
600/il sample removed from each tube and 
centrifuged at 10,0000 for 1 min.
Step four.
5 6
fj R
J _! Lk
( p l a te l e t )  
{ p e lle ts )
150/ilof supernatant 
removed and diluted to 
800/il and read at 550nm.
Figure 4.1: The experimental procedure used to investigate the reduction of 
ferricytochrome (Fc) by platelets in the presence and 
absence of superoxide dismutase (SOD).
OD found in samples from tubes 2 and 6. The difference between tubes 1 and 5 
was also attributable to resting platelets but in the presence of SOD. Comparison 
of these differences in the presence and absence of SOD was used to determine the 
effect of SOD. The effect "attributable to aggregation" was calculated as the 
difference between OD after exposure to aggregating platelets (PRP or PRS agitated 
with collagen) with OD after exposure to non-aggregating platelets (PRP or PRS 
agitated without collagen) that is as the difference between tubes 3 and 5, with SOD, 
and between tubes 4 and 6, without SOD (Fig 4.1). Differences in OD are 
expressed in OD units and are corrected for platelet concentration by taking 100 x 
lO^mm  ^ as unity. Results are shown as mean + 1 standard deviation (SD) and are 
compared by paired and unpaired t-test.
4.5. RESULTS
4.5.1 Preliminarv Experiments.
Using stirred platelets in plasma the OD of Fc rose significantly on exposure to both 
aggregating platelets [0.968 (0.079) vs 0.393 (0.017) OD units p <  0.001] and 
resting platelets [0.955 (0.112) vs 0.393 (0.017) OD units p <  0.001]. Therefore 
tlie effect attributable to aggregation, determined as the difference between the 
effects of exposure to aggregating vs non-aggregating platelets (resting), was small 
and not statistically significant (Mean difference 0.014 (0.041) p= 0 .3) (Table 4.1). 
However stirring with platelet poor plasma and collagen ,or with collagen alone, 
also produced a background reduction of Fc (Table 4.1). This background effect 
added a source of error and potentially masked platelet effects but could be 
eliminated by separation of platelets from plasma by gel filtration and shaking as 
opposed to stirring. Hence gel filtered platelets were used in further experiments.
4.5.2 Definitive Experiments.
The fact that gel filtered platelets were viable and that shaking supported aggregation 
was confirmed by the presence of visible aggregates in all experiments and by 
counting platelets to determine the drop in platelet numbers in representative 
experiments. Collagen induced aggregation of gel filtered, shaken platelets was 
significantly greater than that which occured spontaneously (Table 4.2). Also
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spontaneous and collagen induced aggretation was not inhibited by superoxide 
dismutase (SOD) (Table 4.2).
The time course of Fc reduction on exposure to gel filtered, aggregating platelets is 
seen for three representative experiments in Fig 4.2. In subsequent experiments 
measurement of OD was performed only at 10 and 60 minutes.
Using shaken, gel filtered platelets (Fig 4.1) the absorbance of Fc exposed to resting 
platelets for 60 mins without SOD (tube 2) was not significantly different from that 
exposed to a platelet free preparation (PPS) ( tube 6) in other words tliere was no 
significant effect attributable to resting platelets [1.128 (0.372) vs 1.107 (0.379) OD 
units, mean difference = 0.021 (0.062), p=  0.242] (Fig 4.3). Similarly 
insignificant differences were seen if the diabetic and non-diabetic subjects were 
analysed separately (Fig 4.3). The effect on Fc reduction attributable to aggregation 
was not signigicantly different in the presence or absence of SOD at 10 mins [WITH 
SOD: 0.009 (0.040) vs WITHOUT SOD: -0.026 (0.076) OD units, p = 0.052] 
(Table 4.3) or at 60 mins [WITH SOD: 0.013 (0.064) vs WITHOUT SOD: 0.012 
(0.101) OD units, p=0.987] (Table 4.3). There was no significant difference 
between diabetics and non-diabetics (Table 4.3).
4.6 DISCUSSION
No evidence of Fc reduction or superoxide anion release attributable to resting or 
collagen stimulated aggregating platelets was found in this study. Hence this study 
lends no support to the hypothesis that platelets release O '^ suggesting that this 
cannot be proposed as a mechanism whereby platelets contribute to atherosclerosis. 
In preliminary experiments it was found that plasma contained unidentified species 
capable of reducing Fc. The SOD inliibitable component of this reduction was not 
investigated here, but superoxide generation in serum has been reported (106) and 
glycated proteins and glucose autooxidation were suggested as possible sources (18, 
102, 105, 106). The reduction of Fc seen in the presence of collagen alone cannot 
be explained. Because of anticipated problems in identifying potentially only small 
changes in absorption at 550 nm against this background methods of eliminating this 
interference were sought. This elimination was achieved when gel filtered platelets 
where used and shaken as opposed to stirred. The use of gel filtered platelets might 
explain differences in my results from those of Marcus et al (241). Using washed 
platelets they saw continuous SOD inhibitable reduction of Fc, and presumably
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production in association with resting platelets. This superoxide production was not 
increased by aggregation, questioning its putative platelet origin. Possibly washing 
fails to separate platelets from the active plasma components as efficiently as gel 
filtration. The difference in the results of these studies was not due to the loss of 
function of gel filtered platelets as their viability was confirmed by their ability to 
aggregate in response to collagen.
The possibility that Og' was released but took part in other kinetically more 
favourable reactions, thereby remaining undetected, is unlikely. Gel filtration would 
have removed most of the plasma components such as lipids and proteins which 
would have been capable of undergoing such reactions. can undergo
spontaneous dismutation in aqueous solution (Equation 4.2) but the rate is pH 
dependent and greater at low pH and so less likely at the physiological pH used here 
where the rate constant is 5 x 10^  M'^s"' (13).
Equation 4 .2  + 2H  ^ -  Og + HgOg
The reaction catalysed by superoxide dismutase is pH independent in the pH range 
5.3-9.5 and has a rate constant around 3,000 times that of the spontaneous reaction 
(1 . 6  X 10^  M'^s'^). The rate constant for the reaction of O / ' witli Fc (Equation 4.1) 
is (1.1 X 10  ^M'^s'^) (242) and more nearly approximates to spontaneous dismutation 
but the concentration of Fc (2 x 10"* M) is so greatly in excess of that of the H^ 
concentration (10'^ M) that reaction with the former would be favoured. 
Theoretically lipid peroxides and other secretory products of platelets may be 
capable of reaction with Fc causing its re-oxidation and so masking reduction. As 
no overall effect was observed, for this to be the explanation, the release of exactly 
equivalent amounts of oxidising and reducing species would have to be postulated 
but seems highly improbable.
Because Fc was present in tlie reaction mixture before the addition of platelets it is 
not possible that a burst of O / ' release occurred prior to its addition and was missed. 
I employed physiological concentrations of platelets in this study, and it is possiblle 
that the assay was not sensitive enough to detect the small resultant concentration of 
Oj*'. Platelet concentration at sites of injury may be much higher and larger 
concentration of may be produced in those circumstances.
In agreement with Marcus et al (241) I observed no inhibition of platelet aggregation 
by SOD or Fc. However these results may seem to disagree with those of Salvemini
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et al (243) who reported inliibition of thrombin induced adhesion by both substances 
and inliibition of aggregation by SOD, However this effect was seen only at 
concentrations of thrombin producing less than 45% aggregation, and was lost at 
higher concentrations producing greater percentage aggregation. In the current study 
collagen was used and at doses achieving greater than 70% aggregation and so 
actually in agreement with Salvemini et al, no inliibition was observed. Salvemini 
et al concluded from the inhibition seen at low thrombin dose that 0 /  was involved 
in platelet activation. The results here do not contradict that conclusion. I looked 
at the reduction of Fc in the supernatant surrounding platelets, the platelets were 
removed by centrifigation prior to measurements of OD, and no reduction of Fc was 
observed therefore it can be concluded only that was not released to the external 
environment of aggregating platelets, not that it has no involvment in activation. 
Salvemini et al did not offer an explanation as to why the effect of SOD on platelet 
aggregation is lost at high doses of thrombin. An expiation of that phenomenon may 
also offer another reason why I observed no effect of SOD on collagen induced 
aggregation. The set of reactions leading to aggregation induced by one agonist is 
similar to but different from that induced by other agonists. Some agonists including 
thrombin have modes of action dependent upon their concentration (244). Therefore 
it is possible that O^' dependent reactions are involved in the aggregation induced 
by one concentrtion of thrombin but not by another, and by low dose thrombin but 
not collagen.
The lack of Ox*' release by platelets excludes only one possible mechanism of platelet 
enhanced oxidation of LDL. Platelets have LDL receptors and Og* produced by an 
enzyme system located within the cell membrane may not need to escape it to react 
with bound LDL. They may release other radicals (239) or oxidise LDL by other 
means. Aviram et al (236) has reported that the medium surrounding activated 
platelets (platelet conditioned medium, PCM) enhanced copper stimulated LDL 
oxidation by a mechanism which involved FR, but since PCM alone did not oxidise 
LDL it did not appear to contain the oxidising species per se but enhanced their 
production in an unidentified way (236).
4.7. CONCLUSION.
This study does not support the hypothesis that platelets at rest or during aggregation 
release superoxide anion. This is true for diabetic and non-diabetic subjects. The
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proposal tliat superoxide anion release by platelets may be a mechanism whereby 
platelets contribute to the generation of atherosclerosis is also unsupported by these 
findings. However, only the effect of one agonist, collagen, was studied and work 
with other agonists may be valuable. It has not been excluded tliat platelets enhance 
LDL oxidation by other mechanisms and other interactions between platelets, 
macrophages and lipoproteins not involving LDL oxidation may prove to have more 
important roles in atherogenesis (236, 245, 246)
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CHAPTER FIVE 
PLASMA ANTIOXIDANTS IN DIABETES MELLITUS.
5 J . INTRODUCTION
Since FR oxidation of LDL may increase its atherogenicity then mechanisms that 
impede FR reactions might be expected to protect LDL from oxidation and therefore 
be anti-atherogenic. Diabetic subjects are at increased risk of atherosclerotic disease 
and I wished to ascertain if this might be due in part to impaired FR defences.
This chapter and the next deals with a single study designed to test two hypotheses. 
These hypotheses are
1. Plasma total antioxidant activity, as measured by TRAP, is lower in diabetic
subjects than in healthy controls, thereby exposing diabetics to increased risk
of FR mediated damage.
2. The extent to which the lipids in plasma from diabetic subjects peroxidise will 
be inversely related to plasma total antioxidant activity, as measured by TRAP.
This chapter describes the study and deals with the background, results and 
discussion pertaining to the first of these hypothesis including a discussion of the 
rational for the use of the relatively novel TRAP assay to assess FR defences. For 
the sake of clarity, the second hypothesis is dealt with in chapter six.
5.1.1. The Nature Of Free Radical Defence Mechanisms
Because they involve single electron transfer, any reaction between a radical and a 
non-radical inevitably results in the formation of a new radical. Hence FR reactions, 
once initiated, progress via an auto-catalytic chain reaction. Radicals are annihilated 
only on reaction with other radicals. Undesirable FR processes are limited in vivo 
by many strategies; some are aimed at preventing initiation of tlie chain, others at 
its interruption. Some are specific, others less so.
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a.Preventative Defence Mechanisms.
Non-specific, preventative strategies of control include the fact that FR 
intermediates, produced in the course of normal metabolism, are generally securely 
enzyme bound restricting their reactivity. Also, compartmentalisation of metabolic 
processes means that products of one pathway, including FRs, may have limited 
effects on other pathways. Another non-specific method of control involves binding 
of transition metals (17, 201). As mentioned earlier, copper (CiU) and iron (Fe^ 3  
ions are capable of catalysing FR chain reactions and reactions which result in the 
generation of FRs (Fig 1.2). Few, if any, of these ions are left free but form 
complexes with proteins such as caeruloplasmin, transferrin and ferritin and low 
molecular weight molecules such as ATP. This provides restriction of their catalytic 
potential although there is some debate as to the efficiency of that restriction in 
certain circumstances (15, 247). It has been noted that EDTA-Fe complexes do 
support OH' production in vitro and this raises the possibility that other low 
molecular weight, non-protein transition metal complexes may be active in vivo 
(247, 248). Also, it was found that the iron bound in lactoferrin and transferrin 
could be mobilised, and so was capable of catalysing OH* production when the limit 
of the Fe^ "^  binding capacity of these proteins was approached, and/or the pH 
reduced (247). In addition. Ox" was found to reduce and release iron from ferritin 
implying that vicious cycles of metal ion release and FR production could arise 
(249). Evidence that such iron mobilization does occur and can be pathologically 
relevant in vivo comes from animal studies showing that FR production and damage 
during ischaemia and reperfusion were inhibited by the iron chelator, deferoxamine 
(23). Incomplete restriction of transition metal catalysed FR activity may also have 
a role in diseases of iron overload such as rhesus disease and thalassaemia (250). 
In addition to simply binding copper, caeruloplasmin also has a ferroxidase activity, 
oxidising Fe^ "^  to Fe^^ (251). In this valency state, iron can no longer catalyse the 
Haber-Weiss reaction, which produces OH (15). All of these methods achieve 
control of FR processes by preventing the initiation of harmful chain reactions. The 
same method underlies the more specific effect of catalase and the peroxidases, 
including glutathione peroxidase. By removing HgOx and other peroxides, which can 
be precursors of FRs (Fig 1.2), new radical chain reactions are prevented (26, 219).
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b. Chain Breaking Defence Mechanisms.
Mechanisms in which the "antioxidant" reacts directly with, and disarms, an already 
formed radical may inhibit, not the initiation of the chain reaction, but its 
progression. Mechanisms employing this "chain-breaking" approach are of several 
types (26) but include the enzymic activity of superoxide dismutase (SOD). SOD 
specifically removes O2" by catalysing its reaction with a second Ox" ion causing 
their dismutation to H^Ox (24).
Other chain breaking antioxidants are non-enzymic and can be divided into two 
groups. The first group are molecules generated endogenously for other purposes 
but also capable of antioxidant activity such as uric acid, bilirubin, glutathione and 
the thiol groups of amino acid side chains in proteins (13, 26). The second group 
cannot be synthesised m vivo by man and are provided only by the diet and include 
vitamins C, E, A and the pro-vitamin /3-Carotene (17). In the terminology, as 
applied to fatty and amino acids, these antioxidants might be thought of as non- 
essential and essential respectively.
In the process of radical removal, these non-enzymic chain-breaking antioxidants are 
themselves chemically altered leaving them not only incapable of furtlier antioxidant 
activity but also, at least temporarily, converted to another radical. On first 
inspection the process seems to offer little advantage, merely substituting one radical 
for another, whilst losing the antioxidant. Such sacrificial loss initially appears 
extravagant, especially in the case of essential antioxidants. However, not all 
radicals are of equal potency (17, 201) and the new radical is usually one of lesser 
reactivity, and therefore less capable of damaging macromolecules. Also, there 
frequently exist mechanisms for recycling the antioxidant. For example, the active, 
antioxidant form of vitamin C is the reduced, non-radical ascorbic acid (AA) (252), 
It is oxidised during reaction with such radicals as Oy’ and O H , becoming tlie 
ascorbate radical, semidehydroacsorbate, (SDHA) (Fig 5.1). Although a radical, 
SDHA is less reactive than Ox" or OH'. Recycling begins with the reaction of two 
SDHA radicals which results in the formation of one AA molecule and one 
dehydroascorbic acid (DHA), the latter being neither a radical nor an antioxidant 
(Fig 5.1) (13, 119). In addition DHA is then recycled to AA by a glutathione- 
dependant reductase (Fig 5.2) (13).
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5.1.2. Clinical Relevance Of Free Radical Defence Mechanisms In Atherosclerosis
As already discussed, FR oxidation of LDL may be important in the genesis of 
atheroma. Such oxidation would become more probable in situations in which FR 
defence mechanisms were impaired. Hence these mechanisms may be of relevance 
pathologically and a knowledge of them, and how they might come to be abnormal, 
may add to our understanding of the pathogenesis of atheroma.
These mechanisms may also be of therapeutic importance. Should the oxidation 
theory of atheroma prove correct, manipulation of these mechanisms may offer 
means of treatment and protection against atheromatous vascular disease. The 
mechanisms influenced by diet, such as those involving the essential chain-breaking 
antioxidants, are likely to be the most readily manipulable. Some encouragement 
for this way of thinking has come from studies on probucol. Probucol is a drug 
prescribed to lower plasma cholesterol. However, it is structurally similar to tlie 
antioxidant butylated hydroxytoluene and also has antioxidant properties. In vitro 
it has been shown to reduce cellular and metal catalysed oxidation of LDL (253). 
In vivo, when compared to doses of lovastatin which produce similar degrees of 
cholesterol lowering, probucol also reduced tlie progression of atherosclerotic lesions 
in Wantinabe heritable rabbits (254). These animals are deficient in the LDL 
receptor and serve as a model for Familial Hypercholesterolaemia. This was taken 
to imply that probucol’s anti-atherogenic action was not simply the result of its 
hypocholesterolaemic effect and suggested tlie possibility that its antioxidant 
properties were responsible. It has to be borne in mind of course that probucol may 
have yet other properties, currently unidentified, accounting for this activity.
Like Probucol, ascorbic acid and a-Tocopherol, the most active form of vitamin E, 
reduce cellular and metal catalysed human LDL oxidation in vitro (28, 255). Also 
it has been reported that LDL isolated from humans having taken vitamin E 
supplements displayed resistance to oxidation in vitro (46). Dietary supplements of 
vitamin E which raised plasma levels four fold attenuated atherosclerotic lesion 
development in Watanabe rabbits (256). These studies suggest that the naturally 
occurring antioxidants, vitamins E and C, might also have anti-atherogenic effects. 
It is also possible, but cannot be assumed, that tliey would have the advantage over 
probucol of fewer side effects. Hence pathological insights and therapeutic 
possibilities may be gained by assessment and greater understanding of FR defence 
mechanisms.
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5.1.3. Antioxidants In Diabetes And Ischaemic Heart Disease
Many abnormalities of antioxidant levels have been reported in diabetes and were 
outlined in section 1.3.2. Abnormalities have also been described in ischaemic heart 
disease. In a case control study, lower plasma levels of vitamins E and C were 
found in a group of men suffering from angina. Whereas tlie relationship between 
low vitamin C levels and the risk of angina was confounded by smoking, this was 
not true for vitamin E levels. Further, low vitamin E levels remained related to risk 
of angina even after allowing for age, blood pressure, total and HDL cholesterol, 
triglycerides and weight (199). This suggests an independent, inverse relationship 
between vitamin E levels and risk of angina. Whether low vitamin E is a cause or 
a consequence of angina cannot be concluded from such a relationship, however tlie 
situation is made a little clearer by cross cultural, population studies of apparently
normal volunteers in which vitamin E and C levels were found to be lower in groups 
from areas associated witli high risk of cardiovascular disease compared to those 
from areas associated with low risk (198). If reduced levels predate disease they 
cannot be a consequence and is more consistent with, but still not proof of, a causal 
relationship.
5.1.4 Problems In Interpreting Abnormalities In Antioxidant Levels.
Thus, many abnormalities in antioxidant levels have been noted in tliose suffering 
from diabetes and cardiovascular disease. However, so little is known of how 
antioxidant levels are controlled ifi vivo that interpretation is not straightforward. 
As always, there is the problem as to whether the abnormality is "cause or 
consequence" of the disease process or an epiphenomenon. In addition, because of 
the close links between antioxidants and FRs, antioxidant levels are frequently 
interpreted in terms of FR activity and are even used as indirect markers of FR 
activity. However, this requires great caution as reduced antioxidant levels might 
suggest, for example, greater consumption due to increased FR production, but it 
is also possible that reduced antioxidant activity is the body’s response to reduced 
demand, so reflecting reduced FR production. This type of argument was used by 
Jones et al who found, not reduced levels of caeruloplasmin and iron binding 
proteins, in a group of diabetic subjects, but increased levels (251) and yet they were 
able to conclude that this was still compatible with increased FR activity in diabetes
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and reflected a response to that activity. Despite the difficulties with interpretation, 
there are obviously many studies which do suggest that FR defense mechanisms are 
perturbed in atherosclerosis and diabetes, although there is some doubt as to whether 
antioxidants are reduced as a consequence of the disease or increased as a response. 
Another difficulty with interpreting antioxidant levels in terms of FR activity is that 
FR activity is not the only factor affecting antioxidant levels. Diet and smoking may 
both have major influences on antioxidant intake and survival (169, 195, 197). Also 
age has been reported to be associated with alterations in antioxidant enzyme systems 
(206), vitamin A (257) and vitamin E cocentrations (258).
5.1.5. Problems In Measuring Antioxidant Levels.
As in the studies mentioned above, FR defence mechanisms are often assessed by 
measuring the concentration of one or more individual antioxidants. It is often 
assumed that those measurements reflect overall antioxidant status and FR defences. 
Although stimulating information has been gained by this approach it does have 
problems, even in addition to those of interpretation. These arise because the 
protective activities do not work in isolation but in consort (26). This allows for the 
possibility that a low level of one may be compensated for by elevated levels of 
another, and therefore an alteration in a single antioxidant may not reflect overall 
antioxidant status. One way around this difficulty would be to measure the 
concentration of all antioxidants and, using the stoichiometry of their reactions with 
radicals, calculate tlie total antioxidant activity (260). This is limited in many ways. 
Firstly, not all antioxidants are known. Secondly, the stoichiometry of tlieir 
reactions with radicals is debated (26), and may differ depending on the radical 
involved, but also depending on the environment in which the reaction occurs and 
the concentration of the reactants (261). In addition, complex interactions between 
antioxidants occur for example the vitamin E radical formed during FR scavenging 
is reactivated by interaction with vitamin C (Fig 5.2) (262). In its turn vitamin C 
is reactivated as described above in section 5.1.1. Such interactions mean that 
simple summation of the calculated activities based on concentrations of individual 
antioxidants would be misleading (260).
Some integrated measure of activity would be of greater value. Wayner et al have 
described such a method (127) and it is employed in this work and it measures the 
total peroxyl radical trapping antioxidant parameter (TRAP) of plasma in what is
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almost a bioassay. The principle behind this assay is outlined in the next section. 
It makes no assumption regarding the nature or concentration of individual 
antioxidants in plasma and its value will be contributed to by all species capable of 
reacting with peroxyl radicals, including vitamins C, E, uric acid etc. The fact that 
it relates to the peroxyl radical makes this method particularly appropriate for the 
study of LDL lipid oxidation because, as was discussed in chapter 3, oxidation of 
the lipid, once initiated, is propagated by peroxyl radicals (Fig 3.1).TRAP gives an 
estimate of antioxidant equivalence, as opposed to a concentration, since the 
stoichiometry of reactions between antioxidants and radicals is not one to one.
5.1.6. Principle Of The TRAP Assay.
The precise methodological details of this assay are given in chapter two (Section
2.3.6.). Plasma contains antioxidants and their combined effects confer plasma with 
the ability to inhibit oxidative processes. In the TRAP assay plasma is used to 
inliibit the peroxidation of linoleic acid and the extent of this ability is determined 
by comparing it with that of a known amount of antioxidant (Figs 5.3 and 5.4). In 
the experiment, linoleic acid is mixed with, and peroxidised by exposure to, 2 ,2 '- 
azo-bis(2-amidinopropane) hydrochloride (ABAP) which thermally decomposes with 
the release of peroxyl radicals (Fig 5.3) (127). The peroxidation of linoleic acid is 
accompanied, and so can be followed, by uptake of oxygen (Fig 5.3). The 
peroxidation of linoleic acid, and so the uptake of oxygen, in the presence of plasma 
begins only after a time lag. A typical O2  uptake curve is shown (Fig 5.4). The 
duration of this time lag, or induction phase (Tp), is determined by the antioxidants 
in plasma. Addition of a known amount of antioxidant also produces an induction 
phase (TJ . By comparing Tp and T„ the antioxidant capability of plasma can be 
calculated. In this study the antioxidant used was Vitamin C and a stoichiometry of 
its reaction with peroxyl radicals was taken to be 1.7 (26).
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The equation for calculation of TRAP is derived as follows:- 
Since:-
Jp   ^ [^^conc/  ^ Antioxidants in plasma] x Vol. plasm a  
Tg [conc. of Ascorbate] x n x Vol. A scorbate
where
n =  the number of Peroxyl radicals trapped per ascorbate molecule = 1 . 7  
["conc." of antioxidant in plasma] =  TRAP
Then:-
TRAP = 1.7 X [conc. Ascorbate] x ^  x A scorbateTg Vol. plasm a
where :- [conc. Ascorbate] = SOOjLtmol.l"’ 
Vol Ascorbate = 25^1
Vol plasma =  50jul
TTRAP = 425 X Ta
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5.1 .7 . Summary
Abnormalities in antioxidants may influence the genesis of a more atherogenic LDL. 
Such abnormalities have been reported in diabetes and may help to explain the 
greater incidence of atherosclerotic problems in diabetic patients. However, these 
reports derived from studies making use of arguably simplistic measures of 
antioxidant status. I wished to employ a method, namely the TRAP assay, which 
theoretically determines antioxidant status more accurately and would therefore give 
a more cl ear cut impression of whether or not this status is abnormal in diabetes. 
The problems of how to interpret alterations in antioxidant status remain.
5.2. HYPOTHESIS.
Plasma total antioxidant activity, as measured by TRAP, is lower in diabetic subjects 
than in healthy controls, thereby exposing diabetics to increased risk of FR mediated 
damage.
5.3. SUBJECTS AND STUDY DESIGN
TRAP values were established in seventeen non-diabetic healthy volunteers; their 
characteristics are given in Table 5.1. Diabetic subjects were recruited from among 
the routine diabetic clinic attenders. Patients attending the clinic were asked to come 
"fasting", pre-breakfast or pre-lunch, depending on the time of day of the clinic, 
hence having fasted for more than 3 hours. All patients attending the clinic had 
venous blood drawn for estimation of plasma glucose and HbA^^. Patients were 
approached by the investigator (MEB) who was blind to their clinical details. 
Patients were excluded if not "fasting" otherwise each subject was asked to allow 
an extra 20mls of blood be taken. All eligible subjects agreed. Clinical details were 
subsequently determined by questioning the patients and supplementing their histories 
by reference to the hospital notes. Ten subjects were recruited in this way on each 
of three days within 4 weeks. Their clinical details are are given in Table 5.1. 
Peripheral vascular disease, ischaemic heart disease, nephropathy and neuropathy are 
defined as in the methods section. Subsequently technical difficulties made
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Diabetic
Subjects
Non-diabetic
Subjects
p Value.
Number (n) 30 17
Age (yrs) 60.9(16.2) 42.2(9.5) < 0.001
Smoking (YesiNo) 11:19 4:13 > 0.2'
(%'=0.97)
Sex Ratio (M:F) 14:16 6:11 > 0 .2 '
( f= 0 .4 4 )
Duration (yrs) 9.0(3.0,12.0)
Type of diabetes 
(IDDM:NIDDM)
8:22
Treatment
Diet 7 N/A
Sulphonylurea 6 N/A
Sulphonylurea 
plus metformin
8 N/A
Metformin 1 N/A
Insulin 8 N/A
Complication
None 12 N/A
Micro vascular 11 N/A
Macrovascular 2 N/A
Micro plus macro 3 N/A
Hypertension 2 N/A
HbA,, (%) 
(NR=6.5-8.5)
10.9(2.2) 6.4(0.6) 0.0001
Fasting plasma 
glucose (mmol 1^ )
10.5(4.6) 5.1(0.6) 0.0001
TRAP (umol D) 661.8(173.8) 774.3(103.7) 0.01
Table 5.1: Clinical details of subjects.
N/A : Not applicable.
NR : Normal range.
Values are given as mean (SD) or median (25th, 75th percentile). Comparisons between 
groups are tested using unpaired t-tests or chi-squared test^
estimation of TRAP in four diabetic subjects impossible therefore results are 
presented for twentysix subjects.
Since alterations in certain antioxidants believed to contribute to TRAP have been 
related to age and smoking these features were noted and included in the statistical 
analysis. The possible contribution of duration of diabetes and of metabolic control 
on reduced antioxidant status were assessed by measurement of HbAj^ and by 
recording the time since diagnosis of diabetes, incorporating this data into statistical 
analysis.
As the second limb to this study "peroxidisability" of plasma lipids was measured 
in tlie diabetic subjects and this aspect of the study is dealt witli in chapter six.
5.4. METHODS.
The analytical and stastistical methods used are described in chapter two.
5 .4 .1 . Assavs Performed.
Fasting plasma glucose (FPG)
Glycosylated haemoglobin (HbAjJ 
Total cholesterol (total-Choi)
Triglyceride (TG)
Total Peroxyl Radical Trapping Activity of Plasma (TRAP)
Plasma peroxidisability - these results will be discussed in chapter six ,and it was 
measured in the diabetic subjects only.
5 ^  RESULTS
The age of control subjects was significantly less than that of the diabetic group 
(42.4(9.5) vs 60.9(16.2)years, p =0.001) but age did not correlate significantly with 
TRAP (r=0.017, p =0.915) (Fig.5.5). The proportion of smokers in the diabetic 
group was not significantly different from that in the controls (%^=0.97, d f = l ,  
p= 0 .2) and the TRAP in smokers was not significantly different from that in non­
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smokers (638.4(200.7) vs 744.9(123.3)jamol.U, p=0.09) (Fig.5.6). The TRAP in 
diabetic subjects was found to be lower than in non-diabetic controls (661.8(173.8) 
vs 774.3(103.7)jLtmol.r‘, p =  0.01) (Fig 5.7) however using analysis of variance with 
both diabetes and smoking as independent variables a significant interaction between 
diabetes and smoking was suggested (Table 5.2). Therefore separating the subjects 
into diabetic and non-diabetic smokers and non-smokers revealed that in non- 
smokers TRAP was not significantly different in diabetic and non-diabetic subjects 
(736.5(151.8) vs 754.6(84.3)|tmol.l'Sp=0.70) whereas in smokers TRAP was lower 
in diabetics than in non-diabetics (558.5(161.5) vs 838.3(147.5)/xmoI.l'\ p=0.02). 
Also in diabetics TRAP was significantly lower in smokers than in non-smokers 
(558.5(161.5) vs 736.5(151.8)/^mol.l ', p =  0.01) (Fig 5.8). The inclusion of age in 
the analysis of variance model with diabetes and smoking confirmed that age did not 
significantly influence TRAP (Table 5.2).
Witliin the diabetic group, TRAP did not correlate with age, duration of diabetes 
(Fig 5.9), fasting plasma glucose nor HbA^  ^ (Fig 5.10) in univariate analysis (Table 
5.3). In a multiple linear regression model these relationships remained non­
significant (Table 5.4a). This remained true when smoking was included in the 
model which also confirmed that smoking was a significant determinant of TRAP 
in diabetics (Table 5.4b)
TRAP levels did not significantly differ between those with and without 
complications nor between those with type 1 or type 2  diabetes nor between the 
sexes (Table 5.5).
5.6. DISCUSSION
5.6.1. TRAP And Diabetes.
Although age was different in the diabetic and non-diabetic subjects studied it was 
not found to be correlated with TRAP in this study, in univariate or multivariate 
analyses, and so I will not discuss it frirther in terms of confounding effects upon 
TRAP in diabetes. However, as previously mentioned, age has been associated with 
lower levels of certain individual antioxidants (206, 257, 258). The fact that I find 
overall antioxidant activity not negatively correlated suggests th epossibility that with 
ageing a new balance of individual antioxidants is reached with some falling whilst 
others rise hence acheiving no overall change. In keeping with tit is possibility a
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Dependant
variable
Source of 
variation
F value p value
TRAP Age 0.21 0.887
Presence of 
diabetes
5.993 0.019
Smoking 2.342 0.134
Interaction 
of diabetes and 
smoking
5.791 0.021
Table 5.2: The effect of smoking, the presence of diabetes and age upon TRAP.
The analysis of variance table showing the variance ratios (F) explained by the listed 
variable and the associated level of significance (p).
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TRAP
Correlation
Coefficient P
Age (yrs) n= 26 0.190 0.354
Duration of 
diabetes (yrs) n = 26
-0.099 0.632
Fasting plasma 
glucose (mmol .1"^ ) n = 26
-0.051 0.803
HbAi, (%) n = 22 0.038 0.866
Table 5.3: The correlation of TRAP with age, duration of diabetes and glycaemia in diabetic 
subjects.
Pearson correlation coefficients and the level of significance (p value) of the correlation 
within the diabetic group.
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positive correlation between age and glutathione peroxidase activity was reported by 
Ceballos-Picot et al (206). Also some reports of reduced vitamin E with age (258) 
may be misleading in that they do not correct for lipid changes with age (259). The 
use of TRAP as a measure of plasma antioxidant activity is theoretically an 
improvement upon the use of individual antioxidants as a guide to such activity 
because it is contributed to by all plasma antioxidants active against peroxyl radicals 
and it allows for their interaction. Using individual antioxidants the situation 
regarding the antioxidant status in diabetes was not clear as some groups had found 
that some antioxidants were reduced (119-126) whilst other groups reported 
increases in yet other antioxidants (251). It was hoped that by using TRAP this 
situation might be clarified. Examining the subjects as a whole TRAP did seem to 
be lower in the diabetic subjects studied than in the non-diabetic subjects however 
when the groups were divided again on the basis of smoking it was found that TRAP 
was not significantly different in non-smoking, diabetic and non-diabetic individuals 
suggesting that diabetes alone does not have a significant influence on antioxidant 
status. Taken together with results of those other studies, which suggested changes 
in individual antioxidants, this again suggests, as with the case of ageing, that their 
may be homeostatic mechanisms aimed at maintaining overall antioxidant status 
which function effectively in diabetes. The lack of difference in TRAP in diabetic 
and non-diabetic non-smokers also suggests that differences, in overall plasma 
antioxidant status, do not contribute to the increased independent risk of vascular 
disease associated witli diabetes or tlie developement of other complications and this 
is in keeping with the finding that TRAP in those diabetics with and without 
complications was not significantly different. The lack of difference between 
diabetics and non-diabetics is also consistent witli the lack of correlation between 
TRAP and measures of glycaemia. Another possible explanation for the lack of 
difference in TRAP between diabetics and non-diabetics is that the study is 
insufficiently powerfiil to detect a difference of 1 0 % and indeed the power to do so 
is only 7% - to detect a 10% difference at the 0.05 level with 80% power 64 
patients in each group would have to be studied.
5.6.2. Trap And Smoking.
The finding of a difference in TRAP between diabetics and non-diabetics in the 
whole group but no difference in TRAP when non-smokers alone were assessed
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implied that either smoking was the relevant variable or that an interaction between 
diabetes and smoking existed and these possibilities were tested in an analysis of 
variance, with diabetes and smoking as independent variables. This analysis 
confirmed tliat there was a significant interaction between diabetes and smoking in 
determining TRAP. This is consistent with the finding that smoking confounded the 
relationshp between plasma vitamin C levels and risk of angina (199) in the light of 
the fact that vitamin C is a contributer to TRAP (26). As a consequence of the 
interaction between smoking and diabetes TRAP in diabetic smokers was 
significantly lower than in diabetic non-smokers. Smoking may produce a lowering 
of antioxidant defence in a number of ways. It has often been reported that smoking 
is associated with reduced plasma levels of ascorbic acid (197, 199) and this may be 
a result of reduced intake of this vitamin by smokers (195). Why this difference in 
intake should occur is unknown. It may reflect the fact that smokers are in general 
less health conscious or more resistant to health education advice, including that 
regarding diet, than are non-smokers. It is also possible that smoking alters taste 
and dietary habits of smokers and this has been cited for the changes in intake of 
other nutrients such as linoleic acid in smokers (152). Smoking is related to poor 
social circumstances and it might have been argued that intake of nutrients in 
smokers could be determined by their relatively poorer income. However, in a 
group of pregnant women Haste et al has shown that income played very little part 
in determining micronutrient intake and that smoking habit was its most important 
determinant (263).
In addition to reduced intake, reduction in antioxidant levels might also occur in 
circumstances of increased demand and consumption, as previously discussed. 
Where there is doubt as to the direction of change in demand, as in the case of 
diabetes, interpretation of alterations in antioxidant levels becomes very difficult. 
Smoking is less of a problem in this respect. Cigarette smoke is both a direct source 
of FRs and also contains chemical species which in stimulating neutrophils results 
indirectly in FR production (13, 195). Harats et al also showed induction of lipid 
peroxidation acutely following consumption of 5-7 cigarettes (196). There seems 
little reason to doubt, therefore, that smoking is associated with increased demand 
for antioxidants, and thus a lower antioxidant level is consistent with increased 
consumption in association with smoking in diabetics. An interaction between 
diabetes and smoking which reduces TRAP may help to explain the even greater 
increased risk of vascular disease associated with smoking in diabetes compared to
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that in non-diabetics. As well as indicating that greater consumption of antioxidants 
may occur in diabetes in conjuntion with smoking a lower TRAP, perhaps just as 
importantly, implies that should diabetic smokers be exposed to further sudden 
increase in FR dose, as is proposed after myocardial infartion or other ischaemic 
episode (21-23, 230, 264-266), they would be at even greater risk of FR mediated 
damage and it would be interesting to ascertain whether or not diabetic smokers have 
a particularly poor outcome following such events.
The number of smoking, non-diabetic subjects in this study is small and so I cannot 
reach any conclusions about the effect of smoking in non-diabetics (n = 4) but it is 
interesting that the TRAP levels in non-diabetic subjects is not significantly different 
in smokers vs non-smokers. In fact, the TRAP levels in non-diabetic smokers is, 
if anything, higher than in the non-smokers, raising the possibility that smoking 
induces an adaptive overall increase in antioxidants in non-diabetics. As evidence 
of the possibility tliat adaptive responses can occur, raised erythrocyte glutathione 
(194) and raised alveolar macrophage ascorbate (195) have been found in smokers. 
Perhaps two sources of increased demand for antioxidants overwhelms the body’s 
ability to match that demand in diabetic smokers. The effect of smoking on TRAP 
in diabetics and non-diabetics warrents further investigation and tliis study highlights 
the need to take into account the smoking status of subjects when investigating 
antioxidant levels.
The lack of correlation between HbAj^, fasting plasma glucose and duration of 
diabetes with TRAP is not in keeping with the contention tliat FR activity, and so 
antioxidant abnormalities, in diabetes might be directly related to the degree of 
metabolic upset. On the other hand, HbA^  ^ is a measure of glycaemia and possibly 
the oxidative process involved in glycation and not of FR generation processes 
generally.
The lack of difference between TRAP in those with and without complications is not 
consistent with the hypotliesis that FR activity is involved in the generation of the 
complications of diabetes but this study was not set up primarily to test tliat 
hypothesis and its power to detect a difference is low.
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5.7. CONCLUSION
TRAP was used in tliis study as a measure of antioxidant status because it offered 
advantages over the use of individual antioxidants in assessing that status. It’s use 
has suggested no overall change in antioxidant status in diabetes per se but a 
significant interaction between diabetes and smoking such that TRAP in diabetic 
smokers was significantly lower tlian in non-smokers. This interaction may help 
explain the even greater risk of smoking in diabetics. The lower TRAP in these 
subjects could also leave them exposed to FR damage in circumstances of increased 
FR load such as following ischaemic episodes. A normal TRAP in non-smoking 
diabetics suggests that alterations in overall plasma antioxidant status can not 
contribute to the increased risk of vascular disease in non-smoking diabetics. This 
may suggest that plasma antioxidants are not important in the processes involved in 
the generation of vascular disease but it remains possible that antioxidant status 
elsewhere such as within plasma lipoproteins or in the subendothelial space does 
have an important role.
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CHAPTER SIX
THE RELATIONSHIP BETWEEN PLASMA ANTIOXIDANT ACTIVITY 
AND LIPID PEROXIDATION.
6.1. INTRODUCTION
In the previous chapter the plasma antioxidant status, TRAP,in diabetic and non­
diabetic subjects was compared and some of the the factors affecting it in diabetes 
were explored. Antioxidants should theoretically inhibit FR processes including the 
oxidaton of lipid, thought to be integral to the modification of LDL to more 
atherogenic forms. In tliis chapter, using TRAP as a measure of the antioxidant 
status of plasma, I explore the relationship between plasma antioxidants and the 
ability of lipids in that plasma to oxidise, that is their oxidisability. The reactions 
involved in lipid oxidation have been discribed in chapter three. The method used 
in this chapter to assess FR lipid oxidisability is a variation on standard methods 
Here I will first discuss the possible pathological relevance of lipid oxidation and 
then describe the method employed to assess lipid oxidation and discuss the rational 
for it’s use.
6.1.1. Relevance Of Lipid Peroxidation To Atherosclerosis.
Since its identification, lipid oxidation has been implicated in the pathogenesis of 
many disease processes. In the context of atheroma it is of interest in several ways. 
Lipid oxidation products are markers of FR activity generally and of attack on lipids 
more specifically. Apart from FR markers, they may have a pathological 
significance of their own. As already discussed, in the generation of a more 
atherogenic LDL particle, it is believed that the aldehyde products of lipid 
peroxidation react with and modify ApoB hence altering LDL receptor binding and 
uptake by macrophages resulting in foam cell formation (48). Lipid peroxides may 
also have atherogenic activity distinct from any connection with LDL. Lipid 
peroxides within erythrocyte membranes may alter haemorheological parameters 
favouring thrombosis (6 8 ), also, they have been shown to inhibit anti thrombin III 
activity (267). In addition, platelet aggregation and endothelial cell prostacyclin 
production have been shown capable of modulation by lipid peroxides (268) and
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direct endothelial cell injury and entranced permeability have been induced by lipid 
peroxides (269, 270). All of these features of lipid peroxides suggest potential 
mechanisms whereby they may contribute to atherosclerosis.
Lipid peroxidation may also have a role in other disease mechanisms but it needs to 
be acknowledged, as pointed out by Dormandy (218), that it is integral to in many 
physiological processes and not always a harmful phenomenon.
6.1.2. Lipid Peroxidation In Diabetes And Atherosclerosis.
There is evidence that more lipid peroxidation does occur in diabetes. There is 
some debate, however, as to whether or not this is only true in the presence of 
diabetic complications. Compared to controls, erythrocyte membranes from diabetic 
subjects were found to have more TEARS and the concentration of these substances 
correlated significantly with markers of glycaemic control (6 8 ). Plasma lipid 
peroxides were found to be higher in diabetic subjects compared to controls and 
higher still in those diabetic subjects with “angiopathy” (microvascular disease) 
(210). However, Sato et al reported significantly higher plasma lipid peroxides in 
diabetics compared to controls but when the diabetics were divided into those with 
and witliout angiopathy only those with angiopathy were significantly different from 
controls (65). Similarly Jennings et al found increased diene conjugates only in 
those with microangiopathy (70). Increased lipid peroxides were also reported in 
Type 2 diabetes by Velâzquez et al but only in those with macrovascular disease and 
non-diabetic individuals with macrovascular disease similarly had elevated TEARS 
when compared with controls (67). This confirmed an earlier study which also 
showed that atherosclerosis was associated with increased levels of TEARS but that 
diabetes had no independent effect (271).
6.1.3. Measurement Of Lipid Peroxidation.
Many methods have been developed for the measurement of FR lipid oxidation (32), 
Those most widely used are based on assessing the concentrations of the products 
of the reactions outlined in chapter three (Fig. 3.1.). As discussed in section 3.1.1., 
because most of the measurable products of oxidation are actually derived more 
specifically by peroxidation, peroxidation is the term commonly used when 
describing lipid oxidation and I use it in this chapter. Total diene conjugated fatty
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acids (tDC) and thiobarbituic acid reactive substances (TEARS) were measured in 
this study in the assessment of lipid peroxidation.
L  Total Diene Conjugation ttD Q
The products of lipid peroxidation which have a diene conjugated system of double 
bonds are typically detected by U.V. absorption spectroscopy, made possible by the 
fact that such systems of double bonds have a characteristic absorption peak at 230- 
240nm. If all of the lipids in a sample are extracted into solvent tlie concentration 
of total diene conjugates (tDC) within the sample can measured 
spectrophotometrically with the results expressed in arbitrary OD units. Such a 
measiirment was used in this study as opposed to tlie measure of the absolute 
concentration of specific diene conjugated fatty acids using HPLC and UV detection 
(DCFA) described and employed in chapter three.
b.Thiobarbituric Acid Reactive Substances (TEARS!
Malondialdehyde (MDA) and hydroperoxides are formed during lipid peroxidation 
and MDA and those hydroperoxides which can be broken down to fragments 
including MDA, can be measured by their ability to react with thiobarbituric acid 
(TEA).
HS
o n
-OH
TEA
4 - CH;
MDA
OH HO.
-CH— a i = c i i
OH +
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% SH
HO
Reaction of MDA with TEA gives a pink complex which absorbs at 532nm and 
fluoresces at 553nm. The test for thiobarbituric acid reactive substances (TEARS) 
is one on the most frequently used in assessing peroxidation but its interpretation 
may cause confusion if it is not realised what it is actually measuring. 
Hydroperoxides are not measured directly but are broken down to MDA during the 
test and measured in terms of MDA equivalents. The standard used is MDA and
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the results are expressed in terms of /xmol.MDA.l'h Hence, the test directly 
measures all of the MDA present in a sample and, indirectly only those 
hydroperoxides which breakdown to MDA. However, there is very little MDA 
present in fresh biological samples as it is believed to be removed rapidly in vivo 
(65, 272) and so most TEARS derive from hydroperoxides.
Despite their common use, there are well documented problems with these methods 
of measuring tDC and TEARS in that they are non-specific (32, 272). Moreover, 
sources of tDC and TEARS other than FR attack on lipids have been identified. In 
chapter three a study was described which suggested that diet is a source of DC 
species. Hydroperoxides are also tlie physiological intermediates of enzymic 
reactions, such as those involved in eicosanoid metabolism (270, 16) and may also 
be ingested.
6.1.4. Principle Of The Peroxidisabilitv Assav.
The factors which determine the extent to which the lipids in plasma peroxidise, 
which I will refer to as their peroxadisability, are not well understood but it might 
be anticipated that the nature of the lipids, as substrate, and a balance between 
plasma oxidants and antioxidants would be involved. I wished to assess the 
importance of antioxidants in tliis context by looking at the relationship between 
plasma antioxidants (TRAP) and plasma lipid peroxidisability. Since peroxidised 
material is almost certainly rapidly removed in vivo (27), and there may be several 
sources of such material in plasma, it was felt that a single measurement of tlie 
concentration of peroxidised materials in plasma would reflect a balance between 
production and removal and not necessarily peroxidisability and that peroxidisability 
could better be assessed by measuring the rise in peroxidation products in isolated 
plasma over a period of time. The lipids in plasma will peroxidise spontaneously 
but, if stressed, the process can be accelerated. In this study plasma lipids were 
"stressed" by maintaining plasma at 3TC  and pH 5.5 for 24 hours (273) and 
peroxidisability was assessed by measuring the changes in absorbence due to tDC, 
and in concentration of TEARS. The relative volume of serum to acetate buffer 
required to acheive these final conditions was established and reported by McFarlane 
(273). Ey measuring the change in these species in these circumstances in vitro tlie 
possibility of them arising from alternative sources, such as diet and cellular 
enzymatic processes, is also removed.
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6.1 .5 . Summary.
Lipid peroxidation initiates the process of LDL oxidation which enhances its 
atherogenicity. Products of lipid peroxidation also have other potentially atherogenic 
effects. The mechanism of lipid peroxidation involves FR activity and should by 
impeded by antioxidants. Many groups have shown that lipid peroxidation products 
are more abundant in diabetes. Others have shown reduced antioxidant levels in 
diabetes. I wished to determine if the extent to which lipids within plasma could be 
oxidised was influenced by the antioxidant activity of that plasma. Since the 
concentration of lipid peroxidation products in plasma may not reflect the degree to 
which peroxidation occurs, because these species are both removed from plasma and 
arise there by other mechanisms, thus an in vitro assay of the extent of peroxidation 
in a set period of time was used to reflect "peroxidisability" and the relationship 
between "peroxidisability" and antioxidant activity (TRAP) was studied.
6J, HYPOTHESIS.
The extent to which the lipids in plasma from diabetic subjects peroxidise will be 
inversely related to plasma antioxidant activity, as measured by TRAP.
6.3. SUBJECTS AND STUDY DESIGN.
Peroxidisability was measured as the second limb of the study described in chapter 
five and the subjects in which it was measured were those diabetic subjects described 
in chapter five.
6.4. METHODS
The analytical and statistical methods used were described in chapter two.
6.4.1. Assays performed
These are listed in section 5.4.1.
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6.5. RESULTS.
6.5.1. Peroxicüsabiiitv And TRAP.
There was no correlation between TRAP and either plasma peroxidisability as 
measured by the change in total diene conjugated species (tDC) (r=0.008, p=0.972) 
(Fig 6.1), or as measured by change in thiobarbituric acid reactive substances 
(TEARS) (i;=0.184, p=0.390) (Fig 6.2) in diabetic subjects. The two measures 
of peroxidisability did not significantly correlate with each other (r^= 0 . 1 0 0 , 
p=0.615) (Fig 6.3).
Change in tDC significantly correlated with total cholesterol concentration (r =  0.575, 
p =0.001) (Fig 6.4) but not witli total triglyceride concentration ( r= 0.105, 
p = 0.605), change in TEARS did not correlate with either total cholesterol 
( i\= 0.104, p=0.597) or triglyceride concentration (r,=0.202, p=0.302).
Neither measure of peroxidisability was significantly different in smokers compared 
to non-smokers (Smokers vs non-smokers change in tDC: (1.32(0.67) vs 
1.40(0.65) OD units, p =0.752); change in TEARS: 4.69(3.27,8.62) vs 
6.89(4.69,9.24) jttmol MDA.U, p < 0.100).
6.5.2. Peroxidisabilitv And Diabetes.
Neither measure of peroxidisability correlated with plasma glucose, HbA^^, duration 
of diabetes or age (Table 6 .1). Comparing Type 1 and 2 diabetic subjects there was 
no significant difference in the change in tDC (1.20(0.51), vs 1.42(0.69) OD units, 
p = 0.393) or in TEARS (7.42(5.02,13.29) vs 6.28(3.57,7.75) /xmol MDA.U, p = 
0.231).
Comparing subjects with no complications with those having any form of 
complication or with only macrovascular complications also revealed no significant 
difference in either measure of peroxidisability (Table 6.2).
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M  DISCUSSION
6.6.1 The Relationship Between Antioxidants And Peroxidisabilitv
It has been reported that diabetic lipids, botli plasma and membrane bound, are more 
oxidised than tliose of non-diabetics (65-70, 218). They may be more oxidised 
because of reduced availability of plasma antioxidants, although I did not find a 
reduction in total plasma antioxidants (TRAP) in diabetes other than in association 
with smoking as discussed in the previous chapter. In this study, using an in vitro 
assay, the peroxidisability of lipids in plasma from diabetic subjects was determined, 
and the correlation between peroxidisability and TRAP levels examined. No 
correlation was seen, hence the hypothesis that peroxidisability of diabetic lipids is 
inversely related to plasma antioxidants (TRAP) is not supported by the results of 
this study.
Several reasons may exist for this lack of association. The in vitro conditions by 
which peroxidation was stimulated were arguably unphysiological and so the test 
may be an unrepresentative model of in vivo peroxidation. However, the fact that 
products arise that are known to occur in vivo suggests it is not completely 
unrepresentative and, in conditions of tissue ischaemia, a tissue pH of 5.5 could be 
achieved in vivo. Also, others have employed similarly "unphysiological" 
approaches to stress lipids in vitro, both isolated and in plasma, whilst studying the 
process of peroxidation (27, 47,274). Based on comparable reasoning to this study, 
Arshad et al conducted a study in which Cif  ^ and H^O^, in various concentrations 
and combinations were used in order to stress plasma and they measured the rise in 
concentration of TEARS and cholesterol oxides after a 2hr period of incubation. 
They then took this rise as an indicator of the susceptability of plasma lipids to 
peroxidation. They compared diabetic and non-diabetic plasma and concluded the 
former was more susceptible to peroxidation and that tlie balance between substrate 
factors, oxidants and antioxidants favoured oxidation in diabetes. I did not compare 
diabetics and non-diabetics but tried to verify the hypothesis that antioxidants did 
influence such measurments of lipid peroxidation. Even though I used TRAP, with 
it’s advantages as a measure of antioxidant status, I did not find confirmation of the 
hypothesis.
Assuming that the measurement of lipid peroxidisability used is valid then other 
explanations for the lack of correlation between TRAP and peroxidisability might lie
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in the complexity of the oxidation process, partly introduced by the parcelling of 
plasma lipids into lipoprotein particles. Parcelled towards the core of the particle, 
in a hydrophobic environment, lipids are relatively removed from what happens in 
the aqueous phase of plasma. This, and other complexities, are discussed in the 
following sections.
a  ^ Antioxidants and the stage of peroxidation
Frei et al studied the time course of peroxidation of lipids in plasma and noted that 
the endogenous lipids are oxidised in a similar pattern to the exogenously added 
linoleic acid in the TRAP experiment (Fig 5.4) (27). A lag period existed between 
exposure to FR and the initiation of peroxidation, the lag period was presumed to 
be a reflection of endogenous antioxidants in plasma. The lag period was then 
followed by a period of peroxidation. The lag period coincided with the 
disappearance of ascorbic acid (AA), peroxidation only beginning when the AA had 
been consumed. From this it was concluded that the water soluble AA was a major 
protector of the lipids in plasma. This conclusion may seem at odds with the result 
of the present study in which TRAP, to which AA contributes, did not relate to 
peroxidisability. However, the experimental design here is such that the aspect of 
peroxidation observed is not the lag but the later peroxidation phase, and specifically 
the extent to which peroxidation occurs during the incubation period. Frei does not 
comment on how this aspect of the peroxidation relates to antioxidants. If A A is 
consumed before this stage is entered, AA could not be expected to influence it. 
The current study suggests that the other contributors to TRAP do not either. A A 
has been shown to contribute up to 24%, and vitamin E 5-10%, of the TRAP 
activity whilst uric acid and plasma proteins contribute much of the rest (26, 260). 
The results of studies such as that of Babiy et al are in keeping with the lack of 
influence of other antioxidants, specifically vitamin E, on the extent of lipid 
peroxidation (144). Although looking at isolated LDL as opposed to plasma, and 
measuring vitamin E as opposed to TRAP, they measured the rise in lipid peroxides 
in response to a dose of 7  irradiation, as oxidant stress, and found no correlation 
between vitamin E content of LDL and this rise, which they termed "LDL 
oxidisability" (144). Hence, overall it would seem tliat the extent of lipid 
peroxidation may not be influenced to any detectable extent by antioxidants.
It is possible that unidentified antioxidants or the nature of the PUFA, as oxidisable 
substrate, may be a more important determinant of peroxidisability, as it is measured
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in this study than are the contributors to TRAP. I did not assess the concentration 
of individual FA, but it is worth noting that peroxidisability, as measured by change 
in diene conjugates, although not change in TEARS, was significantly related to the 
concentration of total plasma cholesterol but not triglycerides. This may be a 
statistical error but it might reflect the fact that the cholesterol rich lipoprotein, 
LDL, is more easily oxidised than the TG rich particles. It might also reflect the 
fact that although cholesterol is not as readily oxidised as PUFA, LDL contains 
cholesterol which has been esterified predominantly to linoleic acid. Linoleic acid 
has been shown to be the major source of lipid peroxidation products during LDL 
autoxidation in vitro (142). Lack of correlation between the measures of 
peroxidisability and total plasma TGs might be explained by the fact that a relatively 
smaller proportion of the F As esterified within TGs are polyunsaturated and so 
oxidisable. However there are influences upon the correlations between measures 
of peroxidisability and, TG and cholesterol, other than the relative oxidisability of 
PUFA within cholesterol esters and triglycerides. These same influences may 
explain why anomalies arose such as the finding that tDC and TEARS did not 
correlate with each other and the finding that whilst the change in tDC correlated 
with cholesterol, the change in TEARS did not. These are discussed further in 
section 6 .6 . 1 c.
Even if antioxidants do not have a major role in determining the extent of lipid 
peroxidation once started they may affect other important aspects of peroxidation. 
Considering again the model in which lipids resist oxidation until ascorbic acid, in 
the case of plasma (27), and vitamin E in the case of isolated LDL (28, 46, 213), 
are consumed, it was proposed that the time for which lipids could resist oxidation, 
the lag period, would be determined by antioxidant concentration. However, even 
that proposal may be too simplistic as it has been shown in several studies that the 
lag time does not correlate with antioxidant concentration (27, 28, 46). 
Nevertheless, in a study on isolated LDL undergoing copper stimulated oxidation, 
although the lag time did not correlate with the vitamin E content of LDL, it was 
noted that increasing the vitamin E content of any individual’s LDL did increase the 
lag phase (46). So, assuming when looking at an individual that other variables are 
held constant, this suggests that antioxidants do have a role in determining lag but 
that again other factors are involved and even in the lag phase substrate features may 
be important.
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L. Antioxiclant solubility
Work such as that of Doha et al suggests tliat the phase, lipid aqueous, in which 
the FR initiator and antioxidant exist may also help determine the effectiveness of 
their antagonism (275). In agreement with Frei et al (27) they showed that water 
soluble ascorbic acid (AA) effectively induced a lag in peroxidation of phospholipid 
liposomes when the water soluble initiator ABAP was used but did so only poorly 
when using the lipid soluble initiator, DMVN (azO"bis(2,4-dimethylvaleronitrile)) 
(275). In the TRAP assay the initiator is the water soluble ABAP and so TRAP is 
mainly determined by antioxidants within the aqueous phase and how the antioxidant 
system interacts to control aqueous phase radicals. The site of the initiator in the 
conditions employed to produce peroxidation in this study is not known but may be 
the lipid phase. It is possible, as argued by Halliwell, that lipid hydroperoxides are 
present in trace amounts within the lipoproteins and in the presence of transition 
metals, they decompose with the formation of peroxyl and alkoxyl radicals (2 2 1 ). 
Being in the lipid phase, these radicals may never be available to water soluble 
plasma antioxidants explaining the lack of correlation between TRAP and 
peroxidisability. The corollary might then be that there should be an inverse 
correlation between peroxidisability and lipid soluble antioxidants. Transition metal 
ions were not added in the peroxidisability experiments performed but are almost 
certainly present in trace amounts in the buffer. Also, at pH5.5 the binding of these 
ions within low molecular weight, and protein, complexes in plasma may well be 
reduced, as has been shown for the binding of Fe '^" within transferrin (247). The 
possibility that the metal catalysed process is initiated in the lipid phase is supported 
by studies in methyl linoleate micelles. When the micelle surface was positively 
charged and so repelling positively charged ions, oxidation was inhibited (30, 276). 
Also, if the micelles were treated with triphenylphosphate to remove traces of 
hydroperoxides, again metal catalysed oxidation did not occur (30, 276).
If hydroperoxides do exist in trace amounts in lipoproteins, the question of their 
source arises. Diet is a possibility. Lipoxygenase enzyme activity also results in 
hydroperoxide production. The transfer of these products to LDL has been proposed 
as an alternative way to initiate LDL oxidation (49).
Çi The specificity of the antioxidant
Frei’s work points to yet other complexities in the peroxidation of lipids. Even 
when employing two initiators both releasing FR into the aqueous phase the pattern
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of antioxidant consumption differed. The two initiators, ABAP and activated 
polymorphonuclear leucocytes, would have released different radicals. Their results 
suggest that the antioxidant systems operate differently, depending upon the specific 
radical involved; different radicals first encounter the system at different points and 
may experience a different antioxidant capability.
Taken together, all of these studies imply a complex model of how FRs and 
antioxidants interact in the process of lipoprotein peroxidation. It may be unwisely 
crude to generalise that antioxidants inhibit FR oxidation of lipoproteins. The nature 
of the radical, its solubility and the situation in which it is generated will affect 
which antioxidant best scavenges it. The substrate will also influence the outcome. 
Failure to take all of these factors and their interactions into account may help to 
explain why correlations between antioxidants and peroxidisability have been so 
difficult to establish (27, 28, 46, 144). Returning to the present study, perhaps a 
correlation between TRAP and peroxidisability might have been seen had a different 
oxidation stress been applied to the plasma, as peroxidation might then have been 
antagonised by the antioxidants contributing to TRAP. These arguments have 
experimental and clinical implications. Experimentally, great care will be needed 
in the choice of ’models of stress’ when comparing studies, and when making 
inferences regarding in vivo processes from in vitro studies. Clinically, the 
implication is that if different disease processes produce oxidative stress in a 
different way the prophylactic or therapeutic response will also have to be tailored 
accordingly.
Before concluding I would like to come back to the validity of the peroxidisability 
assay. The two variables used in this study to assess peroxidation, the change in 
tDC and TEARS, do not correlate with each other suggesting that they may not 
equally well represent peroxidation. Which is the more reliable? As discussed by 
Halliwell (13), no currently available test of peroxidation is entirely satisfactory. 
They all measure different things and the most appropriate must be judged by a 
knowledge of the circumstances. There are several reasons why in the 
circumstances here that changes in TEARS may be a less reliable index of 
peroxidation than total DCs;-
i) Even though I was looking at the change in these species, since plasma was used 
the lower specificity of the TBARs assay may remain a problem.
ii) Esterbauer, looking at copper stimulated oxidation of isolated LDL, saw good 
correlation between the rise in tDCs and TBARS once oxidation had begun but only
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up to the point of maximum DC formation (213). With longer incubation, as in this 
study, the correlation was lost. The loss of correlation may be because 
hydroperoxides are less stable than non-peroxide DCs. This means that a proportion 
of both species formed will decompose during the incubation period, so that the 
concentrations measured at the end of the incubation will be an underestimate of the 
total formed but the error will be most marked for the hydroperoxides.
In addition to helping to explain the lack of correlation between the measured change 
in TBARs and tDC during the incubation period, it decomposition of products does 
occur it could also help explain the apparent lack of correlation between measures 
of peroxidisability and TRAP. If decomposition of products is continuously 
occurring then measurement of peroxidisability could be sufficiently inaccurate to 
mask any correlations.
Another concern needs to be addressed. If the time course of peroxidation is such 
that it is complete before the second measurement of products is made the assay 
would actually be measuring maximal extent of peroxidation and not peroxidisability. 
The time course of peroxidation was not examined in this study. It needs to be 
verified before further work using this method of measuring peroxidisability is 
undertaken. All other methods of measuring peroxidisability need to clarify that the 
product being measured is stable under the conditions of the experiment and that a 
plateau phase has not been reached at the time of repeat measurements,
iii) MDA, and so TEA reactivity, can be generated only by PUFA with 3 or more 
double bonds (142). Hence, linoleic acid hydroperoxides with two double bonds, 
despite being the major product of oxidation and the most stable of the 
hydroperoxides formed, will not be detected by the TBARs assay. They will, 
however, contribute to the signal representing DCs. Overall, in the circumstances 
of this study DC measurements are felt likely to be the more appropriate measure 
of peroxidation. These points may help to explain how tlie anomoly mentioned in 
section 6.6.1a could arise whereby the change in total DC correlated with cholesterol 
but the change in TBARS did not. However these considerations also suggest that 
peroxidisability, as measured, may be so influenced by the conditions of the test and 
reflect chemistry other than the relative oxidisability of PUFA esterified to 
cholesterol or glycerol that caution is required in interpreting the results of this study 
and the results of other studies in which similar techniques might be used. 
Another difficulty in this area is that it cannot be assumed that equal amounts of 
oxidising F As will go to form non-peroxide DC and TBARS, and the factors which
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control the balance of oxidation pathways taken are unknown.
6.6.2. Other Influences On Peroxidisabilitv And Its Relevance.
Plasma peroxidisability did not relate to plasma glucose concentration. This is in 
keeping with the finding that addition of glucose to human plasma did not increase 
lipid peroxide formation in vitro (274) but appears to contradict the finding that 
human isolated LDL did show enhanced peroxidation when incubated with glucose 
(102) albeit at supraphysiological concentrations (200mM). It may be that in 
plasma, and so possibly in vivo, there are so many factors which influence 
peroxidisability that the enhancing effect of glucose on LDL peroxidation is 
swamped. Taken together with the finding of others that nevertheless, there may be 
more peroxidised lipids in plasma and tissues of diabetics (68-73, 2 1 0 ), this suggests 
that diabetes may have effects on lipid oxidation, not only at the level of the glucose 
directly increasing peroxidation or altering the lipids such that tliey subsequently 
oxidise more easily, but by altering the oxidative stresses, or by reducing the 
clearance of oxidised lipids or by decreasing antioxidants.
My own study and others, including those discussed here, attempt to help define 
what determines variability in lipid peroxidation. However, in suggesting the 
complexity of in vivo peroxidation they raise another question, namely if there are 
different phases of lipid oxidation is one pathophysiologically more relevant than 
another? Very little work has been done on this but recently the duration of the lag 
phase, during oxidation of LDL isolated from survivors of myocardial infarction, 
was shown to be inversely related to the severity of coronary atherosclerosis seen 
at angiography (140). In keeping with the concept that the nature of the substrate 
might be as important as the concentration of antioxidant, it was also found that the 
duration of the lag phase was inversely related to LDL triglyceride content (140). 
The pathological relevance and correlates of the peroxidation phase as opposed to 
the lag phase have not been similarly studied. I did not set out to explore its 
relevance and my groups are heterogeneous and small, however, peroxidisability was 
not significantly different in those with and without complications. If the 
development of the complications of diabetes is related to FR activity, including lipid 
peroxidation, this suggests that "peroxidisability", as measured in this study, may 
not be a relevant feature of peroxidation.
There was no significant difference between subjects with Type 1 and Type 2
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diabetes in terms of peroxidisability. If peroxidisability is shown to relate to the 
development of atherosclerosis, its similarity in Type 1 and 2 diabetics would be in 
keeping with the excess risk of this complication in both types of diabetes. Smoking 
was not seen to influence peroxidisability. It has also been shown not to alter the 
duration of the lag phase of isolated LDL oxidation (140).
6.7. CONCLUSION
Support for the hypothesis that the peroxidisability of plasma would be inversely 
related to plasma antioxidants (TRAP) has not been found in this study. It is 
possible that the physical parcelling, and so relative isolation, of lipids within 
lipoproteins means that oxidative stresses of different types might be antagonised by 
different combinations of antioxidants. Perhaps had another oxidant stress been 
applied in this study a relationship between peroxidation and TRAP would have been 
observed. It may also be that the presence of lipids within lipoproteins means that 
lipid soluble antioxidants will be more important determinants of peroxidisability 
than TRAP which is mainly contributed to by water soluble antioxidants. The nature 
of the substrate may also influence peroxidisability.
Peroxidisability was not related to glycaemic control and so enhanced 
peroxidisability would not offer any explanation for the association of level of 
glycaemia with the developement of diabetic complications and consistently no 
difference in peroxidisability between those with and without complications was 
found. The lack of correlation between glycaemia and peroxidisability also suggests 
that a raised glucose concentration per se is not enough to enhance lipid peroxidation 
detectably.
The methods availible for the study of peroxidation are frought with difficulties at 
all levels. Although tlie method used here offered some advantages, several 
anomalies were foun which raised doubts about just how valid a measure of 
peroxidisability it was. These doubts need to be born in mind when considering the 
interpretations here.
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C H A PTER  SEVEN
V IT A M IN  E STATUS IN DIA BETES.
7.1 INTRODUCTION
In the previous study the total peroxyl radical antioxidant activity of plasm a (TRAP) 
in diabetic subjects was measured. No relationship between TRAP and the 
peroxidisability of plasm a lipids was observed. Several possible reasons for this 
were discussed. One possibility is that lipid soluble antioxidants are the more 
important protector of lipids, and are poorly represented by TRAP. Therefore, in 
this study, attention is turned to vitamin E, the major lipid soluble antioxidant. The 
need to measure vitam in E status as opposed to simply vitamin E concentrations is 
explained and vitam in E status in diabetes is then compared with that in non­
diabetics. A s o , the relationship between vitamin E status and lipid peroxidation, 
as assessed by plasma TBARS, is explored.
7.1.1. Vitamin E As An Antioxidant
a.The Role Of Vitamin E
The tocopherols and tocotrienols are a group of structurally sim ilar molecules 
capable of antioxidant activity. Vitamin E i s a  generic term applied to a group of 
these molecules which have the same biological activity as the most common and 
reference compound a-tocopherol.
a-TOCO PH ERO L
Vitamin E, which can react with and so inactivate, several oxidising FRs, such as 
On", OH', peroxyl and alkoxyl radicals, functions as a chain breaking antioxidant
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(219), The «-tocopherol radical which results is stable and not reactive enough to 
propagate a chain reaction and, as discussed earlier, can be reactivated by interaction 
with vitamin C (262, 277). The hydrophobic nature of vitamin E localises it, in 
vivo, to lipid-rich sites such as membranes and lipoproteins. Within these sites «- 
tocopherol molecules are believed to be aligned in such a way that the non-polar tail 
is deep within the hydrophobic core of tlie structure and the polar, reactive, alcohol 
group towards the surface (219). However it is mobile within these structures, 
moving both in parallel and perpendicular to the surface (219). This ability to 
move, and its links with surface and core, may explain how vitamin E can both 
interrupt FR reactions at the core, yet be reactivated by the strictly aqueous phase 
vitamin C.
In plasma, vitamin E is present in all classes of lipoproteins, including LDL (278). 
Within LDL, «-tocopherol is the major antioxidant so far identified but 7 - 
tocopherol, j6 -carotene, retinyl stearate and lycopine also occur (28). Evidence that 
vitamin E functions as an antioxidant comes from kinetic studies of lipid 
peroxidation in vitro. During these kinetic studies, oxidation of isolated LDL in 
buffer has been followed by the appearance of DCFA, TBARS or a modified LDL 
taken up more rapidly by macrophages (28,46). Oxidation was seen to occur only 
after a time lag, which coincided with the loss of antioxidants, principally «- 
tocopherol. The duration of the lag period varies widely from individual to 
individual (213), as does the vitamin E content of LDLs and although this raised the 
possibility that the lag might be due to vitamin E, its duration has not been shown 
to correlate with the vitamin E content of LDL, suggesting tliat vitamin E is not the 
sole determinant of the lag period (46). Reasons similar to those discussed in 
chapter six to explain lack of correlation between TRAP and oxidation of plasma 
lipids could be applied again here as could the argument that the nature of the 
substrate also influences the lag period. Despite these considerations, the lag period 
can be used as an estimate of LDL’s resistance to oxidation.
The importance of vitamin E to the protection of LDL is further suggested by the 
finding that enriching LDL with «-tocopherol, by adding it to the medium or by 
supplementing the diet, prolongs the lag period (28, 46). Altliough vitamin E is an 
important antioxidant, in vivo its function may be greatly affected by its interaction 
with vitamin C.
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b. The Interaction Between Vitamin C And Vitamin E
Vitamin C, a water soluble antioxidant, can also prolong the lag phase when added 
to isolated preparations of LDL (213, 255) and may do so in two ways. In addition 
to recycling the «-tocopherol radical (262, 277), it may also intercept FR in the 
aqueous phase, hence preserving the «-tocopherol within lipoproteins (275, 255). 
These interactions may be important in vivo, where LDL circulates in plasma in 
which vitamin C is dissolved. In fact, in plasma, there is a suggestion that vitamin 
C is the major antioxidant protecting (27) plasma lipids as they appeared to start to 
peroxidise when vitamin C was consumed and suggesting that vitamin E has little 
role in that setting. However, the relative importance of vitamin C and vitamin E 
may depend upon the circumstances (275, 276) and the following model suggested 
by the work of Doha et al may explain why the importance of vitamin E may be 
obscured.
During attack by a FR generated in, or released into, the aqueous compartment 
vitamin C initially interrupts the majority of radicals, such that they never reach the 
lipoprotein. Any that do get through this barrier preferentially react with vitamin 
E, producing a vitamin E" radical which is reactivated by vitamin C. During this 
period, vitamin C concentration falls and vitamin E is preserved. Eventually vitamin 
C concentration falls to a level at which it can no longer maintain the equilibrium 
and vitamin E consumption ensues whilst vitamin C consumption continues. Lipid 
peroxidation begins when their concentrations are no longer sufficient to prevent FR 
attack on the lipids.
Should the attacking FR be generated in the lipid component, vitamin E is primarily 
attacked but is reactivated by vitamin C. Vitamin C levels fall whilst vitamin E is 
again preserved and apparently not involved. Eventually, vitamin C concentration 
falls to a level which cannot sustain vitamin E, vitamin E levels decline and lipid 
peroxidation begins.
In such a model, although vitamin C does protect against FRs arising in tlie lipid 
compartment it can do so only if vitamin E is also present and the effect of the two 
together is then greater than the simple sum of their effect if alone (275). Hence, 
although vitamin E is an important antioxidant, it may be that in the more complex 
situations which might arise in vivo these interactions with vitamin C will greatly 
influence its effectiveness. In vivo this interaction is even more useful as vitamin 
C can be recycled. However, there are situations where the interaction can fail. 
Frei et al noted that when the FR source was activated polymorphonuclear
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leucocytes (PMN), Vitamin C was consumed but lipid peroxidation occurred despite 
levels of vitamin E being maintained (27). This could be accounted for by the 
generation of a radical capable of reacting with vitamin C and lipids but not vitamin 
E.
7.1.2. The Role Of Vitamin E In Protection From Atherosclerosis.
Epidemiological evidence exists that plasma vitamin E concentrations are inversely 
related to mortality from ischaemic heart disease (198, 279) and risk of angina 
(199). Apart from its possible role in limiting LDL oxidation other actions of 
vitamin E make it of interest in the study of atherosclerosis in diabetes. As well as 
lipoproteins, lipids within membranes are also vulnerable to attack. Jain et al have 
shown that erythrocyte membranes in diabetes are indeed more peroxised than those 
in control subjects (6 8 ) and speculate that changes in membrane structure and 
fiinction may result, accounting for some of the haemorheological changes observed 
in diabetes which have been attributed a role in atherosclerosis. A similar 
suggestion was made by Urano et al who showed that O y could induce permeability 
changes in liposomes reconstituted fron diabetic and non-diabetic erytrocytes and that 
these changes coincided with increased peroxidation of the lipids (280). They also 
showed that vitamin E protected the liposomes from peroxidation (280). The 
function of other cell types involved in atherosclerosis could be altered by similar 
mechanisms. This could contribute to the abnormal aggregability of platelets in 
diabetes (54). Perhaps more importantly, lipid peroxides can modify eicosanoid 
metabolism thus suggesting another mechanism whereby platelet aggregation might 
be altered by membrane oxidation (111, 281). Related to these suggestions, vitamin 
E has been shown to reduce diabetic platelet aggregation and production of 
thromboxane, a pro-aggregatory eicosaniod (282, 125).
Similarly, eicosanoid metabolism in vascular endothelium and smooth muscle may 
also be involved in the genesis of atherosclerosis (110, 115) and be modulated by 
vitamin E (281). In addition, glycosylation of proteins in diabetes may have 
significance in the development of diabetic complications and glycation has been 
seen to be reduced by vitamin E (103).
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7.1.3. Vitamin E Status versus Vitamin E Levels
Diabetes is a condition known to be associated with increased risk of atherosclerosis 
but the level of vitamin E in diabetes is not clearly known. Platelet levels of vitamin 
E have been noted to be lower in a group of Type I diabetic subjects than in normal 
controls (125), but plasma levels were not reported as significantly different (109, 
125, 282). This confusion required clarification and might partially have arisen 
because vitamin E concentrations in plasma were not measured in relation to plasma 
lipid concentrations. This is important because the concentrations of plasma lipids 
and vitamin E are highly correlated (145, 259) and a normal vitamin E concentration 
in the face of raised lipids may in fact indicate deficiency (285) especially in view 
of the fact that vitamin E protects lipids from oxidation. This notion is confirmed 
by the finding that resistance of red cells to haemolysis induced by H^O ,^ which can 
be used as an assay of vitamin E functional activity, correlates better with the ratio 
of vitamin E to "total lipid" concentrations than witli absolute vitamin E 
concentrations. Since total lipids (triglycerides +  cholesterol 4- phospholipids) are 
rarely measured, Thurnham investigated the use of other vitamin Eilipid ratios in 
determining appropriateness of vitamin E level in man (145) and concluded that the 
tocopherol:cholesterol+ triglyceride ratio was almost as powerful as tocopherol itotal 
lipid ratio in detecting vitamin E deficiency (145) therefore in this study I use 
vitamin E:cholesterol+ triglyceride ratios as a measure of vitamin E status.
7.1.4 Summary
Several effects of vitamin E may explain its inverse relationship with the risk of 
atherosclerosis. One such effect may be its ability to protect PUFA within 
lipoproteins from peroxidation. It has been shown that the effectiveness vitamin E 
is better represented by the ratio of the concentrations of vitamin E to those of 
cholesterol+ triglycerides than by absolute vitamin E concentration alone. Diabetic 
subjects are generally hypertriglyceridaemic but this has not been considered in 
previous reports of their vitamin E concentration. In this study tlie ratio of vitamin 
E concentration to the concentration of cholesterol+ triglyceride is used to assess, 
and is refered to as, vitamin E status and the relationship between vitamin E status 
and a measure of lipid peroxidation in vivo, TBARS, is assessed.
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7.2. HYPOTHESIS.
Individuals suffering from diabetes have lower vitamin E levels relative to levels of 
oxidisable lipid (vitamin E status) than do non-diabetics and lower vitamin E status 
will be associated with evidence of greater lipid peroxidation in diabetes.
7.3. SUBJECTS AND STUDY DESIGN
36 diabetic subjects were recruited from the routine diabetic clinic in a similar
fashion to that described in Chapter 3. Clinical characteristics were obtained, as 
before, by patient history, supplemented by reference to hospital case notes. Blood 
samples were lost on one subject, hence results are presented for 35 diabetic 
subjects. 29 healthy hospital workers volunteered as controls.
7.4. METHODS
Analytical and statistical methods are described in chapter two.
Vitamin E status was determined as the ratio of vitamin E concentration (/uuol.l'^)
to the sum of the cholesterol and triglyceride concentrations (mmol.1‘ 0
The concentration of TBARS was used as an estimate of in vivo lipid peroxidation.
7.4.1. Assavs Performed
Vitamin E
Total Cholesterol (total-Choi)
HDL-Cholesterol (HDL-Chol)
Total Triglycerides (TG)
LDL-Cholesterol (LDL-Chol) by calculation.
TBARS
Fasting plasma glucose (FPG)*
H bA ,;
* in diabetic subjects only
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7.5.  RESULTS
Diabetic and non-diabetic subjects differed significantly in terms of age, gender but 
not smoking status (Tab 7.1). The groups also differed in terms of serum lipids. 
When compared to controls, diabetic subjects were hypertriglyceridaemic 
(1.60(1.30,2.30) vs 1.10(0.80,1.40) mmol.l'\ p =0.001) and had lower HDL-Chol 
(1.20(0.35) vs 1.59(0.39) mmol.1'% p = 0.001), whereas their total-Choi and LDL- 
Chol concentrations were not significantly different (Tab 7.2). Also, in the group 
as a whole, the men studied were significantly older than the females and had 
significantly different serum lipids (Table 7.3). In addition, age significantly 
correlated with total-ChoI ( r= 0.306, p = 0.014) and LDL-Chol (r=0.280, p = 0.025) 
and TG (r,=0.325, p=0.009). Since these differences in age, gender and lipids 
existed between diabetic and non-diabetic subjects, and interactions between them 
could occur, they were allowed for statistically using multiple linear regression 
analysis. Using such analysis to control for age and gender it was confirmed that 
presence or absence of diabetes was a significant determinant of TG and HDL-Chol 
concentrations (Table 7.4), that gender significantly influenced HDL-Chol and that 
age was significantly related to LDL-Chol.
In the group as a whole, vitamin E concentration correlated significantly with total- 
Choi (r,=0.545, p = 0.00i) and TG (r, = 0.353, p=0.004) and total-Chol-fTG 
(r,=0.601, p = 0.001) (Fig 7.1), emphasising the need to consider lipid 
concentrations, and factors affecting lipids when comparing groups in terms of 
measures of vitamin E.
Vitamin E concentration was not significantly different in diabetic and non-diabetic 
subjects (42.6(36.6, 48.8) vs 38.9(32.0, 42.9) /rmoll'\ p =  0.127). In multiple 
regression analysis, with logarithmic transformation of vitamin E concentrations, 
including age, gender, total-Chol, TG, smoking status and presence or absence of 
diabetes, cholesterol (positively) and age (negatively) were the only statistically 
significant determinants of vitamin E concentration (Table 7.5a). The relationship 
with TG concentration just failed to reach statistical significance. This model 
explained 54.4% of the variability in vitamin E concentration. Removing diabetes, 
gender and smoking from the model resulted in little change in the percentage 
variability in vitamin E concentration that was explained (47.1%) (Table 7.5b). 
Vitamin E status correlated inversely with, TG (Fig 7.2) and total-Chol+TG (Fig 
7.3) in the group as a whole whereas tlie relationship with total-Chol was not
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Diabetic
Subjects
Nou-diabetic
Subjects
p Value.
Number (n)
55.9(13.9) 42.7(10.8) 0.002Age (yrs)
26:9 9:20Sex Ratio (M:F)
13:22 :21Smoking (yes:uo)
7.9(2.3,11.5)Duration (yrs)
Treatment
Diet
Sulpbonylurea
Sulphonulurea 
+  metformin
Insulin
Complications
None
Microvascular
Macrovascular
Micro & Macro
Hypertension
10.4(4.1)Fasting plasma 
glucose (mmol 1^ )
10.1(2 .2)HbA,„ (%)
(NR =6.5-8.5)
Table 7.1: Clinical details of subjects.
Values are mean (SD) or median (25th, 75th percentile). Comparisons between groups 
are tested using unpaired t-tests or chi-squared test.
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statistically significant (Fig 7.4). Consequently in those individuals with high total- 
Choi (total-Chol >5.8mmol.r^) vitamin E status was significantly lower than in those 
with total-Choi <5.8m m ol.F (5.67(1.22) vs 5.08(1.08) \  p=0.047) also
in those with TG > 1 .8  mmol.l'* compared to tliose with TO <  1 .Bmmoi.l'^ vitamin 
E status is significantly lower (5.56(1.14) vs 4.71(0.09) /^M.mM'% p =0.003). 
Vitamin E status was not significantly different in diabetic and non-diabetic subjects 
(5,19(1.22) vs 5.48(1.03) jL^M.mM ^ p =0.309) (Fig 7.5). In a multiple linear 
regression model including age, gender, diabetes and smoking, age was significantly, 
inversely correlated with vitamin E status (Table 7.5c). Vitamin E status did not 
correlate with plasma glucose or HbAj^ in diabetic subjects (Tab 7.6).
TEARS concentration was significantly greater in diabetics than in non-diabetics 
(2.40(0.69) vs 1.67(0.63) jumolMDA.f', p < 0.001) (Fig 7.6). Also, TEARS 
concentration did not correlate significantly with vitamin E status (r=  -0.117, 
p=0.358).
In a multiple linear regression analysis including age, gender, smoking, diabetes and 
vitamin E status, diabetes was confirmed as a highly significant determinant of 
TEARS concentration (Table 7.7). However in diabetic subjects, TEARS did not 
significantly correlate with HbAj^ but did statistically significantly correlate with 
plasma glucose and duration of diabetes (Table 7.6).
TEARS concentration significantly correlated witli TG (r,=0.338, p = 0.006) (Fig 
7.7) but not total-Chol (r=0.171,p=0.177). However, in multivariate analysis in 
which diabetes, smoking and age, were allowed for the relationship between TEARS 
and TG concentration failed to reach significance (Table 7.7b).
In diabetic subjects neither vitamin E status nor TEARS concentration were 
significantly different in those with and without complications (Table 7.8) and 
correction for age, gender and smoking did not alter this result.
7.6. DISCUSSION
In agreement with other studies, vitamin E levels were found to correlate with total- 
Chol, TG, LDL-Chol and the sum of total-Chol + TG (145). When assessing 
factors which may influence vitamin E concentration it is necessary to consider 
whether or not those factors do so independently or simply through their 
confounding effects on lipids. Age, gender and diabetes are known to influence 
serum lipid profiles (38, 284, 285). The effect of diabetes on lipid profiles,
110
tH
O
c5&2
(]-P\[ui*K^) H uiuiBjTA
iS1I
1
I
w
‘Is
'>1Üo
F
F(UI
00 o
o
Q
<0
■§
a  uiuiB^TA
'a
0)
I
D-g
I
mI
»n
i
ooop
o
>n
p
oo
r oO
S3p
o
oo
q
o
q
o
g
o
I!
-g^3p)
"O
IIIT3IPh
T3
'P h
Iwrt
U
vq
o>
i
od
(N OrH
O
■g•S
0■g
g
1fl
oof
0•s
1
o
i%
"d
<Ù•Is
?cd
03
■ê
( ,- rv a w io u i’^  S W 8 X
vo
IDI
Ao\
enc5
VO o eS o en 00 o voVO 'd- o 00 Tt" o 00 voo '=!■ o en O o o o
d d d d d d d d d
9en
pq U
s a l t s
d  9  o  o  9 m Q\
IÎ i 00 W)| g
l! H I  1 ? 3 i
co\o m oCO o
d o
o
(,-i'vawioiu'ri) savai
•ë
§
%
1I
I
IUXI
0I<u
r  § 
P I(Dii
With Complications 
n= 21
Without
Complications
u=14
P
TEARS
(umol.l*^)
2.28(0.66) 2.57(0.72) 0.238
Vit E status 
(nmoLmmol)
11.28(3.3) 12.94(1.62) 0.054
Table 7.8: Lipid peroxidation and vitamin E status in those diabetic subjects with and without 
complications.
Data are expressed as mean (SD) and comparisons made by Student’s t-test.
independent of age and gender, was confirmed in this study; diabetic subjects were 
hypertriglyceridaemic and had lower HDL-ChoI than normal controls (82). Smoking 
has also been associated with alterations in lipids and lipoproteins (191) but the 
proportion of smokers in the diabetic group was not significantly different from that 
in the non-diabetic group. The age and gender of the diabetic and non-diabetic 
subjects differed significantly in this study but this was controlled for by multiple 
linear regression analysis.
In addition to an effect mediated by lipids, age and gender may have direct effects 
on vitamin E levels, but this is debated (257). The confusion may arise because the 
confounding effects of lipid alterations have not always been considered. Similarly, 
the possible confounding effect of lipid levels was not considered in reports of 
normal plasma vitamin E levels in diabetes (125). Smoking has been shown to be 
associated with the reduced ability of erythrocytes to resist peroxidation, a defect 
which can be corrected by vitamin E supplementation, however although differences 
in other antioxidants were reported (195, 197) no difference in plasma vitamin E 
levels has been noted between smokers and non-smokers (194, 197).
Taking into account the possibility of confounding influences of age, gender, TG, 
total-Chol and smoking I have shown in this study that vitamin E levels are not 
significantly influenced by diabetes. In fact, in a multivariate regression analysis, 
serum total-Chol and age were tlie significant determinants of vitamin E, age being 
inversely related to vitamin E levels. The reasons for this effect of age are not 
known but reduced intake, absorption, altered metabolism or increased consumption 
are all possibilities. Interestingly, although vitamin E concentrations and TG do 
correlate significantly in univariate analysis, they do not in this multivariate model. 
Another way to allow for lipid concentrations whilst assessing vitamin E 
concentrations is to determine the ratio of vitamin E concentration to lipid 
concentrations. Justification for correcting for lipids in this way is the finding that 
such a ratio has functional relevance in that the ratio correlates better with the 
inhibition of H2 O2  induced erythrocyte haemolysis than does vitamin E concentration 
alone (145). Using the vitamin E to total-Chol+TG ratio to assess vitamin E status 
in this study I found that this ratio was not significantly lower in diabetic subjects 
than non-diabetics and in multivariate regression analysis, diabetes was not found to 
be a significant determinant of vitamin E status. Again, age was significantly 
inversely related to the ratio but the correlation was weak. In keeping witli the 
observation that diabetes mellitus has no effect on vitamin E status is the lack of
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correlation between plasma glucose, HbA^  ^ and duration of diabetes with Vitamin 
E status in diabetic subjects.
I feel it is worth commenting on the behaviour of the vitamin E status with regards 
to lipids. Although mathematically obvious it may have physiological significance. 
Vitamin E concentration increases witli total-Chol and TG levels, however, they do 
not rise in parallel if they did then, as total-Chol and TG rose, the ratio of vitamin 
E to total-Chol and TG , in other words the vitamin E status, would remain the 
same, it does not. The ratio is actually significantly inversely related to TG 
concentration (Fig 7.3), and not related to total-Chol concentration (Fig 7.4). 
Approached in a slightly different way, this means that at higher total-Chol and TG 
levels, the ratio is lower and so in hypertriglycerideaemic and hypercholesterolaemic 
subjects the vitamin E status is significantly lower than in normolipidaemic 
individuals. Several models of how vitamin E concentrations vary with lipids could 
explain this phenomenon but the numbers here are too small to establish which. 
Vitamin E could rise linearly throughout the entire range of lipid concentrations 
with a slope to the regression line of less than 1 or a saturatable system could exist 
where the relationship plateaus beyond a certain level of lipids. No matter what the 
model however ,if a certain amount of vitamin E is required to protect a certain 
amount of lipid the outcome remains that at higher lipid levels relatively too little 
vitamin E may be availible. Perhaps another relevant point is that in multiple 
regression analysis of the determinants of vitamin E concentrations, total-Chol was 
much more significantly associated than was TG and the slope of the relationship 
much steeper with t-Chol (3.45) than with TG (0.54) (Table 7.5). In other words, 
a rise in TG may be less closely matched by a rise in vitamin E than is a rise in 
total-Chol.
Overall, the implication is that with hyperlipidaemia there may be a mismatch 
between Vitamin E and the lipids it protects and the mismatch may be greatest in 
hypertriglyeridaemic states. This may be particularly relevant in diabetes where 
hypertriglyceridaemia is a common phenomenon and may be an independent 
cardiovascular risk factor (82, 286, 287),
In vivo lipid peroxidation as estimated by plasma TEARS was found to be 
significantly greater in this group of diabetic subjects compared to controls, in 
agreement with other reports on diabetic animals and humans (65-69, 288) and is 
consistent with the hypothesis tliat more FR lipid peroxidation occurs in diabetes. 
Further supporting an effect of diabetes, TEARS correlated with plasma glucose,
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although not with HbA^g. Jain et al found the TEARS content of human diabetic 
erythrocyte (REC) membranes did correlate with HbAi^ but did not measure plasma 
glucose (6 8 ). My study and that of Jain et at are in agreement in so far as they both 
imply that glycaemia may influence peroxidation in vivo. The different relationship 
observed with HbAi^ may reflect differences the half-life of the peroxidised amterial 
studied. The TEARS in REC membranes may be more long lived than tliose in 
plasma and so reflect the average glucose exposure over a period of time. HbAj^ 
also reflects the average glucose exposure during the live of an erythrocyte hence 
the observed correlation between the two. Short lived plasma TEARS may be more 
influenced by the immediate ambient plasma glucose.
The mechanism whereby diabetes might cause an elevation in plasma TEARS is not 
clear but was discussed in Section 6.6.2. As argued there although the presence of 
glucose has been shown to enhance the peroxidation of human isolated LDL (100) 
this direct effect of glucose may not be the only explanation for the raised TEARS 
in diabetes and in that section I offered some possible explanation for why Î and 
others have foung that peroxidisability of plasma was unrelated to levels of 
glycaemia (Section 6.6.2) despite the enlianced peroxidation of LDL on exposure to 
glucose and elevated TEARS in diabetics.
The effect of diabetes on TEARS persisted even after controlling for age, gender, 
smoking and vitamin E status. Vitamin E status had no significant relationship with 
TEARS in this multivariate, or in univariate, analysis. This is contrary to the 
hypothesis that lipid peroxidation is inversely related to vitamin E status and other 
factors must be involved in determining plasma TEARS. The possible inaccuracies 
in using TEARS as an estimate of in vivo lipid peroxidation have already been 
discussed (Section 6.1). In addition, there is a great inter-individual variability in 
the PUPA content of cholesterol esters and triglycerides and it may be that vitamin 
E status assessed relative to total-Chol and TG is too crude and it needs to be 
assessed relative to oxidisable PUPA concentration or even more specifically to 
vulnerable double bonds.
In univariate analysis TEARS concentration appeared to correlate significantly with 
TG which would have been in agreement with the findings in streptozotocin diabetic 
rats as discussed by Chisolm (288). No such correlation was found with total-Chol. 
Such a relationship could simply reflect the fact that the TEARS assay cannot detect 
the lipid hydroperoxide of linoleic acid, the major fatty acid esterified to cholesterol 
(28) however it is also consistent with the suggestion tliat triglycerides may be more
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vulnerable to oxidation in vivo and so suggest a mechanism to explain the risk of 
vascular disease associated with hypertriglyceridaemia (286). A further connection 
between TG concentration and lipid oxidation is made by the interesting finding that 
the resistance of isolated LDL to oxidation in vitro is inversely related to the TG 
content of LDL (140). However in the current study the relationship between 
TEARS and TG concentrations just failed to maintain statistical significance in a 
multiple regression model (Table 7.7). If a relationship does exist between TEARS 
and TG this might appear to contradict the finding in chapter six that peroxidisability 
(change in tDC not TEARS) correlated with total-Chol and not TG. This apparent 
contradiction may reflect the fact that TEARS and peroxidisability measure different 
things. TEARS estimates lipid peroxides present in plasma at a given time and 
reflects a balance between their production and removal in vivo whereas 
peroxidisability measured the change in tDC over a period of time in vitro. 
However any contradiction does add further to the doubts discussed in Section 
6 .6 . 1 c regarding the interpretation of in vitro assays of peroxidisability.
7.7 CONCLUSION
This study did not support the hypothesis tliat vitamin E status is lower in diabetes 
and vitamin E status did not correlate with levels of lipid peroxidation in vivo. In 
addition despite normal vitamin E status, the level of lipid peroxidation was found 
to be greater in diabetes, confirming previous reports, and further implying that the 
increased lipid peroxidation which occurs in diabetes, and which may help explain 
the increased risk of cardiovascular disease in diabetes, is not significantly influenced 
by vitamin E status. However, age was found to be inversely related to vitamin E 
status.
Eecause vitamin E levels do not rise in parallel with lipids, and this is particularly 
so for triglycerides, then in hyperlipidaemic states, especially hypertriglyceridaemia, 
significant mismatch between vitamin E and oxidisable lipid may arise. This 
mismatch may result in an increased tendency to lipid oxidation at high lipid levels.
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CHAPTER EIGHT
THE EFFECT OF VITAMIN E AND VITAMIN C 
SUPPLEMENTATION ON 
PLASMA TOTAL PEROXYL RADICAL ANTIOXIDANT ACTIVITY.
VITAMIN E STATUS AND LIPID OXIDATION
M  INTRODUCTION
The study described in this chapter follows on from the background, results and 
discussion of the previous chapters. To recapitulate briefly, there are theoretical 
grounds for expecting that antioxidant vitamins might reduce oxidation of LDL and 
consequently reduce the development of atherosclerosis. In keeping with this view are 
epidemiological studies correlating risk of morbidity and mortality from vascular disease 
with reduced plasma levels of antioxidant vitamins (198, 199, 279). I have shown that 
diabetes interacts with smoking such that total peroxyl radical antioxidant activity of 
plasma (TRAP) in diabetic smokers is lower than in non-smoking diabetics and in 
healthy controls. Both diabetes and smoking are important risk factors for 
atherosclerosis. However, I found no correlation between TRAP and plasma lipid 
peroxidisability ifi vitro. Also vitamin E status was not statistically significantly lower 
in diabetics than in control subjects and again I found no correlation between vitamin 
E status and TEARS, an estimate of lipid peroxidation in vivo. Nevertheless there was 
evidence of increased peroxidation in diabetes provided by the finding of greater 
TEARS concentration in diabetics than non-diabetics
Others have also been unable to demonstrate actual correlation between measures of 
antioxidants and of lipid peroxidation assessed in several ways (27, 28, 46, 143, 255). 
Despite this, it has been found that increasing the antioxidant content of LDL does 
increase the resistance of LDL to peroxidation when subjected to various oxidative 
stresses in vitro (28, 46). There are many possible explanations for this apparent 
contradiction and these have been discussed at length elsewhere (6.5.1), but it seemed 
possible that a correlation between antioxidant levels and peroxidation might better be 
demonstrated by assessing the effects of changes in antioxidant levels upon changes in 
measures of peroxidation within an individual. Hence, I aimed to assess the effect of 
both vitamin C and vitamin E supplementation on antioxidant activity and lipid 
peroxidation. Eecause studies in diabetic rats and humans, which suggested that
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ascorbate metabolism may be abnormal in diabetes (119, 122), implied that 
supplementation in diabetics and non-diabetics might not have the same effect both 
diabetic and non-diabetic subjects were studied.
Plasma TEARS were measured as an estimate of in vivo lipid oxidation. The 
susceptibility of isolated LDL to oxidation was measured using a method described by 
Esterbauer (213), the principle of which is described below. The measures of 
antioxidants employed in this study were TRAP, vitamin E status and uric acid levels. 
TRAP measures total activity as opposed to concentration and thus will take into 
account effect of interactions between antioxidants in plasma. I will discuss the role of 
uric acid as an antioxidant in section 8 . 1 . 2  but it was measured here because its levels 
have been reported to be abnormal in diabetes and the antioxidant activity of vitamin 
C may be closely associated with that of uric acid. In addition uric acid is a major 
contributor to TRAP and therefore I expected that their levels should correlate. The 
method available for measuring uric acid is more robust than the TRAP assay and 
confirmation of a correlation between TRAP and uric acid would help validate TRAP 
measures.
The ultimate aim was to study four groups :-
a) healthy controls
b) non-diabetic individuals with macrovascular disease
c) diabetic individuals without complications
d) diabetic individuals with macrovascular disease.
The study reported here was the first phase and was to act as a pilot for the full study. 
I began by looking at groups a) and d), as I anticipated that if differences were going 
to exist they would be maximum in these groups therefore it is for these groups that 
results are reported here.
8.1.1 The Oxidation Of Isolated Low Density Lipoprotein
The method employed was a modification of that described by Esterbauer (213). The 
precise experimental detail is given in chapter two. LDL is isolated from plasma by 
ultracentrifugation and its in vitro, copper stimulated oxidation studied. Oxidation of 
LDL during the isolation procedure is inhibited by use of betahydroxytoluene (EHT) 
and EDTA throughout, by performing manipulations on ice and by storage at 4"C, in 
the dark. EHT and EDTA are removed, only immediately before use, by dialysis
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against degassed buffers.
Oxidation of isolated, dialysed LDL is then stimulated by addition of copper ions. The 
reactions outlined in Fig 3.1 occur and the process can be followed continuously by 
observing the rise in absorbance at 234nm due to the appearance of diene conjugated 
species (DC). A typical trace is shown diagrammatically in Fig 8.1. and reveals three 
phases of oxidation (213). During the first phase, known as the lag phase, peroxidation 
is essentially inhibited and minimal rise in absorbance occurs. It has been established 
tliat during the lag phase some of the antioxidants in LDL, including vitamin E, 
gradually disappear and it is believed tliat the lag phase terminates when insufficient 
antioxidant remains to prevent peroxidation. However the duration of the lag phase 
(LAG) has not been shown to correlate with the antioxidant content of LDL and so 
LAG cannot be solely dependant upon antioxidants (28, 46). The second phase of LDL 
oxidation is called the propagation phase and during it peroxide and non-peroxide diene 
conjugated species form and so absorbance increases. Factors influencing the rate of 
peroxidation (DC-RATE) and the extent of peroxidation (DC.mg'O are unknown as is 
the reason why PUFA oxidation stops when only a fraction of the potentially oxidisable 
moieties have reacted (143). When peroxidation ends phase three is entered and a 
plateau in absorbance is reached. Decomposition of labile oxidation products is the 
major event identified in this phase. An oxidation experiment allows the following 
measurements to be made from the absorbance curve:-
1. duration of the lag phase (LAG) (minutes)
2. the change in 234nm absorbance reflecting change in total diene 
conjugated species concentration (AAb)
(arbitrary units)
3. duration of propagation phase (PROP) (minutes)
Since the change in absorbance (AAb) directly relates to the rise in concentration of 
diene conjugated hydroperoxides and the extinction coefficient (e^sj for such species is 
29,500 M 'fcm 'f (213) the change in concentration of diene conjugated hydroperoxide 
(DC-CONC) can be calculated as follows
DC-CONC = mol.l-^
^234
Since the LDL concentration used was 0.25 x 10^  mg.l'^ (0.25 mg.mL) the amount of
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Knowing the duration of the propagation phase (PROP) then the rate of formation of 
diene conjugates (DC-RATE) can also be calculated
D C -R ATE = ^ 4  X 4P." nm o l.D C .m g-T m in -'
«234 X PROP
Thus several aspects of LDL oxidation in vitro can be measured however the only 
aspect shown to have any pathological correlate so far is the LAG. As discussed in 
chapter six the lag phase of the in vitro oxidation of LDL isolated from survivors of a 
myocardial infarction was shown to correlate negatively with the extent of 
atherosclerosis seen at angiography (140). Why the LAG might be important is not 
known but theoretically may be because the longer the lag phase tlie less likely it is that 
LDL within plasma or subendothelial sites will be oxidised to more atherogenic forms 
before it can be removed. Thinking along similar lines once LDL starts to oxidise, the 
faster it does so the more likely it will be that it is sufficiently oxidised to be 
atherogenic before removal. This suggests one mechanism whereby rate of peroxidation 
might also be relevant in terms of athorogenesis. Also the rate at which LDL oxidises 
and the extent to which it can do so will help determine how much oxidised material 
exists at any one time. If direct toxicity of lipid hydroperoxides is important in 
atherogenesis tlien rate of peroxidation (DC-RATE) and extent of peroxidation 
(DC.mg'O may also be important considerations regarding atherogenesis. Since all of 
these features of the peroxidation process could theoretically influence atherogenesis I 
have investigated the effect of antioxidant supplementation on the rate and extent of 
peroxidation in addition to the duration of the lag phase. Although the LAG is the 
feature of peroxidation most frequently studied interest is developing in some of the 
other features. For example, the rate of propagation was measured in addition to LAG 
by Cominacini et al who used the development of fluorescence to assess tlie 
predisposition to copper stimulated oxidation of isolated human LDL (289) and its
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relation to ce-tocopherol content. Interestingly they found that the rate of propagation 
and LAG were significantly correlated suggesting that factors which influence one may 
influence the other.
8.1.2 Uric Acid As An Antioxidant.
The final product of purine metabolism is uric acid which is ultimately excreted 
predominately via the kidney (290). However uric acid can also function as an 
antioxidant (13) and there is evidence that uric acid is produced in certain circumstances 
over and above any simple need to remove purines. For example, studies of 
arteriovenous differences in uric acid levels employing cathers in the carotid sinus and 
coronary arteries of human hearts, showed that more uric acid is drained from the heart 
than can be explained by the uptake of purines (291). Assuming that purine balance is 
maintained this implies that the heart eitlier produces more purine than it requires, or 
that the production of uric acid is intended. Also the major antioxidant present in the 
secretions which are released from nasal submucosal glands in response to acetyl 
choline has been characterised as uric acid (292).
Uric acid, when added to plasma, was found to prolong the lag phase before lipid 
peroxidation began (26) when the FR generator was the water soluble ABAP. Added 
to isolated LDL it can also prolong the lag phase before transition metal catalysed 
oxidation begins (213). In parallel with these observations urate present in plasma is 
consumed on exposure to FR sources (27). These observations serve to support the 
impression that uric acid is a radical scavenger and antioxidant. In fact Wayner et al 
calculated that at the concentrations found in plasma urate would contribute between 
35% and 60% of the plasma TRAP (26). Uric acid may function as antioxidant in a 
variety of ways. It may act as a chain breaking antioxidant by reducing radicals, it may 
chelate transition metals and so act as a preventative antioxidant and it may interact with 
ascorbate to prevent its auto-oxidation hence both preserving ascorbate as an antioxidant 
and interfering with vitamin C’s pro-oxidant activity (Section 8.6.2) (29).
The effect of diabetes upon uric acid levels is debated. Some groups have reported no 
difference in plasma uric acid concentrations in IDDM or NIDDM patients compared 
to controls (293) whilst others found hypouricaemia in NIDDM (294) and in IDDM 
which may be explained by a renal tubular defect in urate reabsorption (295, 296) 
secondary to increased reabsorption of glucose. Conversely hyperuricaemia has been 
reported in prediabetes (294) and in association with hypertension,
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hypertriglycei'ideaemia, insulin resistance and hyperinsulinaemia (296) features all 
common in non-insulin dependent diabetes. In fact uric acid concentration has been 
reported to be a predictor of hypertension (298) and a risk factor for coronary artery 
disease (202). The lack of consensus regarding the influence of diabetes on uric acid 
concentrations may arise because diabetes has heterogenous effects on uric acid levels 
depending upon such features as the degree of hyperglycaemia and renal function.
M  HYPOTHESIS
Vitamin C and vitamin E dietary supplementation will increase TRAP and vitamin E 
status of plasma respectively and reduce lipid peroxidation in diabetic and non-diabetic 
subjects.
8 J  SUBJECTS AND STUDY DESIGN
Ten non-insulin dependent diabetic (NIDDM) subjects witli macrovascular disease (as 
previously defined) were recruited. One subject dropped out for non-medical reasons 
and so results presented are for nine NIDDM subjects. Ten healthy laboratory workers 
volunteered as controls. The clinical characteristics of all subjects are given in Table 
8 . 1.
Subjects attended, after an overnight fast, on 4 occasions. Subjects were assessed at 
baseline (Visit 1) and then asked to take Ig of ascorbic acid (vitamin C) daily for 3 
weeks at which time they were reassessed (Visit 2). Following a 3 week washout 
period in which no vitamin supplements were taken subjects were studied for a third 
time (Visit 3) and prescribed 300mg tocopherol acetate (vitamin E) daily for 3 weeks 
when they were seen for final assessment (Visit 4). Subjects were asked to continue 
their normal diets throughout the study period. Diabetic subjects continued their normal 
medication.
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Diabetic
Subjects
Non-diabetic
Subjects
p value
n 9 10
Age (yrs) 61.1(12.9) 41.5(10.8) 0.003
Sex Ratio (M:F) 8:1 7:3 p > 0 .2
f = 1 .0 3
Duration (yrs) 9.4(7.6) N/A
Smoking (yes:no) 3:6 1:9 p > 0 .2
Treatment
Diet
Sulphonylurea +  
Metformin
5
4
Complications
Macrovacsular
Microvascular
9
2 Ia
Table 8.1: Clinical details of subjects
Values aie mean (SD). Groups are comp ai red by unpaired Student’s t-test of Chi-squared 
test.
8.4 METHODS
Analytical methods were as described in chapter two and vitamin E status was 
calculated as before (Section 7.3.2). The statistical methods used to compare groups 
at baseline were as described in chapter two. The difference in age between the groups 
was allowed for using analysis of variance with age as a covariate.
To analyse the effects of vitamin supplementation it had to be taken into account that 
the design of this study was such that, within a subject, the same variable was measured 
repeatedly (4 occasions). Hence a statistical approach capable of allowing for this 
repeated measures design was employed namely the repeated measures analysis o f  
variance as available within the SPSS computer program (299). This technique tests 
the hypothesis that there is no difference in variables over the four measurements made. 
In the context of tliis study the hypothesis becomes that there is no overall effect of tlie 
treatments used. In addition to allowing for repeated measures use of this statistical 
method also reduces the number of paired tests performed and so the probability of 
false positive results. The effect of diabetes, and the covariate age, on the treatment 
effect were included in the analysis. Variance ratios (F) were determined for the 
overall treatment effect and for the influence of diabetes and age on the treatment effect. 
Since including age as a covariate did not significantly alter any of the outcomes 
observed only the F ratios for treatment and diabetes effects are quoted. Where a 
significant overall effect was identified the specific effect of vitamin C or vitamin E was 
assessed using paired t-tests or Wilcoxon sign rank test. The effect of vitamin C was 
determined by comparing results from visits 1 and 2 and of vitamin E by comparing 
visits 3 and 4. Where results were missing for visit 3, visit 1 results were used if there 
was no significant difference in the variable between visits 1 and 3 in the rest of the 
group.
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8.4.1 Assays Performed
Fasting plasma glucose (FPG).
HbA]^.
total-Chol, TG, HDL-Chol - with calculation of LDL-Chol.
TRAP.
TEARS.
Oxidation of isolated LDL with determination of LAG and PROP and calculation of 
DC-Rate and DC.m g'\
Uric Acid.
Vitamin E - with calculation of vitamin E status as the ratio of vitamin E concentration 
to that of the total-Chol+TG concentrations.
8 J  RESULTS
8.5.1 Baseline Characteristics
The clinical characteristics of tlie subjects are shown in Table 8.1. The diabetic 
subjects were older than the controls (61.1(12.9) vs 41.5(10.8) yrs, p = 0.003) but the 
ratios of smokers to non-smokers and of men to women were not significantly different 
in the two groups.
Fasting plasma glucose, HbAi^, TG and LDL-Chol concentrations were significantly 
higher in diabetic subjects than in controls, whereas HDL-Chol was significantly lower 
in diabetics (Table 8.2). Total-Choi concentration was not significantly different in the 
groups.
Neither TRAP (801.0(119.9) vs 789.1(106. l)/rmolU, p =0.823) (Fig 8.2) nor uric acid 
(0.32(0.09) vs 0.23(0.09)mmoll'\ p =0.065) (Fig 8.3) were significantly different in 
diabetics compared to controls. Uric acid significantly correlated with TRAP (r=0.616, 
p =0.009) (Fig 8.4) but not with HbA^g (r=0.230, p =0.375).
There was no significant difference between the groups in terms of vitamin E 
concentration (16.7 (15.4, 23.7) vs 17.9(15.5 21.0);tg.ml'\ p = 0 .0.967) (Table 8.2). 
The vitamin E status was significantly lower in the diabetic group compared to controls 
(4.81(0.92) vs 5.77(0.92)/xM.mM'S p =0.032). However, when age was controlled for 
in an analysis of variance with age as a covariate, diabetes was found not to contribute
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Variable Diabetic 
Subjects 
(n = 9)
Non-diabetic 
Subjects 
(n = 10)
p value
Glucose 
(mmol .1 )^
10.7(4.2) 5.2(0.5) 0.004
HbAi, (%) 10.1(2.9) 6.4(0.6) 0.005
Total Cholesterol 
(mmol.l^)
6.9(1.7) 6.0(0.7) 0.164
Total Triglycerides 
(mmol.E^)
2.4(1.7,3.3) 0.9(0.8,1.7) 0.019
LDL-Cholesterol
(mmol.l^)
4.3(0.5) 3.7(0.5) 0.026
HDL-Cholesterol
(mmol.E^)
1.1(0.3) 1.7(0.4) <0.0001
Vitamin E 
(/rg.ml'^)
16.7(15.4,23.7) 17.9(15.5,21.0) 0.967
Vitamin E status 
(wM.mM^)
4.81(0.92) 5.77(0.92) 0.032
Table 8.2: The comparison of glycaemic control, fasting plasma lipids, Vit E and Vit E status 
in diabetic and non-diabetic subjects at baseline.
Values are mean (SD) or median (25"^ , 75"^  percentile). Comparisons were made using 
unpaired Student’s T-test or Mann-Whitney U-test).
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significantly to the variance in vitamin E status (F=3.036, p=0.105) whereas age did 
explain a significant proportion of the variance (F = 7.363, p= 0 .0 I8 ). The age 
difference between groups did not alter the conclusions regarding other comparisons at 
baseline.
TEARS and the duration of lag phase (LAG) of LDL oxidation in vitro were not 
significantly different between die groups. Nor were the other measured aspects of 
LDL oxidation (Table 8.3).
Considering all subjects together there was no significant correlation between measures 
of lipid oxidation and glycaemic control (Table 8.4) other than an inverse correlation 
between the duration of the propagation phase (PROP) and HbAj ,^ and plasma glucose. 
When diabetic and non-diabetic groups were considered separately this correlation 
between PROP and glycaemia (HbAiJreraained significant for the diabetic subjects 
(r,=0.786, p=0.010) but not the non-diabetics (r,= 0 .316 ,p= 0 .187). Also the rate of 
diene conjugate formation was significantly related to HbAj^ and glucose only in 
diabetics. Vitamin E status did not correlate witli TEARS ( r= 0.148, p =0.546) (Fig 
8.5), nor witli LAG ( r= 0.065, p = 0.800) nor witli other measures of LDL oxidation 
(Table 8.4). TRAP did not correlate with any measure of lipid oxidation (Table 8.4). 
In all subjects TEARS correlated significantly with TG concentration (Table 8.5) but 
not with measures of in vitro LDL oxidation. In the separate groups TEARS correlated 
witli TG in non-diabetics (r,= 0.808, p =0.002) but not in diabetics (r,=0.381, 
p=0.156).
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Lipid Oxidation Diabetic Non-diabetic P
TEARS
(jitmolMDA.L)
2.0(0.4) I.9(0.4) 0.878
Duration of Lag Phase 
(min)
64.3(29.6) 77.5(51.9) 0.511
Duration of Propagation 
Phase (min)
24.4(22.6,29.7) 28.0(23.2,34.4) 0.286
DC formed per mg LDL 
(nmoles DC. mg'' LDL)
207.7(26.4) 205.4(39.4) 0.884
Rate of DC formation 
(nmoles DC. mg'* LDL.min*')
8.3(1.6) 7.5(2.6) 0.436
Table 8.3: The comparison of measures of lipid oxidation between diabetic and control subjects 
at baseline.
Values are mean (SD) or median (25“', 75* percentile). Comparisons were tested using 
unpaired Student’s t-test or Mann-Whitney U-test. DC refers to total di-ene conjugated 
species formed in vitro during the incubation period.
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TEARS
(/fmolMDA.l'O
Correlation
coefficient
p value
Triglyceride
(mmol.P^)
*0.690 0.001
Total-cholesterol 
(mmol .1'^ )
0.163 0.504
LDL-cholesterol 
(mmol .1'^ )
0.218 0.369
Duration of lag 
phase (min)
-0.223 0.375
Duration of propagation 
phase (min)
'-0.238 0.341
DC formed per mg LDL 
(nmoles DC.mg'^ LDL)
-0.060 0.813
Rate of DC formation 
(nmoles DC.mg^LDL.min'^)
0.091 0.711
Table 8.5: The correlation of plasma thiobarbitnric acid reactive substances (TEARS) with 
lipids and measures of in vitro  low density lipoprotein oxidation.
Pearson correlation coefficients are given for normally distributed data and 'Spearman 
rank correlation coefficients for non-norm ally distributed data.
8.5.2 Effect Of Vitamin C And Vitamin E Supplements
Using analysis of variance for repeated measures, and controlling for the effect of 
diabetes it was found that there was no significant difference in glycaemic control, 
plasma lipids (Table 8 .6 a) or TRAP (Table 8 .6 b) on the four study days. On the other 
hand TEARS, uric acid, vitamin E and vitamin E status did significantly differ during 
the course of the study. Diabetes had no significant influence on these outcomes (Table 
8 .6 b). The rate of diene conjugate formation (DC-RATE) also differed over the course 
of the study but diabetes did significantly alter this response (Table 8 . 6  b). No other 
variables differed significantly throughout the study.
Looking in more detail at those variables which did display significant variance during 
the study it was found that there was no significant difference in TEARS between visits 
1 and 2, that is whilst vitamin C was taken, (1.9(0.4) vs 2.1(0.48)/xmol.MDA.l'^ 
p = 0.239). There was a significant fall in TEARS between visits 3 and 4, whilst taking 
vitamin E (2.3(0.6 ) vs 2.1(0.3))nmol.MDA.U, p —0.049). However, TEARS were 
significantly higher at visit 3 than at visit 1 (2.3(0.6 ) vs 1.9(0.4)/xmol.MDA.l'^, 
p -0 .0 1 5 ) (Fig 8 .6 ).
Uric acid fell significantly between visit 1 and 2, whilst on vitamin C, (0.27(0,10) vs 
0.23(0.09)mmol.l'% p = 0.007) but there was no effect of vitamin E (Fig 8.7). Uric acid 
fell in diabetic (0.32(0,10) vs 0.27(0.10)mmol.l'% p =0.026) and in non-diabetic 
subjects (0.23(0.09) vs 0.20(0.07)mmol.l \  p=0.07) such that the mean fall in diabetic 
and non-diabetic was not significantly different (-0.06(0.06) vs -0.03(0.06)mmol.l ', 
p=0.318).
Vitamin E fell significantly during the vitamin C treatment period (17.2(15.4,21.2) vs 
16.6(13.2,17.9)jxg m l'\ p =0.019) and rose significantly during the vitamin E treatment 
period (17.7(15.5,20.4) vs 24.0(20.0, 26.1)/tg.mU, p =0.001) (Fig 8 .8 a). The rise in 
diabetics was not significantly different from that in non-diabetics.
Vitamin E status fell significantly on vitamin C (5.3(1.0) vs 4.8(0.7)ju.M.mM\ 
p = 0.045) and rose on vitamin E (5.4(0.9) vs 7.5(1.6 )juM.mM \  p <  0.0001) (Fig.8 . 8 b). 
The change in vitamin E status and the change in TEARS during vitamin E 
administration did not correlate significantly ( r ,= -0.058, p =0.406) (Fig 8.9).
The rate of diene conjugate formation (DC-RATE) (Fig 8.10) did not fall significantly 
between visits 1 and 2, or between visits 3 and 4, but was significantly lower at visit 
4 than 1 (5.9(2.0) vs 7 .9(2 .2)nm ol.m g\m in\ p = 0.011) when the groups were 
considered together. Diabetes did effect this result (Table 8 .6 b) in that when the groups
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were considered separately the DC-RATE was significantly lower at visit 4 than at 1 
in diabetics (83(1.6) vs 5.1(1.7)nmol.mg'hmin'\ p =0.002) but not in non-diabetics 
(7.5(2.6) vs 6.5(2.l)nmol.mg'hmin'^ p =0.381).
M  DISCUSSION
This study was designed to act as a pilot for a study the principle aim of which would 
be to assess the effects of vitamin C and E on antioxidant levels and lipid peroxidation 
and which would secondarily allow the response be compared in diabetics and non­
diabetics. In this pilot study since the subjects act as their own controls in the design 
used it is not critical, in terms of the main analysis of treatment effect, that the diabetic 
and non-diabetic subjects differed in age and presence of vascular complications. 
However these differences could confound effects interpreted as due to diabetes. I will 
tlierefore concentrate the discussion on the treatment effect but because of the pilot 
nature of the study and because age and the presence of vascular complications in the 
groups would be expected to operate, if anything, in tlie same direction as diabetes, 
exaggerating rather than masking differences between the groups, I have analysed 
differences between groups at baseline and in terms of response to vitamin 
supplementation, looking for trends that might guide future studies and to allow 
statistical power calculations be performed. I did control for age statistically but doing 
so altered only the conclusions reached regarding the comparison of vitamin E status 
between diabetic and non-diabetic subjects at baseline and did not alter the significance 
of the effects of vitamin supplementation therefore I have presented the statistics 
elsewhere without controlling for age. In the definitive study the effect of diabetes on 
baseline characteristics and upon treatment effect would be assessed by comparing 
groups matched for vascular disease and age.
8.6.1 Comparison Of Groups At Baseline.
The differences observed at baseline in plasma glucose, HbAjp, and fasting lipids 
between diabetic and non-diabetic subjects were as expected and as frequently reported 
before (82). I found no significant difference in TRAP between the groups at baseline 
in agreement with results reported in chapter five suggesting again that diabetes per se 
is not asociated with alterations in overall plasma antioxidant status. However the lack
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of difference may be due to the power of the study since the power to detect a 
difference of 10% at the 0.05 level of significance with ten subjects in each group 
would only be 31%. To detect such a difference with a power of 80% would require 
approximately 30 subjects in each group (215, 300) and the differences actually 
observed are much smaller than 10% suggesting that even many more subjects than 30 
might need to be studied. This requires to be taken into account in future studies. 
Uric acid concentrations were not significantly different in the diabetic and non-diabetic 
subjects studied. This does not necessarily mean that diabetes has no effect on uric acid 
but may reflect the balance between two opposing effects of diabetes. These subjects 
had macrovascular disease and were hypertriglyceridaemic and, although it was not 
measured they were also very likely to be insulin resistant (76). These features have 
been associated with hyperuricaeraia (297, 298) and so hyperuricaemia might have been 
anticipated in this group. However, it may be that when hyperglycaemia coexists it has 
an opposing effect, lowering uric acid levels by impairing uric acid reabsorption in the 
kidney, two such opposing influences would result in no overall difference in uric acid 
levels in diabetes as seen here. Lack of statistical power could also explain the 
insignificant result found, although power calculations suggest that 17 subjects in each 
group would be sufficient to detect tlie difference that existed with a power of 80% at 
the 0.05 level. Uric acid concentrations correlated significantly with TRAP, consistent 
with the observation that it is a major contributor to the value of TRAP (26). In view 
of its role as an antioxidant (29), its reported abnormality in diabetes (294-296) and its 
association with cardiovascular risk factors (202, 298), closer evaluation of uric acid 
may be worthwhile.
Vitamin E concentrations were not significantly different comparing diabetic and non­
diabetic subjects whereas vitamin E status was significantly lower in diabetic subjects 
than in controls. Hence correcting for plasma lipids revealed that this group of 
diabetics may have lipids relatively less well protected from oxidation. However when 
age was statistically controlled for diabetes was found not to significantly influence 
vitamin E status and the difference between the groups to be significantly related to 
their age difference. This effect of age is in keeping with the results of chapter seven 
where it was discussed more fully in Section 7.6. The effect of diabetes on vitamin E 
status will require final clarification in age matched comparisons but both of these 
studies would suggest that diabetes per se is not associated with alteration in vitamin E 
status. Power calculations suggest that 17 subjects in each group would allow detection 
of a significant result at the 0.05 level with a power of 80%. Vitamin E status did not
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correlate with any in vitro measure of lipid oxidation or with TEARS and is in keeping 
with the impression that factors other than vitamin E content are involved in 
determining the resistance of lipids to oxidation. Also, TRAP and uric acid 
concentrations did not correlate with TEARS which may again suggest tliat antioxidants 
are not a major determinant of lipid oxidation in vivo or it could reflect the problems 
of using TEARS as a marker of oxidation since TEARS concentrations are determined 
by removal as well as production and TEARS may arise by mechanisms other than FR 
attack on lipids and all of this in addition to the lack of specificity of the TEARS assay. 
No measure of lipid oxidation, including TEARS, was found to be significantly 
different in the two groups at baseline. This is not consistent with the idea that more 
lipid peroxidation occurs in diabetes or individuals with macrovascular disease (67, 
271). Nor is it consistent with my finding in the previous study that TEARS were 
higher in diabetics and suggests that in the case of TEARS this may be due to lack of 
power and indeed from this study I would calculate that to detect a 10% difference in 
TEARS at the 0.05 level with 80% power groups of 64 would have to be examined. 
The difference in the mean LAG between diabetic and non-diabetic subjects of 13 
minutes suggests that 150 subjects would have to be studied to detect such a difference 
at the 0.05 level witli a power of 80%. Although measures of oxidation did not differ 
between diabetics and non-diabetics the duration of the propagation phase (PROP) 
inversely correlated with HbAi^ and fasting plasma glucose. The relationship was 
strongest in the diabetic group but this may simply reflect the wider distribution of 
HbAjc and glucose in the diabetic subjects. Since DC-RATE is derived from PROP it 
was not surprising that DC-RATE was found to positively correlate witli measures of 
glycaemia. However the extent of LDL oxidation (DC.mg'^) did not correlate with 
glycaemia. These results raise the possibility that glucose increases the rate of LDL 
peroxidation but not its extent. Considering that when the experiment is performed, 
LDL is in fact isolated from plasma it cannot be hypothesised that glucose per se is 
having this effect since glucose is no longer present but rather that glucose may modify 
LDL and then that modified LDL peroxides more rapidly. This idea would be 
consistent with the suggestion that glycation and oxidation may be associated (74, 102). 
In vivo, if more rapid peroxidation does occur in association with higher glucose levels, 
but removal of peroxidised material is unaltered, then higher steady state levels of 
peroxidised material would be expected and this might help explain the higher TEARS 
reported by others in diabetic subjects (65-69). In addition if direct toxicity of lipid 
peroxides is an important factor in atherogenesis then increased lipid peroxide
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production rate could be a mechanism whereby hyperglycaemia contributes to 
atherogenesis. In this study despite the correlation between DC-RATE and glucose 
concentration, I did not find that TEARS concentration, a measure of lipid peroxidation 
in vivo, was greater in diabetics than controls nor did TEARS correlate with glycaemia 
and, although this could well be explained by tlie power of the study, it raises ocncern 
about the source of TEARS. If TEARS are derived from LDL oxidation it might be 
expected that those factors which influence LDL oxidation should influence TBARs 
concentration, this was not the case for glucose concentrations. Also, if TEARS do 
derive from LDL oxidation then some relationship between measures of in vitro 
oxidation of LDL and TBARS might have been expected but was not found. The fact 
that TEARS concentration was significantly related to TG concentration would be more 
in keeping with the possibility that they are derived from triglyceride rich lipoproteins 
such as VLDL as opposed to LDL. In the study in chapter seven TEARs also 
correlated with TG, although when age was controlled for this correlation was lost, 
nevertheless reasons why TEARs might correlate witli TG and the significance of such 
a correlation was discussed in section 7.6.
8.6.2 The Effect Of Vitamin Supplementation
In agreement with other studies I found supplementation of vitamin C or E had no 
effect, in particular no adverse effect, on glycaemia or lipid concentrations in diabetics 
or non-diabetics (120, 194, 282, 302). However it has also previously been reported 
that although vitamin C (303) and vitamin E (103) were without effect on plasma 
glucose they nevertheless reduced glycation of haemoglobin and plasma proteins. The 
lack of effect on HbAj^ in my study may have several reasons. Davie et al 
administered vitamin C for 3 montlis and Ceriello et al administered vitamin E for 2 
months whereas supplementation in this study was for 3 weeks. Duration of treatment 
may be important per se but is perhaps made more so by the relatively long half-life of 
haemoglobin in plasma which more nearly approaches 3 months than 3 weeks. Also 
as suggested by Davie et al, the method of measuring haemoglobin glycation may be 
relevant. Complexes of vitamin C with haemoglobin may be detected by agar gel 
electrophesis as glycated haemoglobin, masking any fall in true glycosylated species. 
It may be more appropriate to use affinity chromatography techniques in future studies 
to determine true glycosylation. Glycosylation may be relevant pathophysiologically 
via free radical (18, 131, 288), and non free radical (85, 86), mechanisms and
128
consequently factors affecting it may be important and worthy of further investigation. 
As others have reported large alterations in plasma vitamin C using similar doses to 
those employed in this study I assumed a rise in vitamin C would occur and did not 
measure plasma vitamin C levels per se but anticipated a rise in TRAP levels because 
vitamin C has been reported to contribute up to 24% of TRAP (26). However I 
observed no change in TRAP during vitamin C supplementation. Although statistical 
power must again be considered, other explanations also exist. There is little reason 
to suspect that vitamin C was not absorbed, one possibility which then arises istliat 
other contributors to TRAP fall in proportion to the rise in vitamin C. This is born out 
by this study in that uric acid, and vitamin E concentrations fall during vitamin C 
supplementation and uric acid is a major contributor to TRAP (35-65%) and vitamin 
E a minor one (5-10%) (26). There are several possible explanations for these apparent 
falls in uric acid and vitamin E. Vitamin C is a urocosuric agent inhibiting the 
reabsorption of filtered/secreted uric acid in the renal tubules hence increasing its 
excretion (290, 296), and possibly inducing a fall in plasma levels. Vitamin C can also 
simply interfere with the assay for uric acid (304) falsely suggesting lower levels of uric 
acid and although this would help explain a low measured concentration of uric acid 
during vitamin C supplementation it would not explain the failure of TRAP to increase. 
A simple modification of the uric acid assay can eliminate the possibility of interference 
(304) and should be adopted in future studies. Neither of these problems are known 
to arise with the assay of vitamin E but a third possible reason why uric acid falls on 
vitamin C might also explain the fall in vitamin E. In certain circumstances vitamin C 
can act as a pro-oxidant rather than an antioxidant (252, 305). Uric acid and vitamin 
E could then be consumed in the defence against this pro-oxidant state especially as they 
are both involved in recycling reactions with vitamin C (29).
The pro-oxidant effect of vitamin C is based upon tlie fact that it can oxidise in the 
presence of transition metal ions, especially Fe^+ (252, 276). In the process Fe^ "" is 
reduced to Fe^ "^  which, as previously described, is capable of reacting with lipid 
hydroperoxides and to generate free radicals (FR)(Section 1.2.1). In fact the 
proxidant effect of vitamin C may depend upon the presence of all three components, 
ascorbate, transition metals and hydroperoxides, and may explain the finding that EDTA 
abolished the ascorbate enhanced hydroperoxide-dependent peroxidation of rat liver 
microsomes (305). Presumably as a consequence of such reactions mixtures of vitamin 
C and metal ions can actually be employed experimentally as FR generating systems 
(13, 306). Evidence of the pro-oxidant effect of such combinations is provided by
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findings such as enhanced lipid peroxidation and FR damage in isolated rat nuclei in the 
presence of ascorbate and copper or iron (306). It is argued that in vivo a very careful 
balance of ascorbic acid, transition metal ion availability and metal chelators can 
maintain the equilibrium in favour of an antioxidant effect for vitamin C (252). In 
vitro, by increasing the concentration of only vitamin C in human plasma, it has been 
shown that the antioxidant activity of vitamin C is concentration dependent falling as 
concentration rises however in these circumstances a frankly pro-oxidant effect was not 
observed (261). Administering vitamin C to an intact animal on a normal diet as in this 
study is, however, not the equivalent of in vitro loading of plasma. Ingestion of 
vitamin C is known to increase Fe^^ absorption from tlie gut (307, 308). Hence 
ingestion of vitamin C inevitable means that more Fe^ "^  is also absorbed. This may 
interfere with the balance mentioned above and shift the equilibrium in favour of 
oxidation.
The inability to separate the absorption of Fe^+ from that of vitamin C during vitamin 
C supplementation may explain several reported anomalies. Despite the sparing effect 
of vitamin C on vitamin E in v/7ro,vitamin C fed to guinea pigs did not alter the 
turnover of vitamin E (309) also vitamin C did not reduce the elevated levels of lipid 
peroxidation products (malondialdehyde and diene conjugates) seen in streptozotocin 
diabetic rats (310). However the latter group did report a rise in vitamin E levels on 
vitamin C a discrepancy with ray results which I cannot explain other than in possible 
species differences. The finding that the absolute levels of the oxidised form of vitamin 
C (dehydroascorbate) increase with oral supplementation in human controls and non- 
insulin dependent diabetics is in keeping with the possibility that more unwanted 
oxidation of vitamin C occurs as oral intake is increased (119, 120). Another related 
mechanism whereby vitamin C could enhance FR catalysed reactions is suggested by 
the finding that ascorbate can inhibit the ferroxidase activity of caeruloplasmin and so 
inliibit the oxidation of Fe^^ to Fe^^ (311).
TEARS concentrations changed throughout the course of this study but tlie pattern of 
change was rather odd. They rose during vitamin C supplementation and continued to 
rise after vitamin C supplements had stopped being significantly higher than baseline 
only at visit 3. They then fell significantly between visits 3 and 4 when vitamin E was 
taken. Several explanations could be afforded for this pattern of change but again it 
would be consistent with increased oxidative stress during vitamin C supplementation 
although one would also have to postulate a delayed effect of vitamin C which was not 
anticipated as vitamin C is water soluble and not stored to any extent. It is not clear
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how quickly vitamin C levels return to "normal" when supplementation stops but Davie 
et al did show that 4 weeks after cessation vitamin C concentrations had returned to 
pretreatment levels (303) and if the uric acid effect is due to vitamin C it had resolved 
by visit 3, three weeks after cessation. However the effect on TEARS need not be as 
direct as upon uric acid and display more of a delay. This could be clarified in future 
studies by following vitamin C concentrations and allowing a longer washout after the 
vitamin C phase. Designing the study such that some individuals receive vitamin C 
followed by E, and others E followed by C, would also allow statistical verification that 
no delayed effect existed or interactions between vitamin C and E occurred (312). The 
fall in TEARS which occurred between visits 3 and 4, whilst vitamin E was being 
taken, could be due to withdrawal of a possible oxidative effect of vitamin C or be due 
to the antioxidant effect of vitamin E. A correlation between the change in vitamin E 
status and fall in TEARS would have supported the latter but did not exist. Another 
possible explanation for the TEARS changes is that TEARs concentrations fluctuate 
significantly simply with time and had nothing to do with the trial, this possibility could 
be excluded in future studies by performing more than one baseline assessment during 
a prolonged run in period. The samples pre and post vitamin supplements were assayed 
in a single assay so that the observations are not a batch-effect.
The suggestion of a pro-oxidant, and so possibly, harmful role for vitamin C seems to 
be at odds with accumulating epidemiological evidence of a negative association 
between plasma concentrations of vitamin C and risk of atherosclerotic disease 
morbidity and mortality (198, 199, 279). However from these epidemiological studies 
the estimated intake of vitamin C required to achieve maximum prophylactic effect 
against health hazards including vascular disease was of the order of lOOmg daily (198) 
not the lOOOmg pharmacological doses used in this and other studies. It is possible that 
once optimum levels are exceded adverse effects arise. Apart from possible pro­
oxidant effects of high dose vitamin C other adverse effects such as the formation of 
oxalate kidney stones (313) would need to be considered if ever it were planned to 
advise populations to increase their vitamin C intake substantially. What the optimum 
dose is has yet to be established.
Of the measures of copper stimulated oxidation of LDL in vitro, only the rate of DC 
formation in the propagation phase varied significantly during the study but the 
significant difference did not occur in association with eitlier vitamin C or E 
supplementation but during the intervening period making it difficult to explain and 
questioning its significance. A reduction in the rate of peroxidation is also not
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consistent with the rise in plasma TEARS, although this conclusion presumes that a 
similar slowing of peroxidation occurs iii vivo, and that TEARS are a reflection of LDL 
oxidation neither of which is proven to be so. Also if the reduction of DC-RATE has 
got anything to do with vitamin C administration it is inconsistent with current 
understanding of how vitamin C operates to reduce LDL oxidation. Although vitamin 
C has been shown to increase the duration of the lag phase of lipid oxidation in plasma 
and isolated LDL when added to the medium in vitro it is believed to do so by 
intercepting radicals in the medium or by regenerating tocopherol, whilst remaining in 
the aqueous compartment (275, 276). Vitamin C does not appear to directly associate 
with LDL or alter its composition per se, so that when LDL is isolated from its plasma, 
as it is in this study, it is isolated from any effect of ingested ascorbate therefore it 
would not be expected that vitamin C be associated with alterations in LDL oxidation 
in vitro. This may simply be a false positive result. Even if it were not, the 
pathophysiological relevance of alterations in the rate of LDL oxidation in vitro is 
theoretical and untested currently as discussed earlier (Section 8.1.1).
In addition to the fall in plasma vitamin E concentration and vitamin E status during 
vitamin C supplementation, as already discussed, they both rose significantly during tlie 
vitamin E stage. This effect was unaffected by the presence or absence of diabetes and 
the rise observed in diabetic and non-diabetic subjects was not significantly different 
suggesting that vitamin E is absorbed and handled similarly in both groups. Despite 
this rise of approximately 36% in vitamin E concentrations there was no evidence of 
reduced lipid oxidation either in vivo (TEARS) or in vitro. This is in disagreement with 
studies in which LDL was enriched by either exposure to vitamin E /ethanol mixtures 
in vitro (28, 46, 144, 289) or by oral ingestion of vitamin E prior to LDL isolation (28, 
46). In both types of study vitamin E enriched LDL was found to have prolonged 
LAG. The apparently contradictory results from this study may be explained in several 
ways. I used alLracemic ce-tocopherol acetate (all-rac a-TOH) which is a synthetic 
mixture of the eight stereoisomers of the naturally occur RRR isomer of cx-tocopherol 
(RRR tx-TOH) (219) which was the supplement used in other studies. However tliis 
difference is unlikely to explain the contradictory results because the antioxidant activity 
of these isomers are little different. Taking the antioxidant activity of all-rac a-TOH 
as 100% it was reported that the activity of RRR «-TOH was 110% (314). However 
the bioavailability of all-rac œ-TOH is less than that of RRR a-TOH (315) and I also 
used a smaller dose of vitamin E than was used in the other studies quoted. The result 
of these two facts was that supplementing with 300rag (300IU) in this study resulted in
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a 36% increase in plasma vitamin E concentration. This may simply not be sufficient 
to bring about a change in LDL oxidation since a doubling of vitamin E content of LDL 
was seen to increase by only 30% the dose of y-irradiation required to induce a 
standard amount of peroxidation (144). Also a 2.5 fold enrichment of LDL with 
vitamin E was accompanied by a prolongation of the LAG of copper stimulated LDL 
oxidation from 4-6 hours by 2 hours, in other words a doubling of LDL content of 
vitamin E produced only a 30-50% rise in LAG (46) and to achieve this effect subjects 
ingested 1.45g of RRR ce-TOH. Hence very large doses of vitamin E may be required 
to enrich LDL enough to induce detectable changes in its resistance to oxidation. The 
enrichment achieved in this study was less than in the other studies quoted and may be 
the most important reason for the different results found. However studying the in vitro 
enrichment of LDL from a single donor Cominacini et al found a very close 
relationship between the increase in vitamin E content of LDL and duration of the lag 
phase, and that only small increments in vitamin E content were required to induce 
large changes in LAG. They also found that increasing the vitamin E content was 
significantly inversely related to the rate of propagation (289). An explanation for these 
different observations may be the individual variation which has been found to exist. 
Esterbauer et al studied the effect of doses of vitamin E between 150IU and 1200IU and 
reported that there was marked individual variation in the ability of vitamin E to protect 
LDL from oxidation and in some individuals vitamin E had no significant effect (316) 
and so subject differences between my study and those of others may have contributed 
to differences in results. Subject heterogeneity and the size of doses of vitamin E 
required to alter LDL oxidation suggests again that factors other than vitamin E are 
involved in determining LDL’s susceptibility to oxidation.
If large doses of vitamin E are required to alter oxidation of LDL it brings in to 
question whether or not this can be the mechanism whereby vitamin E appears 
epidemiologically to afford protection from vascular disease. Again from 
epidemiological studies the intake of vitamin E which would appear to provide 
prophylaxis is in the region of 60IU (198) much less tlian the dose I have studied and 
very much less than those shown to reduce LDL oxidation. Perhaps vitamin E works 
to protect against vascular disease morbidity and mortality via one of the other 
mechanisms discussed in chapter seven (Section 7.1.2).
The safety of large doses of vitamin E also remains to be established, 300mg per day 
is pharmacological and a dose of this order (400rag all-rac a-TOH) was observed to 
modify eicosanoid metabolism with reduced platelet thromboxane production in a group
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of insulin dependent diabetic subjects (282). This effect may be quite separate from 
vitamin E ’s ability to inhibit nonenzymatic FR activity and may relate to a modulation 
of the enzymes of the arachadonic acid cascade (281). If to observe enlianced LDL 
resistance to oxidation, doses far beyond those which alter eicosanoid metabolism are 
required the possibility of far reaching unwanted effects arise. Some, like the reduction 
of platelet thromboxane in diabetics (282), may be desirable in terms of atherosclerosis 
but eicosanoids have such wide ranging activities that there are no guarantees that this 
would be so in all instances. Despite that fear, adverse effects of high doses of vitamin 
E have not been convincingly demonstrated (302).
The presence or absence of diabetes did not have any significant effect on any of the 
results discussed above other than on rate of peroxidation in the propagation phase 
however since I have argued that the significant alteration seen on DC-RATE was most 
likely to be a statistical error I do not propose to discuss it further. I acknowledge that 
since diabetic subjects differ from controls in more ways than just tlie presence of 
diabetes I cannot be categorical about this negative effect of diabetes and the definitive 
study in which subjects are matched in terms of vascular disease and age may be 
necessary but since I anticipated that these differences between the groups would 
exaggerate rather than mask differences in the variables of interest I suspect that no 
such differences exist.
In addition to tlie considerations above, including those of dosage of vitamins used, the 
power of this study using 1 0  individuals to detect an effect of vitamin supplements can 
be assessed and is small. Although the paired nature of the study adds to its power 
nevertheless looking at LAG during vitamin E supplementation the power of this study 
to detect 10% alterations at the 0.05 level of significance is only 7% and to detect such 
differences with a power of 80% would require that approximately 390 subjects would 
have to be studied (215).
L I  CONCLUSION
Vitamin C, Ig per day, did not cause a rise in TRAP and in fact was associated with 
a fall in plasma uric acid concentrations and vitamin E status in both diabetic and non­
diabetic subjects. One explanation for these changes is that, at high doses in individuals 
on normal diets, increases in vitamin C concentration are associated with increases in 
Fe^^ and so with a pro-oxidant as opposed to an antioxidant effect. The increases in
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TEARS concentration observed during the trial may reflect a delayed pro-oxidant effect 
of vitamin C.
Supplementation with 300mg of vitamin E per day was associated with a significant rise 
in plasma vitamin E concentration and status but did not cause a rise in TRAP, nor did 
it alter any parameters of in vitro oxidation of LDL in a way which suggested that it 
enhanced resistance of LDL to oxidation. Vitamin E supplementation was associated 
with a fall in TEARS, a measure of in vivo lipid oxidation however these may have 
been unrelated as the change in vitamin E status did not correlate with the change in 
TEARS concentration. TEARS concentration did not correlate with any parameter of 
in vitro LDL oxidation raising several possibilities. TEARS concentration in vivo may 
be more influenced by removal than production or are not derived principally from 
LDL. The correlation of TEARS with TG concentration suggest that they might be 
derived mainly from the TG rich lipoproteins such as VLDL. Lipid hydroperoxides 
detected by the TEARS assay also arise in vivo during eicosanoid metabolism which can 
be modified by vitamin E, perhaps the fall in TEARS on vitamin E is mediated by this 
effect as opposed to an effect on non-enzymatic FR attack on LDL.
The lack of observed effect of these doses of vitamins E and C on the variables 
measured may be that they were too small, however this raises tlie question as to 
whether or not reduced lipid oxidation is tlie mechanism whereby these vitamins appear 
in epidemiological studies to protect against atherosclerotic vascular disease morbidity 
and mortality. This doubt is raised particularly because the doses of these vitamins 
which epidemiological studies suggest would provide protection are of the order lOOmg 
vitamin C and 60IU vitamin E per day. These conclusions appear to apply similarly 
to diabetic and non-diabetic subjects but comparison of healthy controls with diabetic 
subjects without vascular disease, as planned, would have to be performed to verify this 
impression.
Power calculations on the basis of these results suggest that to detect 10% changes, or 
differences, in LAG with 80% power at a significance level of 0.05 approximately 400 
subjects would have to be studied.
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FINAL COMMENTS
Each o f the chapters in this thesis describe individual studies which can stand alone and 
give rise to their own conclusions. These conclusions are discussed in some detail in 
the relevant chapters and I w ill not repeat them all again here, rather I would like to 
outline only the main conclusions, add a few general thoughts and point out again some 
of the interesting questions raised by the studies performed.
The hypothesis underlying, and unifying, these individual studies is that diabetes is a 
state in which more free radical oxidation of low density lipoprotein occurs. If low  
density lipoprotein oxidation is an important event in the genesis o f atheroma then it 
follow s that an increase in the potential for low  density lipoprotein oxidation in diabetes 
would help to explain the association o f  diabetes with atherosclerotic vascular disease. 
There are theoretically many ways in which free radical oxidation o f  low density 
lipoprotein might be influenced by diabetes. In this work I have studied several o f  
these theoretical influences but have found no support for the overall hypothesis. 
Many explanations why the individual studies generated negative results have been 
discussed but one recurring possibility relates to the limitations o f the readily available 
methodologies in the field of free radicals in biology. A lso knowledge of free radical 
processes in v ivo  is currently incomplete, thus the models used to set up more advanced 
hypothesis may be m isleading. I feel advances in methodology and basic knowledge 
of free radical biology arc needed before the questions of their importance in disease 
w ill be clearly answered.
The study described in chapter three directly addressed a long standing question 
reguarding the appropriateness o f using diene conjugated fatty acid concentrations as 
an indirect method of measuring in v ivo  free radical activity. The conclusion was 
reached that diet has such a large influence on diene conjugated fatty acid 
concentrations in biological samples that their use as free radical markers must be very 
limited.
Because questions regarding interpretation o f standard methods o f studying free radicals 
exist I have argued a case for and made use o f some less publisiscd techniques however 
they too raised questions in their interpretation which arc discussed in the rclavant 
chapters.
Looking first for a possible source of excess free radical production in diabetes I studied 
the superoxidc anion production by platelets, as platelets are more aggregablc in 
diabetes and are believed to have a role in atherosclerosis. I have to conclude that
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platelets do not release superoxide anion. This is not to say that platelets do not release 
other radicals or species capable o f reacting to form free radicals or of taking part in 
radical reactions. These are all possibilities which could be explored in the future. 
A lso there are many w ays, other than via  free radical processes, by which platelets 
could influence atherosclerosis.
An assay of the total pcroxyl radical trapping activity (TRAP) o f plasma was employed 
to ascertain whether or not antioxidant levels were less in diabetic subjects than in 
controls. No difference directly attributable to diabetes was observed however the 
possibility o f an interaction between diabetes and smoking which results in reduced 
antioxidant levels was suggested. Studies with larger numbers o f subjects should be 
undertaken to explore this possible interaction further as such an interaction might help 
explain the particularly adverse effects o f smoking in diabetes.
In diabetic subjects plasma antioxidant levels as represented by TRAP did not correlate 
with the peroxidisability of plasma lipids as was hypothesised. Whilst bearing in mind 
the interpretational difficulties generated by the methods used this lack o f correlation 
could also reflect the com plexities o f both the peroxidation process, as it occurs within 
lipoprotein particles, and the interaction of water soluble and lipid soluble antioxidants 
in influencing it. At its simplest it may be that TRAP reflects mainly water soluble
antioxidants.
However in the studies described in chapters seven and eight I did not demonstrate any 
association between vitamin E, the major lipid soluble antioxidant, and lowering of lipid 
oxidation. It was argued that this finding suggested that lipid oxidation is influenced 
more by factors other than, or in addition to, vitamin E. In a very recent study Reaven 
et a l (317) confirmed that the fatty acid com position, lipoprotein density and particle 
size arc also important determinants of susceptibility of low density lipoprotein to 
oxidation. A  so I found that vitamin E status, vitamin E concentration relative to 
plasma lipid concentration, was not lower in diabetic subjects than in controls although 
did correlate inversely with age. Hence again it could not be inferred that lower 
antioxidants in diabetics is a factor in their excess risk o f atherosclerotic disease.
It is also salulory to remember that the case with which lipids oxidise in plasma may 
not be of relevance anyway. It is possible that oxidation in micro-environments such 
as in the intima is more important and influenced by yet different factors.
A  further study in which vitamin C and vitamin E supplements were taken did not 
support the hypothesis that these antioxidants might protect lipids from oxidation. In
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antioxidants and that peroxidisability would be more influenced by lipid soluble 1
fact the possibility o f a pro-oxidant effect o f high dose vitamin C was raised. In 
addition it was observed that low  density lipoprotein was not protected from oxidation  
in v itro  by ingestion o f doses o f vitamin E far in excess of those which epidem iological 
studies suggest reduce the risk o f atherosclerosis. In this study 300m g o f vitamin E 
were taken daily and allowed plasma levels o f vitamin E rise by approximately 30% but 
no significant resistance of lipid to oxidation was seen. In agreement with earlier 
studies, Reaven et a l (317) showed that vitamin E enrichment o f low  density lipoprotein 
by a factor o f between 2-2.5 did increase resistance of isolated low  density lipoprotein  
to oxidaton but this effect was achieved by the ingestion o f  large, pharmacological, 
doses o f vitamin E (1200m g daily). Such studies suggest that the lower risk o f  
atherosclerosis, in populations ingesting diets marginally richer in vitamin E, is not 
gained through an effect o f vitamin E upon lipoprotein oxidation. One possible 
alternative is that vitamin E protects by altering eicosanoid metabolism thus 
prostacyclin/thromboxane activity and platelet function.
The hypothesis that the free radical oxidation of low density lipoprotein is central to the 
dcvelopemcnt o f  atherosclerosis is intriguing as it allows theoretical explanations for 
many o f the associations observed for this process which is involved in much o f the 
morbidity and premature mortality in the western world. The hypothesis remains 
unproven but no doubt deserves, and w ill receive, further exploration.
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